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General introduction and outline of thesis
“I understand pharmacokinetics, as you have explained it, completely. In daily life 
you want me in a perfectly tailored suit and when I am playing sports in baggy sweat 
pants, so I have extra factor concentrate on board to prevent me from bleeding”.
Hemophilia patient, 2015
This quote perfectly summarizes the main message and hypotheses studied in this 
thesis. Medication can be more optimally tailored according to each patient’s charac-
teristics and necessities during varying circumstances. Personalization of treatment can 
improve quality of care and therefore quality of life and may potentially lead to societal 
benefits through cost reduction of treatment.
Hemophilia
Hemophilia patients su!er from a (partial) deficiency of either coagulation factor VIII 
(FVIII) or coagulation factor IX (FIX), caused by respectively F8 or F9 gene mutations. As 
both genes are located on the X chromosome, mainly males are a!ected. Females are 
carriers of these bleeding disorders and therefore generally not or only mildly a!ected. 
Disease severity is classified according to residual plasma FVIII or FIX levels. Patients 
with mild hemophilia have FVIII or FIX levels between 0.05-0.40 IU/mL, leading to bleed-
ing only a"er trauma or during surgery. Patients with moderate hemophilia have FVIII 
or FIX levels between 0.01-0.05 IU/mL, and patients with severe hemophilia have FVIII 
or FIX levels < 0.01 IU/mL. Patients with moderate or severe hemophilia present with 
spontaneous bleeding and bleeding a"er minor trauma, typically in muscles and joints. 
In this thesis, we will focus on hemophilia A. Hemophilia A has a prevalence of 1:5000 
male births, leading to approximately 1600 hemophilia A patients in the Netherlands.1
Diagnosis
A patient is suspected of a bleeding disorder based on atypical bleeding with regard 
to frequency, severity, and/or location. Hemophilia A is diagnosed when FVIII activity 
measurements are abnormal during hemostatic laboratory workup.2 It is essential to 
safeguard accuracy and reproducibility of FVIII activity level measurements as varia-
tions in FVIII activity measurements may lead to misclassification of hemophilia sever-
ity. Subsequently, this will lead to either under or overtreatment of patients and clinical 
complications such as joint damage. In addition, in order to monitor factor replacement 
therapy, reproducible FVIII activity levels are essential to maintain specified FVIII activity 
levels during bleeding episodes and surgical procedures, according to national guide-
lines.3
FVIII activity measurements are generally performed using one-stage assays (OSA) or 
chromogenic substrate assays (CSA).4 The OSA is based on the activated partial throm-
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boplastin time (APTT), using the time until clot formation as its endpoint.5 In the CSA, 
the coagulation system is triggered resulting in factor Xa (FXa) generation. During the 
second step of this test, FXa hydrolyses a chromogenic substrate causing a color change, 
which reflects the amount of FVIII activity in the patient sample.6,7 As a result of dif-
ferent test methods and endpoints, these assays may lead to di!erent FVIII results in 
hemophilia patients with varying F8 mutations.8
Treatment
Mainstay of hemophilia A treatment is replacement of the deficient coagulation factor 
with either intravenously administered factor concentrate also called factor replace-
ment therapy or by administration of desmopressin. Desmopressin increases FVIII by 
inducing the release of von Willebrand factor from Weibel Palade bodies in the endothe-
lium, and can only be used in non-severe hemophilia patients.9 Treatment of hemophilia 
can be divided into prophylaxis to prevent bleeding, or on demand treatment in case 
of bleeding ór to prevent bleeding during hemostatic challenges such as dental- or 
surgical procedures.10 Prophylactic treatment was introduced in 1965 by Ahlberg.11 It is 
based on the observation that moderate hemophilia patients with FVIII levels # 0.01 IU/
mL have far fewer joint bleeds and develop arthropathy less frequently.11 Therefore, it 
was hypothesized that joint bleeding can be prevented in severe hemophilia patients by 
maintaining FVIII levels above 0.01 IU/mL by regular prophylactic doses of coagulation 
factor.12 To achieve this, FVIII concentrate is infused, generally two to four times a week 
using standard half-life FVIII concentrates. When on demand dosing of FVIII concentrate 
or desmopressin is administered, specific FVIII levels and ranges are targeted. Which 
FVIII levels are targeted depends on bleeding severity and location of bleed, type and 
location of surgery and postsurgical day among others.2,3
Interindividual di"erences
Dosing of FVIII concentrate is challenging. Standard practice is to dose based on body-
weight and crude estimations of in vivo recovery and FVIII clearance. The half-life of FVIII 
is roughly calculated by the formula: half-life = 0.693 * Volume of distribution divided 
by clearance. Half-life of standard half-life products is estimated at approximately 10.4 
hours using the estimated standard half-life clearance of FVIII products of 2.4–3.4 mL/h/
kg and a volume of distribution equal to the plasma volume.13,14 Furthermore, dosing is 
based on crude estimations of in vivo recovery assuming that each unit infused per kg 
of bodyweight increases FVIII levels by 0.02 IU/mL.15 However, Bjorkman et al. demon-
strated in 152 hemophilia A patients of all ages that a large variation in achieved FVIII 
levels exists a"er administration of 50 IU/kg FVIII concentrate.16 This is caused by large 
interpatient variability in pharmacokinetic parameters such as clearance and volume 
of distribution. These di!erences were associated with patient characteristics such as: 
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bodyweight, age and height.16-18 Collins et al. subsequently showed that FVIII concentrate 
half-life, ranges between 6 and 25 hours in the hemophilia A population, underlining the 
major challenges when FVIII concentrate dosing is based on bodyweight.19 Our research 
group recently reported a cohort of 119 hemophilia A patients undergoing 198 surger-
ies and showed that 45% of FVIII levels measured were under FVIII target levels during 
the first 24 hours a"er surgery resulting in a higher risk of postoperative bleeding.20 In 
contrast, 75% of all measured FVIII levels five days a"er surgery were above FVIII target 
level with concomitant unnecessary high costs.
Novel treatment strategy: pharmacokinetic (PK)-guided dosing of factor 
concentrates
Optimization of FVIII concentrate treatment in hemophilia A patients can be achieved 
by PK-guided dosing. PK is defined as what happens to the drug in a patient’s body by 
processes of absorption, distribution, metabolism and excretion. PK-guided dosing is 
described as dosing based on the PK parameters of the factor concentrate as derived 
from an individual patient. Individual PK parameters can be assessed by serial sampling 
of (ten or more) blood samples and calculating of PK parameters from the measured fac-
tor levels. Individual PK parameter estimates can also be obtained by Bayesian forecast-
ing, which can be performed with only a limited number of blood samples (two to three) 
per patient. Bayesian forecasting however requires the availability of a population PK 
model. Such a model not only provides typical PK parameter estimates but also their 
corresponding interindividual variability.
To apply population PK models correctly, they should be constructed from heteroge-
neous, well-defined populations and constructed with patient data obtained from 
di!erent settings and under variable circumstances. Not surprisingly, FVIII population 
PK models were first constructed for prophylactic dosing.16,21 Our research group was 
the first to present a perioperative FVIII population PK model for severe and moderate 
hemophilia A patients.22 This perioperative model showed large di!erences in com-
parison to the Bjorkman et al. prophylactic model as larger volume of distribution (1180 
mL/68kg) was observed perioperatively than in the prophylactic setting (240 mL/68 
kg).16,22 Analysis and testing of covariates, which describe the relationship with a specific 
PK parameter in a population PK model, subsequently leads to explanation of inter-and 
intraindividual variability. Therefore, leading to more accurate estimations of individual 
PK parameters and more adequate dosing advices.
The Bayesian forecasting procedure to obtain a dosing regimen works as follows (Figure 
1). Firstly, an individual PK profile is constructed. A patient is administered a FVIII con-
centrate bolus (t=0). At three time points, for example t=4, t=24 and t=48 hours, blood is 
Chapter 1
12
drawn and FVIII levels are determined. The available population model contains informa-
tion from all possible PK profiles (black lines). By combining the individual’s measured 
levels (points) and the population PK model the most probable individual PK profile (red 
line) is obtained with concomitant individual PK parameters. The availability of these 
parameters makes it possible to calculate a precise dosing advice for each individual 
patient, taking specific covariates into account. Despite the fact that PK-guided dosing of 
factor concentrates using rich sampling was described as e!icacious as early as 1993,23 
it has not been applied broadly until more recently in hemophilia.24 This is due to the 
prior necessity of at least ten blood samples e.g. time points to calculate patient’s PK, in 
combination with an obligatory factor concentrate washout period, leaving the patient 
without prophylaxis and unprotected against bleeding. Currently, Bayesian forecasting is 
increasingly applied since population PK models are increasingly available. In combina-
tion with limited blood sampling without application of a factor concentrate wash out 
period, this technique has emerged as a feasible innovation in hemophilia care. 19,25
OUTLINE OF THE THESIS
In this thesis, we will focus on the conditions, strengths, limitations and potential ap-
plications of PK-guided dosing of FVIII concentrate in hemophilia A patients.
The thesis is divided into two parts:
1. Evaluation of current diagnostics and treatment monitoring;
2. Implementation of pharmacokinetic-guided dosing of factor VIII concentrate in 
hemophilia A.
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In order to investigate these themes, firstly we will address the pitfalls in the diagnosis of 
hemophilia A (Chapter 2), and how hemophilia teams and laboratories can avoid these 
when diagnosing hemophilia A by residual FVIII activity level measurements. In collabo-
ration with the External Quality Assessment Program for Thrombosis and Hemostasis 
(ECAT) Foundation, we investigate the quality of FVIII measurements in more than 200 
laboratories worldwide (Chapter 3). As FVIII measurements are essential to optimize 
both the diagnosis and quality of treatment monitoring, accuracy of these measure-
ments is of great importance. Implementation of PK-guided dosing is only feasible if 
data on factor levels observed in the individual patient are precise and reliable. The 
same applies to the data used to construct population PK models. Therefore, knowledge 
and expertise on coagulation factor laboratory assays are indispensable when providing 
PK-guidance of factor concentrate dosing.
Implementation of individualized dosing strategies with FVIII concentrate is the main 
topic of the second part of this thesis. Firstly, a detailed review discusses the background 
of PK-guided dosing covering its advantages and limitations (Chapter 4). Subsequently, 
we describe the design of a randomized controlled trial which compares perioperative 
PK-guided dosing of FVIII concentrate with standard dosing based on bodyweight in 
severe and moderate hemophilia A patients in Chapter 5. In Chapter 6, the preliminary 
results of this unique randomized controlled trial are presented and discussed. As von 
Willebrand factor (VWF) has a potential e!ect on FVIII clearance due to its chaperone 
function, protecting FVIII from proteolytic cleavage in the circulation, VWF will be de-
termined in patients undergoing surgery. Results illustrating VWF kinetics and its role in 
such a perioperative setting will be evaluated in Chapter 7.
As the prevalence of overweight and obese individuals in the general population is ris-
ing, hemophilia A patients are also increasingly overweight and obese. In Chapter 8, we 
investigate the use of various morphometric variables as substitutions for bodyweight 
to dose overweight and obese hemophilia A patients. An extremely obese, severe he-
mophilia A patient who undergoes a laparoscopic sleeve gastrectomy in order to lose 
weight is followed over time and investigated at subsequent time points to gain insight 
into the potential e!ects of significant weight loss on individual FVIII PK parameters 
(Chapter 9). In the last chapter of this thesis, currently available PK-guided dosing tools 
will be compared and impact of modeling di!erences on dosing advices will be analyzed 
(Chapter 10). Finally, the results of this thesis will be discussed in Chapter 11.
Chapter 1
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ABSTRACT
Measurements of factor VIII coagulation activity (FVIII:C) may vary and result in mis-
classification of hemophilia A with delay in initiation of prophylactic treatment. We 
describe two young brothers who were diagnosed as moderate hemophilia patients 
and therefore not prophylactically treated with factor VIII concentrate despite frequent 
bleeding events. These findings emphasize the importance of 1) multiple measurements 
of FVIII:C by certified laboratories; 2) adjustment of treatment when test results do not 
correspond to clinical symptoms; 3) relevance of additional DNA mutation analysis in 
patients with hemophilia A and; 4) treatment in centers with expertise.
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INTRODUCTION
Hemophilia A is an X-linked recessive bleeding disorder caused by a deficiency in 
coagulation factor VIII (FVIII). Measurement of factor VIII coagulant activity (FVIII:C) is 
fundamental in the diagnosis, classification and treatment of hemophilia A, as progno-
sis and treatment intensity di!ers between patient groups. Most severe (FVIII:C < 0.01 
IU mL-1) and some moderate (FVIII:C 0.01-0.05 IU mL-1) hemophilia A patients receive 
intravenously administered prophylaxis with FVIII concentrates to prevent spontaneous 
bleeding, whereas mild hemophilia patients (FVIII:C 0.05-0.40 IU mL-1) receive desmo-
pressin or FVIII concentrates only in cases of acute bleeding or to prevent bleeding in 
case of trauma or surgery.1,2 Furthermore, genetic counseling with factor VIII gene (F8) 
mutation analysis is performed in most patients and/or families to verify diagnosis and 
to establish carriership.
According to Dutch and World Federation of Hemophilia (WFH) guidelines, prophylaxis 
is initiated in children with severe hemophilia a"er their first or second joint bleed.1,2 
Unfortunately, variation in FVIII:C measurements may lead to misclassification of sever-
ity type with concomitant delay in initiation of prophylaxis, as more bleeding events will 
be tolerated in a non-severe hemophilia patient. This brief report aims to emphasize the 
importance of repeated and reliable FVIII:C testing, the importance of clinical symptoms 
and the relevance of DNA mutation analysis in hemophilia.
RESULTS
Case presentation
We present two brothers with a delay in diagnosis of severe hemophilia A, from a family 
with no family history with regard to bleeding disorders.
At the age of ten months, patient A was referred to a hospital a"er persistent bleeding of 
his finger a"er a bite by a house pet. No earlier bleeding was reported and intramuscular 
vaccinations were performed without problems. A"er physical examination and labora-
tory assessments, patient A was diagnosed with moderate hemophilia A, as a FVIII:C of 
0.05 IU mL-1 was established by one-stage assay. In the five following years, diagnosis 
was confirmed by four subsequent measurements of FVIII:C, ranging from 0.019-0.05 
IU mL-1. To exclude concomitant von Willebrand disease (VWD), von Willebrand factor 
(VWF) antigen and ristocetin cofactor activity was measured once and revealed plasma 
concentrations of 1.37 and 1.61 IU mL-1, respectively. In due course, patient A had recur-
rent joint bleeds in multiple, usually smaller, joints as documented in patient log. The 
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majority were caused by (minimal) trauma and most were treated with FVIII replace-
ment therapy resulting in more than 50 FVIII infusions at presentation in our clinic. No 
F8 mutation analysis was performed.
A"er diagnosis in patient A, his brother (patient B) was also tested for hemophilia A. A 
FVIII:C baseline level of 0.03 IU mL-1 was found a"er a single measurement, VWF antigen 
and ristocetin cofactor activity were not measured. Patient B had few bleeding events 
and was only sporadically treated with FVIII concentrate until the age of five years. 
All bleeding events were a"er trauma. Also in patient B, no F8 mutation analysis was 
performed.
At ages of six and five years, both brothers were seen at our hemophilia treatment 
center a"er referral due to a further centralization of care of hemophilia patients in the 
Netherlands.3 Laboratory analysis also by one-stage assay revealed FVIII:C of <0.01 IU 
mL-1, indicative of severe hemophilia. Due to clinical phenotype with frequent bleeding 
and two FVIII:C plasma concentrations <0.01 IU mL-1 in both brothers, prophylaxis was 
initiated immediately at 20 IU kg-1 once a week and rapidly extended. Fortunately, no 
deleterious e!ects on joint function have yet become visible. Subsequently, F8 mutation 
analysis revealed an inversion of intron 22, which is the most common mutation found 
in severe hemophilia A patients.4 Targeted mutation analysis in the mother confirmed 
hemophilia A carriership.
DISCUSSION
This brief report demonstrates a number of important points which can optimize hemo-
philia care. Firstly, lack of awareness that a significant bleeding phenotype in moderate 
hemophilia patients indicates necessity of prophylaxis. Secondly, the pitfalls of only 
sporadic FVIII:C testing and thirdly, omission of DNA analysis to support diagnoses and 
to safeguard genetic counseling in a!ected families. Moreover, it underlines the impor-
tance of centralization of hemophilia care in order to safeguard expertise.
If hemophilia is suspected due to excessive bleeding or due to a family history of the 
bleeding disorder, repetitive FVIII:C testing is indicated. Especially if clinical symptoms 
do not correlate with test results. FVIII:C test results can be influenced by di!erent pre-
analytical variables: di!icult venipuncture, filling of sodium citrate tube, temperature, 
storage as well as type of assay.5-7 These factors may result in unprecise coagulation fac-
tor activity measurements. In addition, it is well-known that discrepancies exist between 
FVIII:C results established by one-stage or chromogenic assay.8,9 In this brief report, 
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only one-stage assay was performed to test FVIII:C, venipunctures were performed by 
experienced medical professionals and samples were most probably processed within 
two hours. However, inter-and intravariation of test results is unavoidable. Therefore, 
external quality control assessment programs are essential to improve laboratory per-
formance and reproducibility of test results. However, both laboratories described, par-
ticipate in such an international program (ECAT external quality assessment program) 
with excellent performance and Z scores between -2 and 2.
Initiating prophylaxis in patients with moderate hemophilia is not clearly described in 
international guidelines. The Nordic guideline prescribes primary prophylaxis in moder-
ate hemophilia when FVIII:C/FIX:C is 0.01-0.02 IU mL-1. However, our experience is that 
most patients with these low plasma concentrations do not experience spontaneous 
bleeding. WFH guidelines prescribe short-term prophylaxis to decrease bleeding o"en 
in combination with intensive physiotherapy.2 In the Netherlands, patients with moder-
ate hemophilia and multiple spontaneous bleeding episodes are prescribed intermit-
tent ‘periodic’ prophylaxis. Consequently, amount and dosing interval of treatment is 
adjusted according to bleeding phenotype.
When diagnosing and classifying hemophilia A, it is also important to consider VWD type 
2 Normandy (type 2N), which is always characterized by low FVIII levels. This type of 
VWD is caused by mutations in the VWF gene at the FVIII-VWF binding site, and is able to 
mimic both moderate and mild hemophilia A.10,11 As VWF protects FVIII from proteolytic 
degradation, mutations in the binding site result in excessive FVIII clearance and there-
fore low FVIII:C plasma concentrations.12 VWD type 2N can be excluded or diagnosed by 
FVIII-VWF binding assay.10
DNA mutation analysis may also be able to facilitate diagnosis of hemophilia severity. 
Most frequent mutations in patients with severe hemophilia A are an intron 22 or intron 
1 inversion of F8.4,13 When these inversions are not present, complete F8 gene mutation 
screening is performed of all exons, exon-intron boundaries and F8 promotor region 
by direct Sanger sequencing. The Worldwide Factor VIII Variant Database currently 
contains more than 2000 F8 mutations in hemophilia A patients (www.factorviii-db.org). 
Nevertheless, in 2-18% of patients, no genetic abnormality is observed dependent on 
type of mutational screening.14-20 Identical mutations may result in di!erent FVIII:C base-
line values, therefore DNA mutation analysis is not always conclusive for hemophilia 
severity. However, type of mutation is still a strong predictor of the clinical phenotype.20
In conclusion, repeated measurements of FVIII:C and von Willebrand factor in certified 
laboratories, critical appraisal of clinical phenotype and hemophilia severity in centers 
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with expertise and DNA mutation analysis are essential in standard care for hemophilia 
A patients. 
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ABSTRACT
Background Both one-stage (OSA) and chromogenic substrate assays (CSA) are used to 
measure factor VIII (FVIII) activity. Factors explaining analytical variation in FVIII activity 
levels are still to be completely elucidated.
Aim The aim of this study was to investigate and quantify the analytical variation in OSA 
and CSA.
Methods Factors determining analytical variation were studied in sixteen lyophilized 
plasma samples (FVIII activity <0.01–1.94 IU/ml) and distributed by the ECAT surveys. 
To elucidate the causes of OSA variation, we exchanged deficient plasma between three 
company set-ups.
Results On average, 206 (range 164–230) laboratories used the OSA to measure FVIII 
activity and 30 (range 12–51) used CSA. The CV of OSA and CSA increased with lower 
FVIII levels (FVIII<0.05IU/ml). This resulted in misclassification of a severe haemophilia 
A sample into a moderate or mild haemophilia A sample in 4/30 (13.3%) of CSA mea-
surements, while this was 37/139 (26.6%) for OSA. OSA measurements performed with 
reagents and equipment from Werfen showed slightly lower FVIII activity (0.93, IQR 
0.88–0.98 IU/ml) compared to measurements with Stago (1.07, IQR 1.02–1.14 IU/ml) and 
Siemens (1.03, IQR 0.97–1.07 IU/ml). Part of this di!erence is explained by the value of 
the calibrator. For CSA, the measured FVIII levels were similar using the di!erent kits.
Conclusions In the lower range (<0.05 IU/mL), analytical variation of FVIII measurements 
is high in both OSA and CSA measurements. The variation in FVIII activity levels was 
partly explained by specific manufacturers. Further standardization of FVIII measure-
ments and understanding of analytical variation is required.
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INTRODUCTION
Correct classification of haemophilia A severity is important as treatment intensity is 
based on categorisation 1. Severe (factor VIII (FVIII) activity levels <0.01 IU/ml) and some 
moderate (FVIII activity levels 0.01-0.05 IU/ml) haemophilia patients receive prophylac-
tic replacement therapy to prevent spontaneous bleeding in joints and muscles while 
mild haemophilia A patients (FVIII activity levels 0.05-0.40 IU/ml) receive desmopressin 
or replacement therapy only in cases of trauma and/or surgery 1-3. Measuring FVIII activ-
ity levels accurately and reproducibly in di!erent laboratories is therefore essential. We 
recently showed that despite excellent performance in the ECAT external quality assess-
ment programme, between-laboratory variation may result in di!erent FVIII levels, and 
consequently, in misclassification of haemophilia severity 4. Limited between-laboratory 
variation in FVIII activity levels is also of importance for the monitoring of treatment in 
patients with haemophilia A, as specific target FVIII activity levels should be maintained 
around surgery and bleeding episodes 1,2,5.
Two assays are widely used to measure FVIII activity: the one-stage assay (OSA) and the 
two-stage chromogenic substrate assay (CSA). Most laboratories use the OSA, which 
is based on the activated partial thromboplastin time (APTT), using the time until clot 
formation as its endpoint 6. In the CSA, the coagulation system is triggered resulting in 
the generation of factor Xa (FXa) 7. In the second step of this test, FXa hydrolyses a chro-
mogenic substrate causing a colour change, which reflects the amount of FVIII activity 
le" in the patient sample. The endpoint in the CSA di!ers from that in OSA, as the CSA 
measures extinction at a plateau phase. Discrepancies in FVIII activity levels have been 
extensively reported between these two assays, depending on the mutation in F8 gene 
8-10.
Nowadays, reagents and equipment to perform FVIII activity measurements are widely 
available. The use of varying products may partially explain the between-laboratory 
variation in FVIII results. However, it is still unclear what the precise impact is of varying 
in reagents and equipment on the variability of FVIII activity measurements 11-14. A pos-
sible explanation may be that particular companies provide the majority of products 
applied for the haemostatic testing which is standard in haemophilia. Most reports focus 
on the specific reagents of one company,12,15-17 rather than analysing a test system from 
one company which consists of calibrator, activator, deficient plasma, and equipment. 
As this is o"en the case in real life situations, causal factors leading to the variation in 
FVIII activity levels should be investigated more extensively.
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To improve quality of measurements in haemostasis laboratories, laboratories follow 
international guidelines and participate in external quality control surveys. The data 
from the ECAT external quality assessments indeed shows that laboratories use all 
components for the FVIII assays from one company in a majority of cases. Therefore, 
ECAT data is highly suitable to investigate the influence of company set-ups on FVIII 
activity level variation. The aim of this study is to investigate and quantify variation in 
FVIII activity when testing by OSA and CSA in surveys conducted by the ECAT foundation. 
In addition, we studied e!ects of replacement of selected reagents in the OSA with those 
from another company on FVIII results.
MATERIAL AND METHODS
Quantifying variation in FVIII activity measurements
More than 200 laboratories working in the field of haemostasis and thrombosis partici-
pate in the ECAT external quality assessment programme for FVIII. Four times per year, 
two lyophilized plasma samples are distributed. To quantify the variation in FVIII activity 
measurements, we selected sixteen samples 1) with FVIII activity levels between <0.01 
IU/ml and 1.94 IU/ml (consensus values), 2) measured by more than 10 laboratories 
by OSA or CSA, and 3) measured between 2010 and 2016. As expected, we found that 
most laboratories use the calibrator, activator, deficient plasma and equipment from 
one company in the OSA. Therefore, three groups were created from the three largest 
companies to compare the CVs in the OSA: 1) Siemens, 2) Stago and 3) Werfen.
To investigate the impact of variation on hypothetical haemophilia severity diagnoses 
which are solely based on laboratory results, FVIII activity levels were subsequently 
classified according to severity type as stated by the World Federation of Haemophilia 1.
Impact of test system on FVIII activity levels in the OSA
From the ECAT external quality assessment programme, four plasma samples were cho-
sen with di!erent FVIII activity levels to investigate the influence of the test system on 
the FVIII activity levels. To cover the range of FVIII activity measurements, the following 
samples from the ECAT surveys were chosen: 1) a severe haemophilia A patient sample 
(consensus value FVIII<0.01 IU/ml), a mild haemophilia A patient sample (consensus 
value FVIII 0.16 IU/ml), a borderline haemophilia A/low FVIII activity sample (consensus 
value FVIII 0.42 IU/ml) and a sample with normal FVIII activity levels (consensus value 
FVIII 1.00 IU/ml). The FVIII activity levels were measured by laboratories participating in 
the ECAT surveys. Next, groups were created of laboratories using calibrator, activator, 
deficient plasma and equipment from one company to investigate the impact of the test 
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system on FVIII activity levels. When the reported FVIII activity levels were below 0.01 
IU/ml, they were considered in the analysis as 0.005 IU/ml. To compare the FVIII activity 
levels between the three companies we used the Kruskal Wallis test as the data were not 
normally distributed. All statistics were performed using SPSS statistics for Windows, 
version 24.0 (IBM Corp, Armonk, NY, USA). A p-value of <0.05 was considered statistically 
significant.
Impact of test system on FVIII activity levels in the CSA
The impact of di!erent test systems in the CSA was also investigated. FVIII activity levels 
were compared between Chromogenix Coamatic, Hyphen Biomed and a test system 
from Siemens in the four plasma samples as described under the subheading of ‘Impact 
of test system on FVIII activity levels in the OSA’. The Kruskal Wallis test was performed 
to analyse the data.
Contribution of deficient plasma and calibrator
As not all laboratories use complete packages from one manufacturer, deficient plasma 
or a calibrator from another company may explain the variation in FVIII results. Unfor-
tunately, this could not be investigated in the ECAT surveys, as most laboratories use 
all the components in the test system from one company. For this reason, we varied in 
deficient plasma on three di!erent machines and its reagents as shown below in table 
1. Calibration curves were created in these set-ups. Using these calibration curves, FVIII 
activity levels were measured in duplicate in three samples; one sample with normal 
FVIII activity levels (consensus value FVIII 1.00 IU/ml), mild haemophilia A (consensus 
value FVIII 0.34 IU/ml) and moderate haemophilia A (consensus value FVIII 0.04 IU/ml).
The influence of the calibrator was investigated by measuring the FVIII activity levels 
in duplicates from the calibrator of Werfen (HemosIL Cal Plasma) and Stago (STA-C.K. 
Prest) in the Siemens set-up as described in table 1. As these calibrators have assigned 
values, we compared the measured FVIII activity levels of the calibrators with their as-
signed values.
Table 1. Set-up of the di"erent packages when varying in deficient plasma.
Company
Siemens Stago Werfen
Calibrator Standard Human Plasma STA-Unicalibrator HemosIL Cal Plasma
Activator FVIII Actin FS STA-C.K. Prest APTT-SynthASil
Deficient plasma FVIII deficient STA Immunodef VIII FVIII Def. Plasma
Equipment CS 5100 Sysmex STA-R Max ACL TOP500
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RESULTS
Quantifying variation in FVIII activity measurements
In the di!erent surveys, on average, 206 (range 164 – 230) laboratories reported results 
from analyses that used the OSA to measure FVIII activity and 30 (range 12 – 51) labora-
tories used the CSA. In surveys with lower FVIII activity levels, the CV was higher (figure 
1A). When comparing FVIII levels measured by OSA with the CSA, the CV was comparable 
between the OSA and the CSA. However, the median absolute FVIII activity levels in a 
sample from a severe haemophilia A patient were similar in the OSA and CSA, with FVIII 
activity levels of 0.005 IU/ml (IQR 0.005 – 0.03 IU/ml) for the CSA and 0.005 IU/ml (IQR 
0.005 – 0.01 IU/ml) for the OSA. When comparing the CV between the laboratories using 
reagents from three companies for the OSA, similar patterns were observed. However, 
separation of products from di!erent companies resulted in higher CVs than the overall 
CV with a CV up to 158% maximally for the Werfen package (figure 1B).
Impact of test system on haemophilia severity classification
The impact of this FVIII variability on haemophilia classification which is solely based 
on FVIII activity levels is significant. This is illustrated by the fact that the severe haemo-
philia A sample was classified as moderate in 37/139 (26.6%) of all OSA measurements 
(figure 2D). When classification is di!erentiated according to company in samples tested 
with OSA, 9/45 (20.0%) of the laboratories working with Siemens classified this sample 
as moderate or mild haemophilia while these percentages were 18/38 (47.4%) for Stago 
and 10/56 (17.9%) for Werfen. Only a small number of laboratories measured FVIII activ-
ity levels with CSA. Overall with CSA, 4/30 (13.3%) classified the severe haemophilia A 
sample as moderate or mild. When results are di!erentiated according to company, mis-
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Figure 1. The coe"icient of variation (CV) is higher when FVIII activity levels are lower. A)The CVs were calculated for 
both one-stage assay (OSA) and chromogenic stage assay (CSA). The circles indicate the CVs calculated from measure-
ments with the one-stage assay (OSA). The squares reflect the CVs calculated from measurements with the chromogenic 
substrate assay (CSA). B) The CV of the OSA was also calculated when FVIII activity levels were measured with products 
from Siemens (circles), Stago (squares), and Werfen (triangles). 
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classification was observed in 1/8 (12.5%) for Chromogenix, in 2/14 (14.3%) for Hyphen 
and in 1/8 (12.5%) for CSA testing with Siemens products. In conclusion, laboratories 
using CSA misclassified severe haemophilia A patients less o"en. However, the number 
of CSA measurements is small.
Impact of test system on FVIII activity levels in the OSA
FVIII activity levels were analysed for the three major companies and shown in figure 
3. In a sample from a healthy person (figure 3A), FVIII activity levels measured with 
products from Werfen (median 0.93, IQR 0.88 – 0.98 IU/ml) were lower than FVIII activity 
levels measured by products from Stago (median 1.07, IQR 1.02 – 1.14 IU/ml) or Siemens 
(median 1.03, IQR 0.97 – 1.07 IU/ml). We also observed this trend in a sample with 0.42 
IU/ml FVIII (figure 3b). The di!erences between the three manufacturers in the samples 
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Figure 2. The distribution of the FVIII activity levels measured by OSA. FVIII levels are shown when measured with 
company set-ups from Siemens, Stago or Werfen.
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with lower FVIII activity levels were minimal, however, small di!erences may have a 
large clinical impact.
We also investigated the influence of di!erent activators in the set-up of all products 
from Siemens. This company had an activator based on ellagic acid and one based on 
silica. In addition, phospholipid concentrations di!er between these activators. We 
were able to compare these activators since enough participants in the ECAT survey 
used these activators. We observed equal FVIII activity values between the activators in 
all four plasma samples (supplementary figure 1).
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Figure 3. Combination of deficient plasma, equipment, calibrator and activator from Werfen causes lower FVIII ac-
tivity levels when FVIII >0.40 IU/ml compared to Stago and Siemens. The red dots are the results from each laboratory. 
The black line represents the median. The error bars represent the interquartile range. Statistical significance is indicated 
as *p <0.05, **p < 0.01, *** p<0.001.
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Impact of test system on FVIII activity levels in the CSA
For the CSA, three kits were most o"enly used: 1) Chromogenix Coamatic (n = 8 – 13), 2) 
Hyphen Biomed (n = 14 – 23) and 3) FVIII Chromogenic assay from Siemens (n = 7 – 10). 
We compared the FVIII activity levels obtained by the three most commonly used kits 
and observed no consistent di!erences in FVIII activity levels between the kits (figure 
4). Some small di!erences were found as the kit from Siemens had higher FVIII activity 
levels in the normal sample (median 1.02, IQR 0.98 – 1.09 IU/ml) compared to the kit 
from Hyphen Biomed (median 0.94, IQR 0.88 -0.98 IU/ml).
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Figure 4. No consistent di"erences in FVIII activity levels between mostly wide used chromogenic assays. The red 
dots are the results from each laboratory. The black line represents the median. The error bars represent the interquartile 
range. Statistical significance is indicated as *p <0.05, **p < 0.01, *** p<0.001.
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E"ect of deficient plasma on FVIII activity
A possible explanation for the variation in the OSA may be variation in the behaviour of 
the deficient plasma. Deficient plasma was therefore also exchanged between company 
set-ups. We observed that using deficient plasma from another company did not influ-
ence FVIII activity levels in samples of a moderate haemophilia A patient or in samples 
containing FVIII activity levels around 0.40 IU/ml FVIII (figure 5). However, in a sample 
from a healthy person, Stago deficient plasma causes slightly lower FVIII results. For 
example the FVIII activity level in a Siemens set-up using Stago deficient plasma results 
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Figure 5. Exchange of deficient plasma into a system set-up with equipment of another company does not change 
the FVIII activity levels. Deficient plasma was exchanged and used in the OSA set-up of another company. Samples mea-
sured with Werfen equipment had lower FVIII activity levels compared to samples measured with Siemens or Stago. Tri-
angles represent FVIII activity levels measured with a deficient plasma from Werfen. Squares represent FVIII activity levels 
measured with a deficient plasma from Stago. Circles represent FVIII activity levels measured with a deficient plasma from 
Siemens. 
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in a FVIII level of 1.00 IU/ml, while Siemens deficient plasma resulted in 1.11 IU/ml and 
Werfen in 1.09 IU/ml FVIII. More importantly, results obtained with Werfen equipment, 
were in general lower compared to FVIII results acquired from Stago and Siemens equip-
ment. The average FVIII activity of the normal sample measured with Werfen equipment 
was 0.86 IU/ml while this was 1.08 IU/ml for Stago and 1.07 IU/ml for Siemens. This 
experiment shows that not only FVIII deficient plasma but other causes may have an 
e!ect on the variation in FVIII measurement.
Di"erences in calibrator
The influence of the calibrator was determined by measuring the FVIII activity in each 
calibrator and comparing the measured FVIII activity value to the assigned value from 
the manufacturer, based on the WHO international standard. The FVIII levels in both the 
STA-Unicalibrator and the HemosIL calibrator plasmas were measured in duplicates on 
the Siemens set-up as described in table 1. The assigned calibration value was 1.10 IU/
ml and 0.98 IU/ml for the STA-Unicalibrator and the HemosIL, respectively, while the 
measured FVIII activity levels of these calibrators were 1.21 IU/ml and 1.12 IU/ml. As 
these values di!ered from the assigned value, it may be that the calibrator is one of the 
causes that results in the variation in FVIII activity measurements.
DISCUSSION
The aim of this study was to quantify and understand in more detail the variation in FVIII 
activity measurements when testing by OSA and CSA in surveys conducted by the ECAT 
external quality control. We showed that the CV in FVIII measurements has an inverse 
relationship with FVIII activity levels. In addition, measurements performed with OSA 
from the Werfen package showed lower FVIII activity levels compared to measurements 
with the Stago and Siemens package. The explanation may be due to di!erences in as-
signed values to the calibrator.
The results of this study showed that the variation between laboratories is higher when 
FVIII activity levels are lower, both in the OSA and CSA. These results are consistent with 
the results by Verbruggen et al. in 2008, who also showed a J-shaped relationship be-
tween FVIII activity levels and CV, for FVIII results predominantly from the OSA 12. In their 
study, the CV increased strongly below 0.20 IU/ml with a maximal CV between 30% and 
40%. Our study demonstrated much higher CVs with a maximum of 121%. This may be 
due to the fact that Verbruggen et al. showed the CVs for samples with FVIII activity levels 
between 0.10-0.20 IU/ml and not lower. Furthermore, it may be that that haemophilia 
treatment centres may be more accurate in general and may more o"en perform both 
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OSA and CSA. A subanalysis was performed comparing the variability of the two assays 
with the data from centres carrying out both assays and no di!erence in CV was observed 
(supplemental figure 2). The CV increases substantially in samples with low FVIII activ-
ity levels (figure 1), although absolute di!erences in FVIII activity levels remain small. 
Therefore, it is important to realise, that although these di!erences are small, they have 
significant clinical consequences as early initiation of prophylactic treatment is largely 
dependent on test results and subsequent classification of haemophilia severity.
FVIII activity measurements were slightly lower when measured with products from 
Werfen, but statistically significant. It was impossible in the ECAT surveys to evaluate the 
cause of this lower FVIII activity by evaluating each component of the OSA separately, as 
laboratories o"en utilise calibrator, activator, deficient plasma and equipment from one 
manufacturer. We attempted to specify the cause of this variation in FVIII measurements 
by evaluating deficient plasmas from di!erent companies (figure 5) in separate experi-
ments. No consistent di!erences were observed when exchanging deficient plasma, e.g. 
deficient plasma from Stago in a Siemens set-up. Despite the fact that small di!erences 
were found, results should be interpreted with caution. In general, a small amount of fac-
tor concentrate may still be present in plasma samples derived from severe haemophilia 
A patients due to prior treatment and an insu!icient wash out period, thus influencing 
FVIII activity levels. In addition, the metrological traceability is only based on a consen-
sus model and no golden standard is available for FVIII measurements. This again raises 
the question how to perform haemophilia classification based on the measured FVIII 
levels as it is still unclear which FVIII activity assay is most optimal.
Another cause for the variation in OSA FVIII measurements may be the calibrator. As we 
found a higher FVIII activity value of the Werfen calibrator in the Siemens set-up, 1.21 IU/
ml instead of the assigned 0.98 IU/ml, this may lead to an underestimation of FVIII levels 
in the Werfen package, explaining the lower FVIII activity results that we have observed. 
However, as previously mentioned, we do not know the true values. It is important to 
realise that despite the fact that companies calibrate their reference material against 
plasma FVIII international standards, di!erences may still be present in FVIII values 
between the various test systems.
Several other hypothetical explanations exist which may explain variation in both assays. 
Firstly, of course, preanalytical variables may influence the measurements 18,19. However 
in the ECAT surveys, these preanalytical variables are not applicable as all laboratories 
receive the same lyophilized plasma sample. Nevertheless, di!erences in dissolving 
lyophilized plasma may also be considered a preanalytical variable. Secondly, variation 
in characteristics of di!erent batches of reagents, deficient plasmas and calibrators 
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may also cause di!erences in FVIII activity levels. In the ECAT surveys, many di!erent 
lot numbers were used by the di!erent laboratories, and therefore we do not expect 
that typical properties of a single lot will be able to influence the results from the ECAT 
surveys. Finally, previous studies have shown that some activators (STA Cephascreen 
(Stago) and Actin FS (Siemens)) are not optimal in diagnosing severe haemophilia A 
patients which may also have influenced the FVIII activity levels found in this study 12.
High between-laboratory CVs may influence diagnoses of haemophilia A patients 
between hospitals as reported previously 4. Already, small absolute di!erences in FVIII 
activity may result in misclassification and suboptimal treatment. This emphasizes the 
importance of the following three aspects in haemophilia management 1) performance 
of other relevant tests such as DNA mutation analysis aid in classification as well as 
repeated testing, taking lowest levels as basis for treatment; 2) adjustment of treatment 
is obligatory when test results do not correspond with clinical symptoms; and 3) treat-
ment of haemophilia patients in certified and specialized centres in which (paediatric) 
haematologists specialized in rare bleeding disorders and the diagnostic criteria and 
clinical presentation of these disorders is of utmost importance. Laboratories should 
also be aware that incorrect patient diagnosis is still possible despite excellent analytical 
performance in quality control surveys. In addition, to reduce the large between labora-
tory CV both in the OSA and CSA, standardization is required for example by an external 
quality control as the ECAT foundation. Current developments in method harmonization 
may also reduce the large between-laboratory variability.
In conclusion, FVIII activity levels are negatively associated with CV for both the OSA and 
CSA. The variation in the OSA may be attributed to the di!erent components used in 
current FVIII assays. As no golden standard is available for FVIII measurements, it is not 
possible to judge which result is superior. Future studies focusing on standardization of 
FVIII measurements and in depth education on available tests are required to further 
improve haemophilia diagnosis and patient management.
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ABSTRACT
Replacement therapy with clotting factor concentrates (CFC) is the mainstay of treatment 
in hemophilia. Its widespread application has led to a dramatic decrease in morbidity 
and mortality in patients, with concomitant improvement of quality of life. However, 
dosing is challenging and costs are high. This review discusses benefits and limitations 
of pharmacokinetic (PK)-guided dosing of replacement therapy as an alternative for cur-
rent dosing regimens. Dosing of CFC is now primarily based on body weight and based 
on its in vivo recovery (IVR). Benefits of PK-guided dosing include individualization of 
treatment with better targeting, more flexible blood sampling, increased insight into 
association of coagulation factor levels and bleeding, and potential overall lowering 
of overall costs. Limitations include a slight burden for the patient, and availability of 
closely collaborating, experienced clinical pharmacologists. 
45
Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?
HEMOPHILIA AND CURRENT TREATMENT
Background of the disease
Hemophilia A and B are X-linked inherited bleeding disorders characterized by deficien-
cies of factor VIII (FVIII) and factor IX (FIX), respectively. Prevalence is estimated at 1 in 
5,000 male births for hemophilia A and 1 in 30,000 male births for hemophilia B.1,2 FVIII 
and FIX enhance formation of thrombin and consequently stabilize the hemostatic clot 
by increased fibrin formation. Disease severity is classified according to residual FVIII 
or FIX coagulation activity in plasma.3 Mild hemophilia patients have FVIII or FIX levels 
of 0.05-0.40 IU mL-1, moderate patients FVIII or FIX levels of 0.01-0.05 IU mL-1 and severe 
patients FVIII or FIX levels of less than 0.01 IU mL-1. Mild hemophilia is characterized by 
an increased risk of bleeding a"er trauma or surgery. Moreover, severe as well as moder-
ate hemophilia patients su!er from spontaneous bleeding or bleeding a"er minimal 
trauma in muscles and/or joints, potentially resulting in disabling arthropathy.4 Strik-
ingly, bleeding phenotype di!ers between hemophilia patients with identical baseline 
FVIII or FIX levels and is probably influenced by inter-individual variation in patient char-
acteristics such as age, body weight, modifying factors within the hemostatic system, 
behavioral factors and daily (sporting) activities and other yet unidentified factors.5-10 In 
addition, it may be influenced by inter-individual variation of half-life of clotting factor 
concentrates (CFC) administered either prophylactically or on demand (Table 1). 
Table 1. Factors influencing bleeding phenotype in hemophilia patients 
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Current treatment with replacement therapy
Replacement therapy with CFC can be given to prevent spontaneous or repetitive 
bleeding (prophylaxis), or “on demand” to treat acute bleeding and prevent bleeding 
at the time of dental or surgical procedures. Current CFCs are either of recombinant or 
plasma-derived origin. Prophylaxis is the mainstay of treatment in hemophilia. Its intro-
duction has dramatically changed the lives of many hemophilia patients. Consequently, 
hemophilia has evolved from a crippling disease with a shortened life expectancy into 
a disease with a normal life expectancy, significantly less joint arthropathy and accept-
able quality of life.11,12 
Prophylaxis
Prophylaxis was introduced in 1965 by Ahlberg and is based on the observation that 
moderate hemophilia patients with FVIII or FIX levels above 0.01 IU mL-1 have far fewer 
joint bleeds and less subsequent arthropathy.13 Therefore, it was reasoned that joint 
bleedings could be prevented in severe hemophilia by keeping FVIII and FIX levels above 
0.01 IU mL-1. To achieve this, CFCs must be regularly infused generally two to four times 
a week in hemophilia A and one to three times a week in hemophilia B.14-17 Prophylactic 
treatment profoundly reduces frequency of bleeding and improves joint status as dem-
onstrated by Manco Johnson et al. in a randomized controlled trial.11 Various guidelines 
for prophylaxis are available of which Table 2 shows a selection of those most o"en 
applied. The e!icacy of prophylaxis in preventing joint bleedings is largely dependent 
on maintaining minimal FVIII and FIX trough levels of 0.01 IU mL-1 in the patient. More-
over, time spent below trough levels is associated with number of bleeding events.18 
However, in standard clinical practice, trough levels are rarely measured and dose and 
Table 2. Prophylactic dosing regimens for hemophilia A and B. 
Prophylaxis Hemophilia A Hemophilia B
Dose 
(IU kg-1)
Frequency dosing
(n/ week)
Dose 
(IU kg-1)
Frequency dosing
(n/ week)
Utrecht protocol-Dutch
(Low dose prophylactic 
regimen) 14 
15-30 three 15-30 two 
Malmö protocol – Nordic 
(High dose prophylactic 
regimen) 17 
25-40 three 25-40 two 
UKHCDO 16 25-50 four Not provided*
WFH 15 According to 
Utrecht or Malmö 
protocol
According to 
Utrecht or Malmö 
protocol
*Recommendations for patients with hemophilia B are not provided given the paucity of published evidence.
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frequency of prophylactic infusions are only adjusted when spontaneous or frequent 
bleeding occurs. 
On demand treatment
When patients are treated “on demand” either for acute bleeding or in a dental and/or 
surgical setting, dosing of CFC is aimed to achieve FVIII and FIX levels above a certain 
threshold/ trough and below a certain maximum to avoid waste of CFC and high costs 
without clinical e!ect according to various guidelines (Table 3). 
More specifically, when acute bleeding occurs FVIII and FIX peak levels are generally 
considered particularly important, although they are rarely monitored. Targeted peak 
levels are dependent on both severity and location of bleeding. In Dutch guidelines14, 
FVIII or FIX peak levels of 0.30 IU mL-1 for minor bleeds, 0.50 IU mL-1 for severe bleeds 
and 1.00 IU mL-1 for life threatening bleeds are targeted. In severe or life threatening 
bleeds, it is more important to take trough levels into account. These FVIII and FIX levels 
are sometimes monitored but o"en merely estimated, and maintained based on the 
opinions of the treating physician. In the perioperative setting, mainly trough levels 
are considered important. Although, at initiation of surgery a specific peak FVIII and FIX 
range is targeted according to all guidelines. Overall, targeted perioperative FVIII and 
FIX trough levels depend on the invasiveness of the dental and/or surgical procedure 
and postoperative day, with e.g. Dutch guidelines prescribing FVIII or FIX trough levels 
of 0.80-1.00 IU mL-1 during the first 24 hours a"er surgery; 0.50-0.80 IU mL-1 1 to 5 days 
(24-120 hours) a"er surgery; and 0.30-0.50 IU mL-1 >5 days a"er surgery (Table 3). 
Peak FVIII and FIX levels are estimated based on average in vivo recovery (IVR) of FVIII 
or FIX concentrates and amounts of CFC (IU) infused per kilogram body weight. This 
IVR-based dosing originates from studies that show that each infused unit of CFC per 
kilogram results in a mean increase of 0.02 IU mL-1 for FVIII and 0.01 IU mL-1 for FIX.9,19 
Application of this formula only provides a rough estimate of the maximum plasma 
concentration of FVIII and FIX a"er infusion. More explicitly, it does not take the phar-
macokinetics (PK) of administered CFC of the individual patient into account, e.g., clear-
ance, volume of distribution, and half-life (Figure 1). Application of these PK parameters 
results in a more precise estimate of peak FVIII and FIX but also enables calculation of 
FVIII or FIX levels and the formulation of recommendations on frequency and timing of 
dosing of FVIII and FIX concentrates. 
When describing PK of the various CFC in hemophilia, di!erences are apparent between 
products. In both recombinant and plasma-derived FVIII concentrates, average half-life 
is estimated at 10.4 hours [95% CI 7.5-16.5] in adults and 9.4 hours [95%CI 7.4-13.1] in 
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Table 3. Target ranges with peak and trough FVIII and FIX levels and duration of administration ac-
cording to a selection of available guidelines. 
Hemophilia A Hemophilia B
Predefined 
target ranges
(IU mL-1)
Duration
(days)
Predefined 
target ranges
(IU mL-1)
Duration
(days)
Dutch 14
Major surgery
Preoperative 0.80-1.00 0.80-1.00
Postoperative 0.80-1.00 1 0.80-1.00 1
0.50-0.80 2-5 0.50-0.80 2-5
0.30-0.50 >6 0.30-0.50 >6
Minor surgery
Preoperative 0.80-1.00 0.80-1.00
Postoperative >0.50 Depending on 
procedure
>0.50 Depending on 
procedure
Nordic 17
Major surgery
Preoperative 0.70-1.00 0.70-1.00
Postoperative 0.60-0.80 1-3 0.60-0.80 1-3
0.40-0.60 4-6 0.40-0.60 4-6
0.30-0.40 7-9 0.30-0.40 7-9
Minor surgery
Preoperative >0.50 >0.50
Postoperative 1-5 depending 
on procedure
1-5 depending 
on procedure
WFH 15 No significant resource constraints
Major surgery
Preoperative 0.80-1.00 0.60-0.80
Postoperative 
0.60-0.80 1 - 3 0.40-0.60 1 - 3
0.40-0.60 4 - 6 0.30-0.50 4 - 6
0.30-0.50 7 - 14 0.20-0.40 7 -14
Minor surgery
Preoperative 0.50-0.80 0.50-0.80
Postoperative 0.30-0.80 1 - 5 0.30-0.80 1 - 5
Significant resource constraints
Major surgery
Preoperative 0.60-0.80 0.50-0.70
Postoperative 0.30-0.40 1 - 3 0.30-0.40 1 - 3
0.20-0.30 4 - 6 0.20-0.30 4 - 6
0.10-0.20 7 - 14 0.10-0.20 7 -14
Minor surgery
Preoperative 0.40-0.80 0.40-0.80
Postoperative 0.20-0.50 1 - 5 0.20-0.50 1 - 5
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children.20 This lower half-life in children can be explained by a higher clearance of FVIII 
in childhood probably due to the fact that VWF levels increase with age.21 Contrastingly, 
no relationship between age and terminal half-life is observed for FIX concentrates.22 
Di!erences in PK of current FVIII and FIX concentrates are also significant. FVIII clearance 
is lower than FIX clearance (2.4-3.4 mL h-1 kg-1 versus 3.8-8.4 mL h-1 kg-1) 23, due to the 
binding of FVIII to its carrier protein VWF which protects FVIII from proteolytic degrada-
tion.24,25 
Although, FVIII has a lower clearance in comparison to FIX, FIX has a much larger volume 
of distribution (Vd). This larger volume of distribution of FIX is due to FIX binding to 
the vascular endothelium and di!usion into interstitial fluid on account of its lower 
molecular weight when compared to FVIII (FIX: 57 kDa ; FVIII: 280 kDa).26,27 This results 
in a longer half-life for FIX compared to FVIII (18-34 hours and 11-16 hours, respectively) 
as half-life is calculated roughly by t1/2 = 0.693*Volume of distribution (Vd)/ clearance 
(CL).23 
Limitations of current treatment guidelines
Underlying the presently used dosing calculations is the assumption that all patients 
demonstrate similar PK of administered CFCs. However unfortunately, this is not the 
case. Bjorkman et al. were the first to report the significant inter-individual variations 
in PK a"er the administration of a standard bolus of FVIII or FIX concentrate in a large 
population. Significant di!erences were observed with regard to in vivo recovery (IVR), 
clearance and half-life with FVIII half-life varying from 6-25 hours and FIX half-life from 
25-56 hours between individuals.8,20,28,29 Collins et al. showed that the e!icacy of pro-
phylactic treatment is based on time spent above certain FVIII trough levels 30 and that 
Figure 1. Description of pharmacokinetic (PK) parameters using non-compartimental principles. A"er bolus infusion 
of clotting factor concentrate, FVIII or FIX plasma levels increase until the maximum concentration is reached (Cmax). The 
in vivo recovery (IVR) is calculated by body weight (BW) (kilograms) x observed increase in FVIII/FIX plasma levels divided 
by the dose. Half-life is derived from the clearance (Cl) and volume of distribution (Vd) and is defined as the time required 
for the concentration to halve. Finally, area under de curve (AUC) is the integral of the concentration-time curve. 
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therefore half-life and frequency of CFC dosing are more important than IVR of CFCs. 
Despite these findings, current treatment guidelines for replacement therapy are still 
based on IVR-based dosing regimens, which do not take the inter-individual variation of 
pharmacokinetics of CFCs into account. 
Furthermore, as is observed in the general population, obesity also increasingly occurs 
in hemophilia patients.31 This will result in in higher FVIII and FIX consumption if pro-
phylactic and on demand treatment is persistently based on body weight and IVR-based 
dosing regimens. Importantly, increasing body weight is not linearly associated with 
increasing volume of distribution as assumed by IVR-based dosing regimens.32 There-
fore, these higher costs of treatment may not be necessary to safeguard hemostasis. 
Obviously, current global constraints of health care budgets, obligates hemophilia com-
munities worldwide to generate dosing algorithms in hemophilia with optimal results 
for patients and minimal costs for society. 
Moreover in the perioperative setting, we recently demonstrated that current dosing 
leads to significantly lower and higher FVIII and FIX levels than targeted in hemophilia 
A and B 33, (Hazendonk et al. in preparation). In moderate and severe hemophilia A pa-
tients, a large proportion of trough and steady state FVIII levels were found to be below 
or above predefined target ranges. Specifically, 45% of FVIII measurements were below 
the FVIII target range within first 24 hours a"er surgery and 75% above the target range 
during hospitalization more than six days a"er surgery.33 Potentially, more optimal 
maintenance of perioperative target ranges could result in a reduction of 44% of CFC 
consumption, when ignoring logistical aspects of care.33 In a recent retrospective study 
on perioperative management in moderate and severe hemophilia B patients, 60% of 
FIX measurements were below target and 59% FIX levels above target during hospital-
ization more than six days a"er surgery (Hazendonk et al. in preparation). Although 
the terminology of under- and overdosing suggests putting the patient at risk which is 
not the case as perioperative complications were minimal, these data do underline the 
limitations of current dosing algorithms primarily based on body weight using IVR-based 
dosing, as well as potential cost-e!ectiveness of alternative algorithms.
PHARMACOKINETIC (PK)-GUIDED DOSING IN HEMOPHILIA
Principles of PK-guided dosing 
To address inter-individual di!erences in PK of CFC and to employ more e!ective dos-
ing, PK-guided dosing is a potential strategy. PK-guided dose-calculations are based 
on individual PK parameters in relationship to the population PK model and obtained 
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by Bayesian analysis using statistical so"ware (NONMEM®). In a population PK model 
for CFC, relationships between dose and achieved FVIII or FIX levels are described by 
PK parameters of all individuals in the population under review. This makes it possible 
to describe both inter-individual and intra-individual variability within this population 
dataset. In general, an important condition for implementing PK-guided dosing, is that 
intra-individual variability is smaller than inter-individual variability. Identified covari-
ates explaining variability can be used to further improve constructed models, while 
unknown factors are labeled as residual errors. The principal strength of PK-guided dos-
ing is that a population PK model not only represents identified covariates influencing 
PK parameters, but also takes the unknown modifiers of PK into account as they are 
described by the population data included in the model. 
Importantly, Bayesian adaptive dosing is only possible when population PK models 
are representative of the individual patient and her or his specific clinical setting. Con-
structed models should therefore comprise a wide variation in patient-related (age, body 
weight, endogenous baseline FVIII/FIX, blood group) and circumstance-related factors 
(prophylaxis, on demand dosing during hemostatic challenges such as acute bleeding 
and surgery). For example, the recently published perioperative FVIII population PK 
model showed a significantly larger peripheral volume of distribution in comparison to 
the prophylactic PK model by Bjorkman et al. (1180 ml/68 kg versus 240 ml/68 kg).8,34 
Further, to optimize current population models it is important to include o"en under-
represented patient populations, such as children and overweight/obese patients since 
PK parameters in these populations may di!er significantly. 
Construction of individual PK profiles and population PK models 
Extensive work performed by Bjorkman et al. has made PK-guided prophylactic dos-
ing with limited blood sampling in hemophilia possible.35 Prior to the construction of 
these population PK models, individual PK curves were constructed through extensive 
blood sampling (>10 samples), with an obligatory wash-out period, leaving the patient 
at potential risk of bleeding. Currently, individual PK profiles for FVIII and FIX can fortu-
nately be constructed with limited blood sampling and without a wash out period (Table 
4).35-37 Di!erent PK sampling models exist for rFIX and pdFIX, as it was already previ-
ously shown, that the PK of these two products di!er.9 Using Bayesian analysis and a 
representative population PK model, individual PK estimates can be iteratively updated, 
providing prophylactic dosing advice and prediction of achieved FVIII and FIX levels.38 
Perioperatively, several research groups have estimated preoperative loading doses of 
FVIII and FIX a"er constructing individual PK profiles.39-43 However, until recently it was 
not possible to iteratively dose patients in the perioperative setting owing to the lack of 
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population PK models for this specific setting. Construction of perioperative PK popula-
tion models for both moderate and severe hemophilia A 34 and B, mild hemophilia A 44 
and in the near future for von Willebrand disease 45 will eventually make this possible for 
several bleeding disorders. 
The most important covariate in FVIII population PK models for hemophilia A patients, 
will most likely be von Willebrand factor (VWF) as patients with blood group O have 25% 
lower VWF levels. This is supported by findings that blood group O versus non-O is a 
significant covariate of clearance in the perioperative setting, with 26% higher clearance 
rates for patients with blood group O.45 Furthermore, it was also shown by Kepa et al. 
that blood group was associated with FVIII half-life.46 However, this e!ect of blood group 
O was not previously observed in a steady state prophylactic setting 47 and therefore 
not considered to be a covariate in available prophylactic population PK models. Most 
likely, this di!erence can be explained by an increase of VWF due to inflicted endothelial 
damage and its role in the acute phase reaction a"er surgery.48 
Pharmacogenomics may also play an important role in the PK of coagulation factor 
concentrates. Many genes are known to modify the hemostatic system and the clearance 
Table 4. Limited blood sampling strategies to construct individual PK curves. 
The upper panel shows a graphic example of a Factor VIII (FVIII) concentrate PK profile. A FVIII concentrate bolus is ad-
ministrated followed by FVIII measurements (red points). Using a population PK model, FVIII plasma levels (red line) are 
calculated using individual PK parameter estimates derived from Bayesian analysis. To estimate FIX PK, similar principles 
are applied, although FIX blood sampling occurs at di!erent longer time points as FIX concentrate half-life is longer. 
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of coagulation factors. As VWF serves as carrier protein for FVIII, mutations in the bind-
ing site of VWF to FVIII can result in lower levels of FVIII, also known as von Willebrand 
disease type 2N. In addition, the R1205H mutation in the D3 domain of VWF, also known 
as VWD Vicenza, results in reduced plasma VWF levels with ultra-large VWF multimers 
and therefore leading to an accelerated clearance of both VWF and FVIII.49 Although, 
not only mutations in the VWF gene influence FVIII levels as ABO blood group has also 
a strong relation with FVIII levels. Blood group O is associated with lower FVIII levels 
compared to other blood types even when adjusted for VWF antigen.44 In addition, the 
CHARGE has consortium reported multiple genetic loci in clearance receptors of VWF 
and/or FVIII which were associated with FVIII levels, for example STXBP5 and SCARA5.50 
Furthermore, polymorphisms in one of the clearance receptors of FVIII/VWF, LRP1 gene, 
are also associated with both FVIII and VWF plasma levels.51 
Benefits of PK-guided treatment 
As early as 1997, Carlsson et al. showed benefits of a PK-guided dosing approach for 
prophylaxis.7 This small study was designed as a randomized cross-over study compar-
ing PK-guided dosing of prophylaxis with standard prophylactic dosing in 14 individuals 
during a period of two times six months. Strikingly, a reduction of CFC administration 
of 30% was achieved. The number of reported bleedings was similar in both treatment 
arms.7 Such a reduction can have a significant financial impact, since annual costs 
for replacement therapy in the Netherlands amount to more than 126 million euros.52 
Before drawing conclusions, however, it is important to prospectively evaluate these 
outcomes of PK-guided dosing in adequately designed and powered studies.53 Cur-
rently, a randomized controlled trial comparing PK-guided perioperative treatment of 
CFC in moderate and severe hemophilia A patients is in place to analyze the amount 
of CFC administered, time spent to achieve targeted FVIII levels, as well as sta! invest-
ment and costs, all in accordance with the economic health principles established by 
Hakkaart-van Rooijen.53,54 This study may result in clear conclusions regarding the cost 
e!ectiveness of PK-guided dosing.
Another benefit of PK-guided dosing is that both prophylactic and “on demand” dos-
ing will be based on actual FVIII and FIX trough and peak levels or FVIII and FIX levels 
predicted by population PK models, instead of current FVIII and FIX estimates based 
on IVR-based dosing. Furthermore, FVIII and FIX sampling can be made flexible and 
not necessarily fixed at certain time points before or a"er infusion, once models are in 
place. Moreover, PK-guidance will optimize dosing as knowledge will increase with re-
gard to the relationship between FVIII and FIX levels and bleeding in individual patients 
and patient groups. In addition, an increase in dosing will not only depend on actual 
bleeding and a reduction of dosing can be considered by the treating professional in 
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consultation with patients and parents. Importantly, the dose and frequency of CFC of 
patients on prophylaxis should only be reduced if clinically justified and impact should 
be monitored with regard to bleeding events, bleeding pattern and joint status (Table 5). 
Over time, more exact targeting of FVIII and FIX levels may also lead to reliably lowering 
of target levels of treatment. Especially in hemophilia B, studies and clinical experience 
suggest that lower target levels may be acceptable.15,55 In a recent retrospective study on 
perioperative management in moderate and severe hemophilia B patients, 60% of FIX 
measurements were below target, without clinical relevant bleeding and independent 
of the severity of surgical procedures (Hazendonk et al. in preparation). Srivastava et 
Table 5. Benefits and limitations of PK-guided dosing based on population PK models as alternative 
for body weight and IVR-based dosing regimens
Advantages  Conditions and remarks
1.  Better targeting of FVIII and FIX levels with 
minimal burden to patients. 
2. More flexible blood sampling
Although limited blood sampling decreases frequency 
of blood sampling, two/three samples for individual PK 
profile are still obligatory.
Population PK models should however be representative 
of population and specific setting.
Once PK-guided dosing is in place.
3.  Insight into association of FVIII and FIX trough 
and peak levels and bleeding
  Future possibilities to construct both PK and 
pharmacodynamic (PD) models and to further 
understand pathophysiology of hemostasis
Further development of global hemostatic assays 
measuring hemostatic potential also essential.
4.  Possibility to potentially lower FVIII and FIX 
target values, due to more reliable targeting
Intensive collaboration between experienced clinical 
pharmacologist and (pediatric) hematologist necessary. 
Realization of risks and intensive monitoring of clinical 
impact of lowering of FVIII and FIX levels obligatory.
5.  Facilitation of actual personalization of 
treatment according to lifestyle 
Continuous adaptation of dosing regimen according to 
lifestyle also necessary. Individual PK profiles must be 
potentially repeated every 3-4 years. Adherence must be 
discussed.
6. Potential reduction of overall treatment costs Prospective studies to evaluate actual impact on costs are 
obligatory.
7. Further enrichment of population PK models Intensive collaboration between experienced clinical 
pharmacologist and (pediatric) hematologist necessary.
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al. showed that lower trough FVIII (0.20-0.40 IU mL-1) and FIX (0.15-0.30 IU mL-1) levels 
0-72 hours a"er surgery were not accompanied by bleeding complications since only 
one patient experienced bleeding due to a lack of surgical hemostasis.55 Furthermore, 
International WFH guidelines for perioperative treatment in hemophilia A and B patients 
recommend FIX levels 0.20 IU mL-1 lower than FVIII levels (Table 3).15 In countries with 
significant financial constraints, even lower FIX target ranges are suggested.15 Interest-
ingly, various European guidelines do not di!er regarding perioperative target ranges for 
hemophilia A and B 14,17,56 as reported in a survey by the European Therapy Standardiza-
tion Board in 2009.57
PK-guided dosing will also facilitate individualization of dosing according to individual 
lifestyle and activities, therefore achieving true personalization of treatment. When 
targeting weekly FVIII and FIX levels, personal activities and preferences should be 
taken into account, as bleeding risk is closely related to these factors.58-60 Moreover, non-
adherence should be discussed as implementation of minimal dosing schemes may lead 
to an increased risk of bleeding.61-63 Patients and families should be aware of time points 
when factor concentrate levels are low or high and consider additional dosing when 
bleeding risk is significant. 
All benefits of PK-guided dosing are also applicable with regard to upcoming enhanced 
half-life (EHL) products. Moreover, costs of treatment will directly depend on the dose 
and frequency of treatment and therefore on individual PK and population PK param-
eters. Furthermore, the ongoing discussion of the association of trough levels and the 
role of peak levels with regard to bleeding will be made more transparent. This is espe-
cially relevant in EHL products as higher troughs will be possible and treatment peaks 
will be less frequent.64 
Limitations of PK-guided treatment
Important limitations with regard to PK-guided dosing include the requirement of close 
collaboration with a clinical pharmacologist with expertise in PK modeling. Furthermore, 
time investments by patients, parents and medical professionals may be substantial as 
individual PK profiles must be performed regularly (every three to four years depending 
on patient characteristics) and perioperative PK-guided iterative dosing requires daily 
dosing recommendations. Solutions to overcome these limitations are the availability 
of web portal-based consultancies for PK-guided dosing advice, as established by Iorio 
21, for instance, and as developed by a pharmaceutical company for the prophylactic 
setting.65 Both initiatives to implement a closer collaboration and to educate both pro-
fessionals and patients are valuable for future patient care. Transparency and reliability 
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of the data used to construct underlying population models are of course of crucial 
importance in such settings. 
FUTURE ROLE FOR PK-GUIDED DOSING OF FACTOR CONCENTRATES IN 
HEMOPHILIA CARE AND RESEARCH PERSPECTIVE
Replacement therapy has led to the high standard of hemophilia care in high-income 
countries. However, recent studies show that treatment is suboptimal; although bleed-
ing is rare, both under- and overdosing of CFC occur. We believe that PK-guided dosing 
as the alternative to body weight and IVR-based dosing, will play an important role in 
further individualization of therapy. We have summarized the anticipated improve-
ments in Table 5. 
Future research should include studies prospectively validating constructed population 
PK models but also combining PK with pharmacodynamic data (e.g. bleeding events, 
global hemostatic test results) and simulations to determine minimal FVIII and FIX levels 
required for adequate hemostasis in the individual patient and in populations. These 
data may subsequently support studies aiming at lower target levels in specific bleeding 
disorders.
There are no suggestions that implementation of PK-guided dosing will lead to an 
increased risk of inhibitor development. It is well-known that risk factors of develop-
ment are peak treatment moments in younger children, which is o"en the case in the 
perioperative period. Use of PK-guided dosing may be able to prevent extreme peaks. 
However, future studies will be needed to prove such a hypothesis.
CONCLUSION
We believe that PK-guided dosing deserves attention as a means of ensuring the indi-
vidualization of treatment in hemophilia since benefits are significant and limitations 
can be overcome. The burden for patients and parents appears to be minimal. Accord-
ingly, we call on patients, medical professionals, clinical pharmacologists, hemostatic 
laboratories and pharmaceutical companies to join hands in applying this approach for 
all CFCs, in hemophilia and other bleeding disorders requiring CFC replacement therapy. 
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SUMMARY
Background Haemophilia A is an X-linked inherited, rare bleeding disorder, caused by a 
deficiency of coagulation factor VIII (FVIII). Previous studies in prophylactic dosing have 
demonstrated that FVIII consumption can be significantly reduced by individualizing 
dosing based on combined analysis of individual pharmacokinetic (PK) profiling and 
population PK data (Bayesian analysis). So far, no studies have been performed that 
address perioperative concentrate consumption using iterative PK-guided dosing based 
on a PK population model. 
Methods The “OPTI-CLOT” trial is an open-label, prospective, multicentre randomized 
controlled superiority trial (RCT), aiming to detect a 25% di!erence in perioperative 
FVIII concentrate consumption with iterative Bayesian PK-guided dosing in comparison 
to the standard dosing procedure. Sixty haemophilia A patients # 12 years of age, with 
FVIII plasma levels $ 0.05 IUml-1 will be included requiring FVIII replacement therapy 
administered either by continuous or bolus infusion for an elective, low or medium risk 
surgical procedure.
Results The proposed study aims to investigate a novel perioperative iterative PK-
guided dosing strategy, based on a recently constructed perioperative PK population 
model. This model will potentially decrease underdosing and overdosing of clotting fac-
tor concentrate and is expected to overall reduce FVIII consumption by minimally 25%. 
Moreover, participating hospitals will gain experience with PK-guided dosing, facilitat-
ing future implementation of this intervention which is expected to optimize current 
care and reduce costs of treatment. 
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INTRODUCTION
Haemophilia A is an X-linked inherited bleeding disorder, caused by a deficiency of 
coagulation factor VIII (FVIII). Patients with severe (FVIII <0.01 IUml-1) and moderate 
severe (FVIII 0.01-0.05 IUml-1) haemophilia A experience spontaneous bleeding, mainly 
in muscles and joints, or bleeding a"er minor trauma. Prophylactic substitution of FVIII 
concentrate intravenously, several times a week, aiming for a trough level of above 0.01 
IUml-1, generally prevents severe joint damage and subsequent long term disability. 
Surgery necessitates an intensive regimen of factor replacement therapy, as factor levels 
are normalized for 7-14 days. Therefore, overall in the perioperative period, a patient 
may consume up to 15% of his regular annual use of clotting factor concentrate. Annu-
ally, overall costs of haemophilia treatment In the Netherlands are estimated at %130 
million, of which more than 90% consists of costs for concentrates 1-3. 
In the perioperative period, target trough levels dictated by National and International 
Guidelines are exceeded in the perioperative setting. This seems due to di!iculties in tar-
geting these levels but also due to the fact that doctors are inclined to dose generously 
in order to avoid low factor activity levels and subsequent bleeding risk 4-6.Treatment is 
extremely e!ective as perioperative bleeding is rare in haemophilia patients in countries 
where concentrates are adequately available. Refining of perioperative dosing strate-
gies seems warranted to optimize replacement therapy in the individual haemophilia 
patient and to increase quality of care by avoiding both under dosing and overdosing. 
Rationale: Pharmacokinetic-guided dosing may be cost-reductive 
Large inter-individual di!erences in the pharmacokinetics (PK) of FVIII concentrates 
have been demonstrated, making PK-guided dosing a potential strategy to improve 
clinical outcome and possibly cost-e!ectiveness of dosing in prophylactic, on demand 
and perioperative settings 7. Bayesian PK-guided dosing is the combined analysis of 
individual PK parameters in regard to the population parameters. Using this approach 
only three samples are needed to describe a complete PK curve 8. 
Using a Bayesian approach in the prophylactic setting, Carlsson et al. 9 reported a dose 
reduction of 30% without an increase in bleeding in a randomized cross-over study of 
two six months’ periods, comparing PK-guided dosing with standard dosing. However, 
prophylactic population PK models cannot be extrapolated to the perioperative situ-
ation, as surgery forms an uncomparable haemostatic challenge. Moreover, Longo et 
al. reported excessive FVIII consumption and clearance in 50% of surgical hemophilia 
patients due to unidentified factors 10. 
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Current perioperative management in haemophilia
In surgery, earlier studies on perioperative management in haemophilia have compared 
continuous infusion with intermittent bolus infusions. Batorova et al. 11 reviewed eleven 
case series and concluded that continuous infusion of FVIII and factor IX is safe and ef-
fective in situations requiring intensive replacement therapy such as surgery and major 
bleedings. Strikingly, there was a wide variation in targeted haemostatic levels, dosage 
regimens, modes and duration of therapy. Eight of these studies concluded that continu-
ous infusion is more cost-e!ective than intermittent bolus administration by reduction 
of total clotting factor consumption 12-19. In two studies, bolus injections were prospec-
tively compared to adjusted continuous infusions, demonstrating 30-36% reduction of 
FVIII consumption in the latter 12,19. Preoperative PK profiling was reported in 3 out of 
8 haemophilia A case series, but was not specified. 13-15,17,19,20. A perioperative study by 
Batorova and Martinowitz 12 showed that if targeted FVIII levels are actually maintained, 
a reduction of consumption and therefore costs of up to 70% may be attained. Mulcahy 
et al. 15 retrospectively evaluated adjusted continuous FVIII infusions in a single centre 
study and concluded that close monitoring of FVIII levels in itself with strict regulation 
of infusion rate alone, may significantly reduce FVIII consumption. 
So far, iterative Bayesian PK-guided perioperative dosing has not been performed as 
perioperative PK population models for clotting disorders have not been available. 
Recently, we have however constructed a population PK model from retrospective 
perioperative FVIII data 21, facilitating Bayesian adaptive dosing of FVIII in the periopera-
tive setting. We hypothesize that application of this approach may improve quality of 
haemophilia care as both underdosing and overdosing are avoided. Potentially, it will 
also decrease FVIII consumption and lower costs of treatment.
OBJECTIVE
The objective of this study is to investigate whether perioperative PK-guided dosing of 
FVIII concentrate in haemophilia A patients receiving FVIII replacement therapy using 
a Bayesian approach, leads to a significant reduction in perioperative clotting factor 
consumption. 
METHODS
Trial design
The “OPTI-CLOT” trial is a prospective, multicentre randomized controlled superiority 
trial (RCT), aiming to detect a di!erence in perioperative FVIII consumption with iterative 
PK-guided dosing in comparison to the standard dosing procedure, the latter primarily 
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based on body weight. FVIII levels will be targeted in the middle of each target range 
defined in the perioperative guidelines of the National Haemophilia Consensus, unless 
stated otherwise by treating physician. 
In all patients six weeks before surgery, a preoperative PK profile will be constructed 
using only three blood samples without a wash out period but with exact notation of 
prior doses in the week before PK profiling; individual PK parameters will be assessed 
by Bayesian analysis (Figure 1). Subsequently, patients will be randomized a"er strati-
fication according to mode of FVIII administration (continuous or bolus), type of surgi-
cal procedure (low or medium risk) and treatment centre as is usual in a multicentre 
trial and subsequently allocated to one of two perioperative treatment arms: (A) the 
intervention arm in which dosing is adjusted on basis of the individual preoperative PK 
parameter estimates and iterative perioperative Bayesian analysis; or (B) the standard 
treatment arm in which dosing regimen is established by the physician according to 
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Figure 1. Flowchart. A"er inclusion a PK profile will be constructed preoperatively prior to stratified randomization; indi-
vidual PK parameters will be assessed using Bayesian analysis. In the intervention arm dosing will be administered based 
on the individual PK parameter estimates. With daily FVIII levels available the bayesian approach will be used to iteratively 
adjust the daily dose. In the standard treatment arm dosing will be set by the treating physician according to the standard 
dosing regimen described in the National Haemophilia Consensus in the Netherlands based primarily on bodyweight with 
target plasma FVIII values as set in the Consensus, unless otherwise specified. Adjustments will be performed by the treat-
ing physician without knowledge of the preoperative profile of the patient. 
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the standard dosing regimen. At least 60 patients will be needed to detect a di!erence 
of minimally 25% in consumption of FVIII concentrate during the perioperative period 
between treatment arms. Safety is guarded by generally daily monitoring of FVIII levels, 
as is now standard procedure. Perioperative haemostasis will be assessed during the 
entire perioperative period. 
Study population
Patients will be included from six large Academic Haemophilia Treatment Centres in the 
Netherlands: Erasmus University Medical Centre Rotterdam, Academic Medical Centre 
Amsterdam, Radboud university medical centre, University Medical Centre Utrecht, 
University Medical Centre Groningen and Leiden University Medical Centre. 
Inclusion criteria: 
- Severe and moderate haemophilia A patients with FVIII levels $0.05 IUml-1;
- # 12 years of age at inclusion date;
- Undergoing elective, low or medium risk surgery as defined by surgical risk score 
(Koshy et al.22); 
- Under replacement therapy with FVIII concentrate, (plasma derived or recombinant) 
by continuous or bolus infusion; 
- Written informed consent, according to METC guidelines. 
Exclusion criteria:
- Patient with other congenital or acquired haemostatic abnormalities.
- Withdrawal of (parental) informed consent.
- Due to additional e!ect on FVIII clearance: detectable FVIII inhibiting antibodies 
(>0.2 Bethesda Units) at study inclusion.
- General medical conditions which may interfere with participation in the study.
Outcome measures
Primary endpoint: 
1. Total amount of infused FVIII concentrate (IU per kilogram) during the perioperative 
period per postoperative day (up to 14 days a"er surgery); 
Secondary endpoints: 
1. Achieved FVIII levels (IUml-1) a"er FVIII infusion. 
2. Duration of hospitalization (day of release - day of surgery/ start of continuous or 
bolus FVIII infusion); 
3. Perioperative haemostasis as quantified by standardized form; 
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4. E!ects of baseline VWF antigen, propeptide values and blood type on FVIII clearance 
and identification of other potential modifiers; 
5. Economic analysis of costs in both treatment arms. 
Interventions
Overall treatment protocol in all patients, independent of treatment arm
In all patients, a PK profile will be constructed six weeks before surgery prior to stratified 
randomization. A"er a standard bolus of FVIII of 50 IU per kilogram, FVIII levels will be 
measured in three blood samples of 1.8 ml citrate blood, withdrawn at t=4, t=24 and 
t=48 hours a"er FVIII clotting factor concentrate infusion, according to Björkman et al. 
8. The individual PK parameters are assessed by Bayesian analysis. During PK profiling, 
exact information on three prior FVIII doses before the standardized FVIII infusion will 
be gathered to predict residual FVIII level in each individual patient. Treating physicians 
and nurses will be blinded for PK profile results in both arms. 
In both treatment arms, target ranges for FVIII values will be applied as set by the 
National Haemophilia Consensus aiming for the middle of each range, unless stated 
otherwise by treating physician (table 1) 4. In all patients in both treatment arms, FVIII 
levels will be monitored as is momentarily standard clinical practice, which is generally 
daily, during the perioperative period. 
Specification of treatment arms
Trial/ Intervention arm: 
The FVIII dose prior to the start of the surgery will be based on the required FVIII target 
level according to the National Consensus and individual PK parameters as obtained 
from the preoperative PK profile according to Björkman et al.8 and exact information of 
three prior doses of FVIII concentrate preceding the date of surgery. Subsequent doses 
will be adjusted iteratively using Bayesian analysis on basis of daily therapeutic moni-
Table 1. Target trough levels of FVIII in the perioperative period according to the National Haemo-
philia Consensus 
Time postoperative Target range FVIII levels (IUml-1) OPTI-CLOT Target FVIII level (IUml-1)
Day 1 0-24 hours 0.80-1.00 0.90
Day 2-5 24-120 hours 0.50-0.80 0.65
Day >6 > 120 hours 0.30-0.50 0.40
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toring of FVIII using our own perioperative population PK model based on retrospective 
data of severe and moderate severe haemophilia patients undergoing surgery21. 
Daily therapeutic monitoring of FVIII is part of current standard clinical care and FVIII 
values will be analysed locally. Results will be blinded for the treating physician and 
nurses. The FVIII levels and administered FVIII doses will be communicated by the labora-
tories of each specific site with the clinical pharmacologist. The clinical pharmacologist 
is responsible for the calculation of the individual dose using the Bayesian approach. 
The clinical pharmacologist will send the FVIII dosing recommendations to the treating 
physician, who will subsequently adjust dosing. Target levels according to Consensus or 
otherwise set by the treating physician will be safeguarded by an unblinded haematolo-
gist with experience in haemophilia treatment. 
Trial/ Standard treatment arm: 
The standard perioperative dosing regimen, as described by the Consensus, consists of 
a FVIII bolus dose directly prior to surgery of 50 IU kg-1, followed by either continuous 
infusion or intermittent daily bolus infusions. The rate of infusion (IU hour-1) is obtained 
by multiplying the patient’s bodyweight (kg) with clearance (3-4 ml kg-1 hour-1) and tar-
get FVIII level (IU ml-1). Subsequent FVIII clotting factor concentrate dosing will be based 
on daily monitoring of FVIII levels and adjusted according to doctor’s opinion, based on 
a standard clearance of 3-4 ml kg-1 hour-1 and FVIII levels are targeted in the middle of 
each target range as set by the National Haemophilia Consensus, which decrease per 
postoperative day (Table 1) 4. Dosing adjustments will be performed by the treating phy-
sician on basis of the daily monitored FVIII levels, without knowledge of PK parameters 
collected in the individual preoperative PK profile. 
Bayesian-analysis
In the treatment arm individual PK parameters will be assessed iteratively by application 
of Bayesian analysis as implemented in the NONMEM® so"ware (Icon, Dublin, Ireland). 
For Bayesian analysis a population PK model will be used constructed on the basis of 
the PK data from an earlier retrospective perioperative study 21. Based on the derived 
individual Bayesian PK parameters an optimal dosing scheme will be calculated during 
perioperative use, taking mode of administration of concentrates (continuous or bolus 
infusion) and desired target FVIII value into account. As for continuous infusions, indi-
vidual estimates for clearance are needed. With regard to intermittent bolus infusions, 
estimates for both clearance and volume of distribution are needed.
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Sample size
Based on earlier data and economic relevance, we aim to detect a di!erence in mean 
FVIII concentrate use in IU kg-1 which equals 150 IU kg-1 or a 25% reduction in use of 
clotting factor. To study this with a power of 80% and a two-sided & of 0.05, a sample size 
of minimally 60 patients is necessary. To allow for dropouts, 65 patients will be included 
in the total study. One patient per centre, except Erasmus MC (n=5) will be treated ac-
cording to protocol to test local logistical processes. These patients will not be evaluated 
with regard to primary endpoints, only with regard to secondary endpoints.
Economic analysis will be performed from a health care perspective taking all health care 
costs into account. We will calculate and compare the costs of PK profiling consisting of: 
bolus of 50 IU kg-1 FVIII minus prophylactic doses required, time invested by haemophilia 
caretakers, two and three FVIII test samples (in standard clinical practice, usually one in 
vivo recovery FVIII level is performed), generation of PK profile by Bayesian analysis and 
perioperative iterative Bayesian analysis to the standard dosing procedure consisting of: 
establishment of treatment protocol by haemophilia expert, and perioperative dosing 
adjustment calculations by haemophilia expert. Theoretical consequences of PK pro-
filing on prophylactic dosing regimen in the following years, at one year a"er surgery, 
both reduction and increase of dosing, will also be taken into account in this economic 
evaluation. Actual medical costs will be calculated by multiplying volume of health care 
use with corresponding unit prices. Costs will be valued using the National guidelines 
for economic evaluation studies 23. 
CONCLUSION
The proposed study aims to investigate an innovative individualized perioperative PK-
guided dosing strategy, which is expected to reduce FVIII consumption and therefore 
costs by minimally 25%. Strengths of the study are the number of participating centres 
and study design. The application of both perioperative Bayesian guided dosing and a 
specific perioperative population PK model has not been performed before. Further-
more, the inclusion of children is important, as inter-individual clearance of clotting 
factor is exceptionally variable at younger ages. As a direct consequence of the study, 
participating hospitals will gain experience with PK-guided dosing facilitating future 
implementation of this promising intervention. 
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ABSTRACT
Background Von Willebrand factor (VWF) is crucial for optimal dosing of factor VIII (FVIII) 
concentrate in hemophilia A patients as it protects FVIII from premature clearance. To 
date, it is unknown how VWF behaves and what its impact is on FVIII clearance in the 
perioperative setting. 
Aim Investigate VWF kinetics (VWF antigen (VWF:Ag), VWF glycoprotein Ib binding 
(VWF:GP1bM) and VWF propeptide (VWFpp) in severe and moderate perioperative 
hemophilia A patients included in the randomized controlled perioperative OPTI-CLOT 
trial. 
Methods Linear mixed e!ects modeling was applied to analyze VWF kinetics. One-way 
and two-way ANOVA were used to investigate perioperative VWF propeptide/VWF anti-
gen ratios and associations with surgical bleeding. 
Results Fi"y-nine patients with median age of 48.8 years (IQR: 34.8–60.0) were included. 
VWF:Ag and VWF:GPIbM increased significantly postoperatively. Both blood type non-
O or medium risk surgery were associated with higher VWF:Ag and VWF:GPIbM levels 
compared to blood type O and low risk surgery. VWFpp/VWF:Ag was significantly higher 
immediately a"er surgery than 32-57 hours a"er surgery (p<0.001). Lowest VWF:Ag quar-
tile (0.43–0.92 IU/mL) was associated with an increase of FVIII concentrate clearance of 
26 mL/h (95% CI 2–50 mL/h) compared to highest VWF antigen quartile (1.70–3.84 IU/
mL). VWF levels were not associated with perioperative bleeding F(4,227)=0.54, p=0.710. 
Conclusion VWF:Ag and VWF:GPIbM levels increase postoperatively, most significantly 
in patients with blood type non-O or medium risk surgery. Lower VWF antigen levels did 
not lead to clinically relevant higher FVIII clearance. VWF antigen or VWF:GPIbM levels 
were not associated with perioperative hemorrhage. 
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INTRODUCTION
A deficiency of coagulation factor VIII (FVIII) leads to diagnosis of hemophilia A, an X-
linked bleeding disorder characterized by bleeding typically in joints and muscles, or 
bleeding a"er minor trauma and/or surgery. Mainstay of treatment is replacement ther-
apy with FVIII concentrates which is administered both prophylactically in more severely 
a!ected patients, and on demand to treat bleeding events or to prevent bleeding during 
dental or surgical procedures in all patient categories 1. Previously, we reported a study 
in 119 hemophilia A patients undergoing 198 surgeries and showed that perioperative 
FVIII concentrate dosing is challenging using current guidelines based on bodyweight 
2. In this retrospective study, 45% of all FVIII levels measured in the first 24 hours a"er 
surgery were below target levels as prescribed in Dutch guidelines 3, with a hypothetical 
higher risk of bleeding. In addition, 75% of FVIII levels measured 120 hours a"er surgery 
were above targeted FVIII levels with concomitantly unnecessary higher treatment costs. 
As von Willebrand factor (VWF) protects FVIII from proteolytic cleavage, premature acti-
vation and clearance from the circulation, VWF is crucial to achieve adequate FVIII levels 
during FVIII concentrate dosing. Importantly, ratio between VWF propeptide (VWFpp) 
and VWF antigen (VWF:Ag) can be used as a marker for both VWF synthesis, secretion 
and clearance. More specifically, VWF:Ag and VWFpp are secreted equimolarly but are 
independently cleared with di!erent half-lives of 8-12 hours and 2 hours, respectively 
4,5. We hypothesized that specific knowledge on how VWF behaves and influences FVIII 
clearance in perioperative hemophilia A patients is relevant to optimize FVIII dosing. 
The role of VWF in the perioperative period has previously been investigated in 30 
healthy individuals, mainly women, undergoing orthopedic surgery by Kahlon et al. 6. 
This report showed that both VWF:Ag and VWF ristocetin cofactor activity (VWF:RCo) 
decrease during a surgical procedure and increase directly a"erwards with concomitant 
decrease and increase of FVIII levels. These results however cannot be translated to our 
population due to gender di!erences, as primarily men are diagnosed with hemophilia. 
In addition, levels of VWFpp were not measured in these patients. Moreover, FVIII in 
our population is derived from replacement therapy and therefore not released due to 
endogenous mechanisms.
Therefore, we aimed to investigate VWF kinetics in perioperative hemophilia A patients 
and the influence of VWF on FVIII clearance. This will provide novel insights into: 1) fac-
tors that modify VWF levels; 2) influence of VWF on FVIII concentrate pharmacokinetic 
parameters, especially FVIII clearance; and 3) association of VWF levels with periopera-
tive bleeding. 
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PATIENTS AND METHODS 
Patients
Patients were diagnosed with severe or moderate hemophilia A and included in the 
perioperative OPTI-CLOT trial 7. The OPTI-CLOT trial is a randomized controlled trial, 
which aims to compare pharmacokinetic (PK)-guided FVIII concentrate dosing with 
dosing based on bodyweight (standard treatment). Patients are stratified according 
to surgical risk (medium versus low risk) and mode of FVIII concentrate administration 
(bolus administration versus continuous infusion). All patients had baseline (lowest) 
FVIII activity levels $ 0.05 IU/mL, were #12 years of age, did not have FVIII inhibitory 
antibodies (Bethesda Units; BU < 0.2 IU) and underwent elective surgery. Patients were 
enrolled from six Academic Hemophilia Treatment Centers in the Netherlands (Erasmus 
University Medical Center Rotterdam, University Medical Center Groningen, University 
Medical Center Utrecht, Radboud university medical center Nijmegen / Maxima Medi-
cal Center, Veldhoven, Leiden University Medical Center/ Haga Hospital, The Hague, 
Amsterdam University Medical Centers). This study was approved by the Institutional 
Review Board of the Erasmus University Medical Center and all patients gave written 
informed consent before enrollment according to the declaration of Helsinki.
Patient and surgical characteristics were collected and included blood type, age, body-
weight, body mass index (BMI), ideal bodyweight, FVIII concentrate consumption, surgi-
cal risk score and perioperative hemorrhage 8,9. Perioperative hemorrhage was based 
on the definition for a clinically relevant bleed as stated by the International Society 
of Thrombosis and Hemostasis (ISTH). More specifically for our analyses, this included 
bleeding complications either leading to hemoglobin decrease of # 1.24 mmol/L, neces-
sitating additional FVIII concentrate treatment and/or red blood cell transfusion, and/or 
a second surgical intervention and/or prolongation of hospitalization. 
Blood sampling and laboratory measurements 
Blood samples were drawn at baseline ($ 3 days before surgery), immediately a"er first 
dose of FVIII concentrate (t=15-30 minutes), postoperatively in recovery room, beginning 
of first day a"er surgery (t=16-33 hours) and at the beginning of second postoperative 
day (t=33-57 hours). FVIII levels were measured locally at each treatment center, using a 
one-stage clotting assay. VWF:Ag, VWF:GPIbM and VWFpp were measured at two central 
laboratories (VWF:Ag and VWF:GPIbM in Erasmus University Medical Center Rotterdam; 
VWFpp in Leiden University Medical Center). VWF:Ag was measured using polyclonal 
rabbit anti-human VWF antibody and horseradish peroxidase conjugated anti-human 
VWF antibody (DakoCytomation, Glostrup, Denmark) in an enzyme-linked immunoas-
say. VWF activity was measured as VWF:GPIbM. VWF:GPIbM was measured with the In-
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novance VWF Ac reagent (Siemens Healthcare Diagnostics, The Hague, The Netherlands) 
on a Sysmex CS 5100 (Sysmex, EttenLeur, The Netherlands) using the manufacturer’s 
protocol. In this test, polystyrene particles coated with anti-GPIb monoclonal antibodies 
were added and particle agglutination was measured as a change in turbidity. VWFpp 
was determined by enzyme-linked immunoassay using Sanquin antibodies (Amster-
dam, The Netherlands) 10. 
Population pharmacokinetic modeling
Individual FVIII PK parameters e.g. clearance and volume of distribution were estimated 
using nonlinear mixed-e!ects modeling so"ware NONMEM v7.4 (ICON Development So-
lutions, Ellicott City, MD, USA). To determine perioperative FVIII concentrate PK param-
eters, our published perioperative population PK model for FVIII concentrate dosing in 
severe and moderate hemophilia A patients was utilized 11. The following PK parameters 
were estimated: clearance (CL), inter-compartmental clearance (Q), volume of distribu-
tion of central (V1), peripheral (V2) compartment, and elimination half-life (T1/2). R 
so"ware v3.6.1 (R Core Team (2019)) and Xpose v4.5.3 were used for data exploration 
and model diagnostics 12.
Statistical analyses
Descriptive statistics were expressed as medians and interquartile range (IQR), or as 
numerical counts with percentages. To identify e!ect of di!erent variables in the peri-
operative period on VWF:Ag or VWF:GPIbM, a linear mixed-e!ects model was applied on 
log transformed VWF:Ag or VWF:GPIbM using the lme4 package in R. In this model with 
log(VWF:Ag) or log(VWF:GPIbM) as outcome, relationships with blood type, surgical risk, 
BMI and age were investigated. This method was also used to identify VWF e!ect on FVIII 
PK parameters in the perioperative period. One-way ANOVA was used to identify statisti-
cal di!erences in ratios VWFpp/VWF:Ag or VWF:Ag/VWF:GPIbM in the perioperative pe-
riod, both log transformed as a result of non-normality. A two-way ANOVA was applied 
on log transformed VWF:Ag and/or VWF:GPIbM and their association with postoperative 
hemorrhage. Posthoc tests were performed with a Bonferroni correction. A p-value of 
0.05 was considered statistically significant. All statistical analyses were performed us-
ing R so"ware v3.6.1 (R Core Team (2019)). 
RESULTS
Patients characteristics 
Table 1 presents general characteristics of the study population. In this analysis, a total 
of 59 patients were included from the perioperative OPTI-CLOT trial of which 38 patients 
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(64.4%) had severe hemophilia A. Median age was 48.8 years old (IQR: 34.8 – 60.0 years) 
with a median bodyweight of 87.0 kg (IQR 50.4 – 133.5 kg). Nine of the 59 patients expe-
rienced a postoperative bleeding event.
Perioperative VWF and FVIII levels
In the perioperative period, patients were treated with FVIII concentrate, aiming for tar-
get FVIII levels as stated in Dutch guidelines. Figure 1 shows that FVIII increases, as well 
Table 1. General characteristics of the study population
No. (%) or median [IQR]
Patient characteristics
Total no. of patients 59
Age (years) 48.8 [34.8 – 60.0]
Severe hemophilia (FVIII<0.01 IU/mL) 38 (64.4%)
Blood group O 34 (57.6%)
Height (cm) 178 [172 – 185] 
Bodyweight (kg) 87.0 [74.2 – 95.3]
Body Mass Index (kg/m2) 26.4 [23.3 – 29.7]
Ideal bodyweight (kg) 71.0 [66.8 – 76.3]
History of inhibiting FVIII antibodies 11 (18.6%)
Baseline VWF:Ag (IU/mL) 1.09 [0.88 – 1.42] 
Baseline VWF:GPIbM (IU/mL) 0.89 [0.65 – 1.25] 
Clotting factor VIII concentrates
Octocog alfa # 17
Octocog alfa* 20
Moroctocog alfa^ 4
Plasma derived FVIII concentrate& 3
Turoctocog alfa## 15
Surgical characteristics
Surgical risk** 
Low 30
Medium 29
Mode of FVIII concentrate administration
Bolus 30
Continuous 29
Postoperative hemorrhage
No 50
Yes 9
#Kogenate®; *Advate®; ^Refacto AF®; &Aafact®; ##NovoEight®
**Surgical risk was defined according to Koshy et al 8. Low surgical risk includes e.g. porth-a-cat removal/insertion and 
dental surgery. Medium risk includes e.g. total hip or knee replacement and tonsillectomy. 
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as VWF:Ag and VWF:GPIbM levels. As is depicted in Figure 1B, VWF:Ag increased postop-
eratively from preoperative median of 1.09 IU/mL (IQR: 0.88 – 1.42) to a postoperative 
median of 1.53 IU/mL (IQR: 1.14 – 1.82) 48 hours a"er surgery with significant interpa-
tient variability. Interpatient variability and increase of VWF:GPIbM was even greater, as 
at average two-fold di!erences were observed for each postoperative patient (Figure 
1C) with preoperative median values of 0.89 IU/mL (IQR: 0.65 – 1.25) to a postoperative 
median of 1.74 IU/mL (IQR: 1.04 – 2.57) 48 hours a"er surgery. In contrast, VWFpp only 
increased immediately postoperatively. In the majority of patients, rapidly decreasing 
VWFpp levels were observed during the first day following surgery (t=16.0 - 32.7 hours). 
Figure 2A and 2C show fluctuations per individual of VWFpp/VWF:Ag ratio and local 
regression or locally estimated scatterplot smoothing (LOESS) line over time. A LOESS 
line is a non-parametric approach which aims to create a smooth line through all the 
data points available by fitting multiple regressions in local neighborhood. The VW-
Fpp/VWF:Ag ratio di!ered between subsequent time points as determined by one-way 
ANOVA (F(4,290) = 4.21, p = 0.003). VWFpp/VWF:Ag was higher immediately a"er surgery 
when compared to 48 hours a"er surgery (p < 0.001), supporting an increased acute 
Figure 1. Factor VIII (FVIII) and von Willebrand factor (VWF) in the perioperative period stratified by surgical risk 
score. Spaghetti plots of A) FVIII; B) VWF:Ag; C) VWF:GPIbM; D) VWFpp. Each patient is represented by a black line. The red 
line indicates the local regression or LOESS line, which follows densest part of the data.
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production and/or release of large amounts of VWFpp due to surgical intervention. 
Figure 2B and 2D show that VWF:Ag/VWF:GPIbM ratios decrease slightly over time with 
statistically significant di!erences when calculated over the total perioperative period 
as determined by one-way ANOVA (F(4,232) = 4.25, p = 0.002). Bonferroni posthoc testing 
showed that VWF:Ag/VWF:GPIbM is also statistically significant when a) preoperative 
VWF:Ag/ VWF:GPIbM is compared to VWF:Ag/VWF:GPIbM 48 hours a"er surgery (p = 
0.004); b) and VWF:Ag/VWF:GPIbM immediately a"er surgery is compared to VWF:Ag/
VWF:GPIbM 48 hours postoperative (p = 0.024).
VWF dynamics in perioperative setting 
To analyze how VWF levels e.g. VWF:Ag and VWF:GPIbM evolve over time due to altera-
tions in synthesis, secretion and clearance, a linear mixed e!ect model was created. As 
VWF:Ag was not distributed normally, a log transformation was performed. In this model 
Figure 2. Ratios of VWFpp/VWF:Ag and VWF:Ag/VWF:GPIbM di"er in the perioperative period. 
Figure A and B are spaghetti plots of VWFpp/VWF:Ag and VW:Ag/ VWF:GPIbM in the perioperative period. Each patient is 
represented by a black line. The red line indicates local regression or LOESS line, which follows the densest part of the data. 
A) VWFpp/VWF:Ag ratio, which can be used as a measure for VWF secretion in the acute phase. VWFpp/VWF:Ag is higher 
immediately a"er surgery compared to ratios before the surgery.  B) VWF:Ag/VWF:GPIbM ratio represents also the acute 
phase response of VWF. This ratio decreases over time. C and D) boxplots of VWFpp/VWF:Ag and VW:Ag/ VWF:GPIbM ratios 
for each perioperative time point. For each boxplot, whiskers depict 2.5th and 97.5th percentile of the data, whereas the box 
depicts the interquartile range. Median of data is depicted by black horizontal line inside the boxplot. 
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with log(VWF:Ag) as outcome, relationships with blood type, surgical risk, BMI and age 
were analysed Time was set at t=0 at moment of first incision by the operating surgeon 
and considered a nonlinear function in the model. Firstly, the most extensive model with 
interaction terms between time and blood type, time and age, and age and BMI was 
investigated. A model with both random intercepts and random slopes was proven not 
superior to only random intercepts when testing with a restricted maximum likelihood 
test (p = 0.42). Therefore, analyses were continued with the extensive model with only 
random intercepts. Subsequently, all interaction terms were removed from the random 
intercept model to investigate if interaction terms improved the model. Models were 
fitted under maximum likelihood as the F-test could not be computed and denominator 
degrees of freedom could not be (reliably) defined. The likelihood ratio test (LRT) also 
showed that interaction terms were not able to improve the model (p = 0.14). Finally, the 
nonlinear characteristic of the time variable was investigated by creating a model with 
a linear function of time. Comparing these models with LRT resulted in a statistically 
significant di!erence (p = 0.037), meaning that nonlinear terms of time were important 
contributors to the model. Model assumptions were evaluated with residual plots, and 
did not show violation of model assumptions, as is documented in supplementary 
Figure 2. 
The final model describing log(VWF:Ag) in the perioperative period is demonstrated 
in table 2. The expected di!erence in log(VWF:Ag) between patients with blood type 
O and non O is -0.16 (95% CI -0.30 - -0.01) if patients are comparable with regard to 
age, bodyweight, BMI, surgical risk and when sampled at identical time points during 
perioperative follow-up. Transformation of data results in exp(-0.16) = 0.86. Clinically 
this means that perioperative hemophilia patients with blood type O may have 14% 
less VWF:Ag when compared to patients with blood type non O, if all the other variables 
are kept constant. The expected di!erence in log(VWF:Ag) between medium and low 
risk surgical procedures was 0.29 (95% CI 0.13 – 0.43) if patients were comparable with 
regard to age, bodyweight, BMI, surgical risk and when sampled at identical time points 
during perioperative follow-up. Transformation of data resulted in exp(0.29)=1.33. 
When translated into clinical terms, this means that patients with a medium surgical 
risk may have 33% higher VWF:Ag levels compared to patients undergoing low surgical 
risk surgery if all other variables are kept constant. The influence of perioperative tim-
ing is reflected in the e!ect plot, which is included in supplementary Figure 1. Similar 
results were obtained when creating a linear mixed e!ect model of log(VWF:GPIbM) of 
which results are included in supplementary table 1 and supplementary Figure 3. Figure 
3 also depicts impact of blood type (Figure 3A) and surgical risk (Figure 3B) and on FVIII, 
VWF:Ag and VWF:GPIbM. In this figure, it is clearly demonstrated that blood type non O 
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and medium surgical risk result in higher VWF:Ag and VWF:GPIbM levels when compared 
to blood type O and/ or low surgical risk . 
Individual VWF and FVIII PK parameters 
The PK parameters clearance, volume of distribution (central and peripheral) and 
elimination half-life were calculated using a perioperative FVIII population PK model 
13. As this model is only valid starting from initiation of surgery, PK parameters were 
Table 2. Associations between the determinants blood type, surgical risk, age, BMI and the outcome 
log(VWF:Ag). Linear mixed-e"ects modeling was used to determine the associations with the out-
come log(VWF:Ag). Time was set at t=0 at moment of first incision by the operating surgeon and was 
defined as a non-linear function. Especially blood type non-O and medium surgical risk were associ-
ated with higher VWF:Ag levels perioperatively. 
Fixed e!ects Coe!icient 95% Confidence 
interval
P-value
Intercept -0.132 -0.543 – 0.28 0.535
Time since start surgery (hours) 0.002 0.001 – 0.004 0.000
Time since start surgery2 (hours) 0.000 0.000 – 0.000 0.040
Blood type, type O -0.157 -0.305 – -0.008 0.042
Surgical Risk, medium risk 0.286 0.134 – 0.438 0.001
Age (years) 0.003 -0.002 – 0.008 0.188
BMI (kg/m2) 0.003 -0.010 – 0.015 0.682
Figure 3. Both blood type and surgical risk a"ect perioperative VWF:Ag and VWF:GPIbM levels. For each boxplot, 
whiskers depict 2.5th and 97.5th percentile of the data, whereas the box depicts interquartile range. Median of data is de-
picted by the black horizontal line inside the boxplot. A) shows boxplots over time separated by blood type. Hemophilia 
A patients with blood type non O have higher VWF:Ag and VWF:GPIbM levels compared to patients with blood type O. B) 
shows lower FVIII levels for surgeries with a lower surgical risk, as the Dutch guidelines advise lower FVIII target levels. Both 
VWF:Ag and VWF:GPIbM are lower postoperatively in low risk surgeries. 
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calculated from first postoperative time point onwards until 48 hours a"er surgery. 
Figure 4 shows no di!erences between time points for clearance (one-way ANOVA 
(F(2,152) = 0.02, p = 0.98), volume of distribution (one-way ANOVA (F(2,152) = 0.12, p = 
0.89) and elimination half-life (one-way ANOVA (F(2,152) = 0.43, p = 0.65). To investigate 
how FVIII clearance evolves over time and to evaluate VWF:Ag influence on clearance, 
another linear mixed e!ect model was created. This final model with FVIII clearance as 
outcome, time as a linear function (in hours) and VWF:Ag (in IU/mL) was divided into 
four categories (quartiles), both were added as fixed e!ects in the model, with time as 
an additional random e!ect. The lowest VWF:Ag level quartile (0.43 - 0.92 IU/mL) was 
associated with a minimal increase of 26 mL/h (95% CI 2 – 50 mL/h) in FVIII clearance 
when compared to the highest VWF:Ag level quartile of (1.70 – 3.84 IU/mL) (Table 3). In 
addition, sub analyses showed that FVIII clearance was not associated with mode of 
administration (bolus administration versus continuous infusion), when adding mode 
of administration in the model as an additional fixed e!ect.
Perioperative bleeding
Both VWF:Ag and VWF:GPIbM were shown to increase postoperatively, suggesting an 
overall increase of procoagulant hemostatic factors . As some hemophilia A patients 
experience bleeding despite perioperative replacement therapy, associations between 
lower VWF:Ag and VWF:GPIbM and perioperative bleeding were investigated. Nine of the 
59 study patients experienced bleeding, requiring additional FVIII concentrate treat-
ment. In figure 5 results of two-way ANOVA are visualized which analyzes interactions 
between VWF:Ag and perioperative bleeding. No association between log(VWF:Ag), 
bleeding and perioperative time point was found F(4,227) = 0.54, p = 0.710) as patients 
with perioperative bleeding had similar log(VWF:Ag) levels when compared to patients 
without bleeding. Additionally, no association was found between log(VWF:GPIbM) of 
perioperative patients with and without surgical bleeding F(4,227) = 0.80, p = 0.525). 
Subanalysis showed that 4 of 24 (17%) patients had a VWFpp/VWF:Ag ratio >1.5 imme-
Figure 4. No di"erences between FVIII PK parameters at various time points in perioperative follow up period.  For 
each boxplot, whiskers depict 2.5th and 97.5th percentile of the data, whereas the box depicts interquartile range. Median 
of the data is depicted by the black horizontal line inside the boxplot. A) Similar FVIII clearance; B) Similar volume of dis-
tribution in steady state (Vss) during the perioperative follow up period and; C) The elimination half-life of FVIII does not 
di!er postoperative. 
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diately a"er surgery with a bleeding complication, while this was the case in 5 of 31 
(16%) patients with a ratio <1.5. A Fisher exact test confirmed no statistically significant 
di!erence in risk between the subgroups (p value = 1.000).
DISCUSSION
The present study was designed to investigate VWF and its influence on FVIII clearance 
in perioperative hemophilia A patients. Both VWF:Ag and VWF:GPIbM increased postop-
eratively but with large interpatient variability. Blood type non-O and medium surgical 
risk however were associated with higher perioperative VWF:Ag or VWF:GPIbM levels 
compared to blood type O and low surgical risk. Importantly, di!erences in VWF were as-
sociated with only minimal changes in FVIII concentrate clearance. Furthermore, VWF:Ag 
Table 3. The association between VWF:Ag and FVIII concentrate clearance in the perioperative period. 
A linear mixed e"ects model was created with FVIII concentrate clearance as an outcome and time 
since start surgery and VWF:Ag as fixed e"ects. Time was set at t=0 at moment of first incision by the 
operating surgeon and was defined as a linear function. Time since start surgery was also set as a ran-
dom e"ect. VWF:Ag was categorized according to quartiles. The reference category was the highest 
quartile with VWF:Ag levels between 1.70 – 3.84 IU/mL. 
Fixed e!ects Coe!icient 95% Confidence 
interval
P-value
Intercept 183 161 – 205 0.000
Time since start surgery (hours) 0 0 – 0 0.647
VWF:Ag
First quartile (0.43 – 0.92 IU/mL) 26 2 – 50 0.034
Second quartile (0.92 – 1.33 IU/mL) 23 0 – 46 0.056
Third quartile (1.33 – 1.70 IU/mL) 9 -10 – 28 0.367
Figure 5. VWF:Ag or VWF:GPIbM are not associated with postoperative bleeding. 
For each boxplot, whiskers depict 2.5th and 97.5th percentile of the data, whereas the box depicts the interquartile range. 
Median of the data is depicted by the black horizontal line inside the boxplot. Boxplots in light blue represent hemophilia 
A patients without postoperative bleeding, darker blue depicts patients with a postoperative bleeding. A) FVIII levels were 
similar between patients with and without postoperative bleeding. Of course, FVIII levels were low before surgery as all 
these patients received replacement therapy with FVIII concentrate. B) No association in VWF:Ag levels between patients 
with and without a bleeding; C) Finally, VWF:GPIbM levels were also similar between patients with and without a bleeding. 
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and VWF:GPIbM levels were similar between patients with and without postoperative 
hemorrhage. 
To the best of our knowledge, VWF levels in perioperative hemophilia A patients have 
not been studied in detail. Therefore, we are the first to describe VWF kinetics in he-
mophilia A patients undergoing elective surgery. Similar to results observed in mainly 
female patients without a bleeding disorder undergoing orthopedic surgery , VWF:Ag 
and VWF:GPIbM increased over time 6. This can be explained by increased release of 
VWF from Weibel Palade bodies in the vascular endothelium due to adrenergic stress 
reactions and other related mechanisms causing endothelial activation such as blood 
flow turbulence, blood pressure variation, medication, hemostatic challenge due to 
surgery, and possibly increased VWF release to compensate for perioperative increase of 
VWF clearance 14,15. In our study, besides a release of mature VWF (VWF:Ag), an increased 
release of VWFpp from Weibel Palade bodies was observed as VWFpp/VWF:Ag ratios 
increased significantly directly a"er surgery with a subsequent decrease. Normally in 
steady state, VWFpp and VWF are present in plasma with a molar ratio of 1:10 16. When 
acute release of both VWFpp and mature VWF (VWF:Ag) occurs, the molar ratio between 
VWFpp and VWF:Ag may increase up to four/five-fold 16. However, VWFpp/VWF:Ag ratio 
is expressed in units, thereby set to one, and not expressed in molar amounts. An acute 
release of both VWFpp and VWF:Ag results in equal increases in molar amounts, but 
when interpreted as units, the increase of VWFpp will be much higher. Initially, during 
an acute release phase, VWFpp/VWF:Ag ratio increases due to increases of both VWFpp 
and VWF:Ag. However as VWFpp has a half-life of approximately two hours, and VWF:Ag a 
half-life of 8-12 hours, rapid VWFpp increase will also diminish within a short time period. 
Our findings support this hypothesis as VWFpp/VWF:Ag ratio was shown to normalize 48 
hours a"er surgery. In addition, the VWFpp/VWF:Ag ratio will also normalize as a result 
of a probable increased consumption of VWF:Ag a"er surgery. 
Acute phase VWF response may also be quantified by calculating VWF:Ag/VWF:GPIbM 
ratio. As VWF:Ag/VWF:GPIbM ratio decreased during subsequent postoperative days in 
our study, we hypothesized that this may be a consequence of the following pathophysi-
ological mechanisms. Firstly, higher ADAMTS13 activity may be present due to surgery 
as a result of increased release of high molecular weight (HMW) VWF multimers. How-
ever, this is unlikely as Kahlon et al. has shown that ADAMTS13 actually decreases a"er 
surgery. Secondly, constitutive secretion of VWF from the endothelium may increase, 
resulting in more low molecular weight (LMW) VWF during surgery17. As strictly regulated 
VWF secretion from Weibel Palade bodies results in more HMW VWF multimers, more 
constitutive secretion with more LMW VWF may lead to a smaller VWF:Ag/VWF:GPIbM 
ratio. Thirdly, utilization of large HMW VWF multimers during surgical clot formation 
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may lead to decreasing postoperative VWF:Ag/VWF:GPIbM ratios, as HMW VWF multim-
ers have the highest platelet binding activity. 
Most likely, observed interpatient variability of VWF is multifactorial. However, in our 
linear mixed-e!ect model, blood type and surgical risk were shown to most relevant 
when predicting VWF:Ag fluctuations over time. As it is well known that VWF levels are 
on average 25% lower in patients with blood type O, it was not surprising to find blood 
type as an important risk factor for lower VWF levels 18. Patients undergoing surgery with 
a medium surgical risk were associated with higher VWF:Ag levels compared to those 
with a low surgical risk, explained by greater physical adrenergic (shear) stress reactions 
as a consequence of more extensive surgery. Influence of VWF levels of age and BMI were 
unexpectedly small. Prior studies have identified age and BMI as important covariates 
when predicting VWF levels 19,20. Therefore, exclusion of these variables was overruled. 
Unfortunately, extensive testing of VWF:Ag modifying factors was limited, due to small 
patient numbers. 
Although the highest quartile VWF:Ag levels (VWF 1.70 – 3.84 IU/mL) was associated 
with a decrease of 26 mL/h (95% CI 2 – 50 mL/h) in FVIII clearance when compared to 
lowest VWF:Ag level quartile (0.43 – 0.92 IU/mL), VWF e!ects on FVIII clearance were only 
minimal and not as important as expected. However, a recent pilot study by Loomans 
et al. was also not able to show a decreased FVIII clearance with increased FVIII half-life 
a"er intravenous desmopressin infusion before FVIII concentrate administration. Study 
hypothesis was also that endogenous VWF increase a"er desmopressin would positively 
a!ect FVIII levels 21. In our study, su!iciently high VWF levels, as is characteristic for the 
perioperative setting in non-VWD patients, may lead to a threshold e!ect and therefore 
not significantly a!ect FVIII clearance. Therefore, if patients have su!iciently high VWF 
levels, dosing of FVIII concentrate need not be adapted based on these VWF levels. 
However, it is important to realize thatPK parameters in our study were calculated with 
a perioperative population PK model without a time-dependent variable for clearance. 
This makes it more di!icult to observe subtle changes of FVIII clearance over time 11. 
Therefore, a limitation of our study is that the design may not be ideal to establish VWF 
e!ects on FVIII clearance during the perioperative time period. The novel perioperative 
population FVIII PK model under construction and enriched with prospectively collected 
VWF and FVIII levels from our randomized controlled OPTI-CLOT trial be will lead further 
elucidate FVIII clearance mechanisms. 
Only a small number of study patients e.g. nine out of 59 (15%), experienced periopera-
tive bleeding. Bleeding was not associated with VWF levels or VWFpp/VWF:Ag ratio. In 
addition, no statistically significant di!erences were observed in VWF:Ag or VWF:GPIbM 
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when comparing patients with surgical bleeding and patients without bleeding. We 
could not prove the hypothesis that VWFpp/VWF:Ag ratios higher than 1.5 were associ-
ated with perioperative bleeding as higher VWF clearance could potentially lead to an 
inadequate primary hemostasis. Capacity for statistical analyses were however limited 
due to small patient and complication numbers. 
In conclusion, we are the first to report on VWF kinetics and FVIII clearance in periopera-
tive hemophilia patients. VWF increased perioperatively in hemophilia A patients with 
blood type and surgical risk as most important predictors of VWF increase. VWF levels 
only showed a small e!ect on FVIII clearance and were not associated with perioperative 
hemorrhage. We recommend further investigation into VWF and its role in the periopera-
tive period of hemophilia A patients by refinement of current population PK models with 
VWF data and ultimate population PK-pharmacodynamic modelling to further unravel 
pathophysiological mechanisms of the hemostatic system. 
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Supplementary Figure 1. E"ect plot of linear mixed e"ect model describing log(VWF:Ag) in the perioperative period 
in blood type O versus non O patients and low risk versus medium risk surgical patients. Red line represents the linear 
mixed e!ects model of log(VWF:Ag) during the perioperative period for a mean patient of this cohort with a BMI of 26.4 kg/
m2 and age of 48.8 years. The dotted line represents the 95% confidence interval. 
Supplementary Figure 2. Scatter plots of the residuals versus the fitted values to check model assumptions for the 
linear mixed e"ects model investigating associations between the determinants blood type, surgical risk, age, BMI 
and the outcome log(VWF:Ag). Scatter plots derived from the linear mixed e!ect model of log(VWF:Ag), showing no viola-
tion to the model assumptions. A) Standardized residuals versus fitted values; B) Marginal residuals versus fitted values.
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Supplementary Figure 3. E"ect plot of linear mixed e"ect model describing log(VWF:GPIbM) in the perioperative 
period in blood type O versus non O patients and low risk versus medium risk surgical patients. Red line represents 
the linear mixed e!ects model of log(VWF:Ag) during the perioperative period for a mean patient of this cohort with a BMI 
of 26.4 kg/m2 and age of 48.8 years. The dotted line represents the 95% confidence interval.
Supplementary Figure 4. Scatter plots of the residuals versus the fitted values to check model assumptions for the 
linear mixed e"ects model investigating associations between the determinants blood type, surgical risk, age, BMI 
and the outcome log(VWF:GPIbM). Scatter plots derived from the linear mixed e!ect model of log(VWF:GPIbM), showing 
no violation to the model assumptions. A) Standardized residuals versus fitted values; B) Marginal residuals versus fitted 
values.
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Supplementary Table 1. Associations between the determinants blood type, surgical risk, age, BMI 
and the outcome log(VWF:GPIbM). Linear mixed-e"ects modeling was used to determine the associa-
tions with the outcome log(VWF:GPIbM). Time was set at t=0 at moment of first incision by the op-
erating surgeon and was defined as a non-linear function. Especially blood type non-O and medium 
surgical risk were associated with higher VWF:GPIbM levels perioperatively.
Fixed e"ects Coe"icient 95% Confidence interval P-value
Intercept -0.351 -0.931 – 0.230 0.242
Time since start surgery (hours) 0.007 0.006 – 0.009 < 0.001
Time since start surgery2 (hours) 0.000 0.000 – 0.000 < 0.001
Surgical Risk, medium risk 0.302 0.091 – 0.518 0.007
Blood group, type O -0.291 -0.502 – -0.082 0.009
Age (years) 0.004 -0.003 – 0.010 0.300
BMI (kg/m2) 0.008 -0.010 – 0.025 0.395
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ABSTRACT
Background Patients with severe and moderate hemophilia A are treated prophylacti-
cally with factor VIII (FVIII) concentrate. Individualization of prophylaxis can be achieved 
by pharmacokinetic (PK)-guided dosing.
Aim In this study, the performance of three PK tools (myPKFiT™, WAPPS and NONMEM®) 
is compared.
Methods In 39 patients, with severe or moderate hemophilia A, blood samples were 
collected 4, 24 and 48 hours a"er administration of 50 IUkg-1 of recombinant FVIII 
(Advate® (n=30) or Kogenate® (n=9)). FVIII dose, FVIII activity and patient characteristics 
were entered into the three PK tools. Obtained PK parameters and dosing advises were 
compared.
Results MyPKFiT™ provided PK parameters for 24 of 30 patients receiving Advate®, 
whereas WAPPS and NONMEM® provided estimates for all patients. Half-life was di!erent 
between the three methods: medians were 12.6h (n=24), 11.2h (n=30) and 13.0h (n=30) 
for myPKFiT™, WAPPS and NONMEM® (p<0.001), respectively. To maintain a FVIII trough 
level of 0.01 IUmL-1 a"er 48h, doses for myPKFiT™ and NONMEM® were 15.1 and 11.0 
IUkg-1 (p<0.01, n=11) and for WAPPS and NONMEM® were 9.0 and 8.0 IUkg-1 (p<0.01, n=23), 
respectively. In nine patients receiving Kogenate®, WAPPS and NONMEM® produced dif-
ferent PK-parameter estimates; half-life was 15.0h and 12.3h and time to 0.05 IUmL-1 was 
69.2h and 60.8h, respectively (p<0.01, p<0.01, n=9). However, recommended doses to 
obtain these levels were not di!erent.
Conclusions The three evaluated PK tools produced di!erent PK parameters and doses 
for recombinant FVIII. Hematologists should be aware that recommended doses may be 
influenced by the choice of PK tool.
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INTRODUCTION
Severe and moderate hemophilia A patients o"en receive coagulation factor VIII (FVIII) 
concentrates prophylactically. The aim of prophylactic treatment is to prevent sponta-
neous bleeding in joints and muscles by achieving a FVIII activity >0.01 IUmL-1 [1]. A"er 
administration of a dose, the concentration-time profile of FVIII is determined by the 
individual’s pharmacokinetic (PK) parameters [2]. For several FVIII concentrates, these 
parameters have been reported to exhibit considerable inter-patient variability [3–8], 
resulting in large di!erences in half-life [9]. As a result, dosing of FVIII can be optimized 
by assessment of the individual PK parameters and adjustment of the dose accordingly 
[10,11].
Bayesian techniques are frequently used for patient-tailored dosing [12,13]. In Bayesian 
analysis, individual PK parameters estimates are obtained by combining the informa-
tion from the individual patient (administered dose, observed concentrations, specific 
characteristics such as age and body weight) with information from a specific cohort 
of patients (population). A"er Bayesian analysis, the individual PK parameters can be 
used to evaluate several di!erent dosing regimens and to choose the most appropriate 
dosing regimen for a specific patient.
Recently, two PK dosing tools (PK tools) for FVIII concentrates have become available 
for hemophilia healthcare practitioners, myPKFiT™ and Web-Accessible Population 
Pharmacokinetic Service-Hemophilia portal (WAPPS) [14,15]. Both tools use Bayesian 
techniques. MyPKFiT™ is designed to estimate individual PK parameters and dose regi-
men for a single brand of recombinant FVIII (Advate®), whereas for WAPPS individual PK 
parameters can be estimated for other FVIII brands as well.
Individual PK parameters, provided by Bayesian techniques, are influenced by the 
population parameters from population PK models used in the analysis. Ideally, these 
population PK models should be validated [16]. For both myPKFiT™ and WAPPS, the 
exact population PK parameters are unknown. Moreover, results of validation studies 
have not been published. Therefore, in this study, individual PK parameters and recom-
mended doses for recombinant FVIII in severe and moderate hemophilia A patients were 
estimated by myPKFiT™ and WAPPS and compared to estimates from NONMEM® using 
population PK models from literature.
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METHODS
Population data
Patients with severe and moderate hemophilia A were enrolled in this study. The Medi-
cal Ethical Committees in all participating centers approved the study; all participants 
gave informed consent. This study was conducted in accordance with the Declaration 
of Helsinki. For each patient, age, body weight, blood group, a record of neutralizing 
antibodies (in the past), and the (lowest) endogenous baseline level were collected. 
Furthermore, if a patient was on prophylaxis, information for at most six previously 
administered doses was collected. In each patient, blood samples were collected 4, 24 
and 48 hours a"er administration of 50 IUkg-1 Advate® (Shire) or Kogenate® (Bayer), as 
proposed by Björkman et al. [13,17]. For patients using prophylaxis, no washout period 
was taken into account. FVIII was measured using a one-stage aPTT-based clotting as-
say [18]. A flowchart of which patients were analyzed by a specific PK tool is shown in 
Supplementary Figure 1.
Pharmacokinetic tools
Two online PK tools were used to obtain estimates of individual PK parameters and 
individual dose regimens: myPKFiT™ (Baxalta (now part of Shire), www.myPKFiT.com, 
version 2.0) and Web-Accessible Population Pharmacokinetic Service for Hemophilia 
(WAPPS, www.wapps-hemo.org, version 3.0) [14,15]. MyPKFiT™ has been developed 
for PK analysis of Advate® solely, whereas WAPPS provided individual PK parameters for 
other brands of FVIII as well.
MyPKFiT™
In myPKFiT™, the following information was entered: date of birth and body weight of 
the patient, endogenous baseline level, administered dose with one possible previous 
dose and observed FVIII. The following PK parameters were produced for patients that 
received Advate®: clearance (CL), distribution volume in steady-state (Vss), terminal 
elimination half-life (t') and time to 0.01 IUmL-1. The latter parameter is defined as a 
FVIII activity of 0.01 IUmL-1 above the endogenous baseline level.
Besides estimation of PK parameters, myPKFiT™ also provided the dose to achieve a 
target FVIII within a specified interval (24, 48 or 72 hours a"er dose administration). 
Herewith, the target FVIII was defined as the FVIII above the endogenous baseline level, 
i.e. for a patient having an endogenous baseline level of 0.01 IUmL-1, a target FVIII of 0.03 
IUmL-1 is achieved when a FVIII of 0.04 IUmL-1 is observed. Doses were obtained for target 
FVIII levels of 0.01 IUmL-1, 0.03 IUmL-1 and 0.05 IUmL-1 within the 48 and 72 hours interval.
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In myPKFiT™, individual PK parameters for patients with a body weight outside the range 
5 - 120 kg were not provided by the PK-tool, as the implemented population PK model 
was apparently not constructed using data from patients having body weights outside 
this range. Furthermore, dose regimens were only provided by myPKFiT™, if these were 
in accordance with the Summary of Product Characteristics (SmPC) of Advate® [19]. 
Therefore, only doses between 10 and 100 IUkg-1 could be obtained.
Furthermore, it was possible to indicate whether a wash-out had been performed. In this 
case, a pre-infusion level could be specified or, if this pre-infusion level was unknown, 
the dose prior to the loading-dose could be entered. In the latter case, the pre-infusion 
level was given as output by myPKFiT™. This pre-infusion level was compared to esti-
mates for the pre-infusion FVIII obtained using NONMEM®.
WAPPS
In WAPPS, the following information was specified: date of birth and body weight of 
the patient, endogenous baseline level, administered dose, observed FVIII, type of 
coagulation test used to measure FVIII and the brand of the administered product. One 
pre-infusion FVIII could be specified (taken shortly prior to the loading-dose). However, 
pre-infusion FVIII measurements were not measured in this study.
WAPPS provided PK parameters estimates for both Advate® and Kogenate®. Estimates for 
the following parameters were reported: t', time to 0.01 IUmL-1, time to 0.02 IUmL-1 and 
time to 0.05 IUmL-1. For calculating the time to a specific target FVIII, the endogenous 
baseline level was taken into account. Therefore, the time to a specific target FVIII was 
only provided by WAPPS, if the endogenous baseline level was lower than this target 
level.
Furthermore, WAPPS provided dose recommendations of FVIII trough levels 0.01 IUmL-1, 
0.03 IUmL-1 and 0.05 IUmL-1 within the 48 and 72 hours interval, which were obtained 
until the 24th of July 2017. As similar to the time to target FVIII, dose regimen were not 
provided if the target FVIII was equal to or below the endogenous baseline level.
NONMEM®
Bayesian analysis was performed in NONMEM® using population PK models specific for 
Advate® and Kogenate® (Supplementary Table 1), as reported by Björkman et al. [6,7]. In 
both population models, PK were described using two-compartment models in terms 
of clearance (CL), volume of distribution of the first and second-compartment (V1, V2) 
and inter-compartmental clearance (Q). Data, obtained from severe and moderate 
hemophilia A patients, was used to construct both population PK models [6,7]. The 
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population PK model described by Björkman et al. [7], as applied for the Kogenate® data, 
contained inter-patient variability as well as inter-occasion variability for both CL and 
V1, respectively. Both variabilities were taken into account using an exponential model, 
as specified by Karlsson and Sheiner (1993) [20].
In both reported population PK models, endogenous baseline levels were considered 
using di!erent methods. In this study, the endogenous (lowest) baseline level from each 
patient was taken into account, as recorded in the patient file. An endogenous baseline 
level can be accurately estimated by nonlinear mixed-e!ect modelling or by Bayesian 
analysis only if well-timed sampling data are present, for instance a"er a long wash-out 
period. Since this data was not available in the present study, the measured endogenous 
(lowest) baseline level for each patient was used to obtain individual PK parameter 
estimates instead of using an estimated baseline value, as comprised in the population 
PK model from Björkman et al. [7]. Hereby, the (lowest) endogenous baseline level was 
subtracted from all measured FVIII levels, prior to the estimation of the individual PK 
parameters by Bayesian analysis.
A"er programming the models in NONMEM®, PK parameters estimates were obtained for 
each patient by Bayesian analysis. The following information was used as input: the time 
of dose administration and measurement of FVIII levels, and the age and body weight.
For imputation of terminal elimination half-life, time to target FVIII and the dose, neces-
sary to keep FVIII above a target level of 0.01 IUmL-1, 0.03 IUmL-1 and 0.05 IUmL-1 during 
an interval of 48 and 72 hours, analytical equations were derived using the Mathematical 
Expressions library from Dubois et al. [21] (see Supplementary Table 3). Vss was imputed 
by the summation of V1 and V2. As mentioned above, myPKFiT™ and WAPPS used dif-
ferent approaches to calculate the time to target concentration. Both approaches were 
implemented in R-so"ware (R Core Team (2017), version 3.4.1) [22], allowing compari-
son of the di!erent output generated by the PK tools. For the calculation of time to 0.01 
IUmL-1, 0.02 IUmL-1 and 0.05 IUmL-1, the estimated maximum achieved FVIII a"er dose 
administration was used.
Comparison of pharmacokinetic tools
All statistical comparisons were performed using paired Wilcoxon signed-rank tests in 
SPSS® version 24.0 (IBM Corp., Armonk, N.Y., USA). Values were summarized as medians 
and corresponding ranges (min – max), and a p-value below 0.05 was used to define a 
significant di!erence.
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Validation of population PK models
The availability of an independent dataset, i.e. a dataset that was not used to construct 
the model, allows the (external) validation of a population PK model [16]. As popula-
tion PK parameters implemented in myPKFiT™ and WAPPS were not available, only the 
population models from literature were validated. Population predicted concentrations 
(PRED) were obtained using typical values of the population PK parameters, corrected 
for age and body weight. Individual predicted concentrations (IPRED) were obtained by 
using the individual PK parameters produced a"er Bayesian analysis. Both PRED and 
IPRED were imputed at the same time points as compared to the observed FVIII. The 
validity of the applied population PK models was evaluated by constructing plots of 
PRED and IPRED versus the observed FVIII (goodness-of-fit plots).
Furthermore, the models were validated by construction of prediction-corrected visual 
predictive checks (VPCs) [23]. These plots are created by Monte Carlo simulation and 
show whether the applied population PK model adequately describes the median 
observed concentrations as well as the inter-patient variability [24]. In this study, for 
each patient, 1000 Monte Carlo simulations were performed in NONMEM®. Prediction-
corrected VPCs were constructed using PsN [25] and a R-so"ware package developed by 
Keizer et al. [26].
RESULTS
Population data
In total, PK assessments were collected for 39 patients. Thirty patients received Advate®, 
of which 23 had severe and 7 had moderate hemophilia A having endogenous baseline 
levels of less than 0.01 IUmL-1 and between 0.01 and 0.05 IUmL-1, respectively (Table 1). 
Nine patients (4 severe and 5 moderate) received Kogenate®. No patients with inhibitors 
were included, although three patients (8%) had a history with neutralizing antibodies 
(Table 1). The observed FVIII activity a"er a bolus infusion of 50 IUkg-1 FVIII concentrate 
is shown in Figure 1.
Advate®: NONMEM® versus MyPKFiT™
MyPKFiT™ provided individual PK parameter estimates for 24 patients receiving Advate® 
(Table 2). In the other six patients receiving Advate®, PK parameter estimates were not 
provided due to an ‘unacceptable goodness-of-fit’ error. The latter error indicated that 
the FVIII measurements of the individual patient were outside the limits of prediction for 
the population model.
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Table 1. General characteristics of the study population
Total cohort Adults Children
No. (%); or median [min-max]
Patient characteristics
No. of patients 39 33 6
Age (years) 40.2 [7.6 - 76.7] 48.3 [18.4 - 76.7] 14.1 [7.6 - 17.6]
Body weight (kg) 82.0 [28.0 - 105.0] 85.7 [60.8 - 105.0] 64.0 [28.0 - 75.0]
Height (cm) 177.5 [135.0 - 192.0] 179.5 [148.0 - 192.0] 170.0 [135.0 - 185.0]
Severe hemophilia A (<0.01 IUmL-1) 27 (69) 22 (67) 5 (83)
On prophylaxis 28 (72) 23 (70) 5 (83)
Blood group Oa 24 (62) 19 (58) 5 (83)
Neutralizing antibodies (historically)b 3 (8) 3 (9) -
Replacement therapy with factor concentrate
Product
Patients using Advate® 30 (77) 25 (76) 5 (83)
Patients using Kogenate® 9 (23) 8 (24) 1 (17)
Availability of output a!er PK analysis
PK-tool
MyPKFiT™ 24 (62) 21 (64) 3 (50)
WAPPS 39 (100) 33 (100) 6 (100)
Time of blood-sampling
First measurement (h) 4.0 [2.1 - 4.6] 4.0 [2.1 - 4.6] 3.9 [3.3 - 4.1]
Second measurement (h) 24.0 [20.2 - 28.1] 24.0 [20.2 - 25.9] 26.4 [23.8 - 28.1]
Third measurement (h) 48.0 [44.2 - 52.1] 48.0 [44.2 - 50.9] 48.4 [45.6 - 52.1]
No. = number; kg = kilogram; cm = centimeter; IUmL-1 = international units per milliliter. a for one patient blood-group was 
not assessed. b maximum measured inhibitor concentration was 0.9 BU.
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Figure 1. Observed FVIII plasma level versus time for all patients that received 50 IUkg-1 Advate® (n=30) or Kogenate® (n=9). 
The black dots represent the measured FVIII for all patients. The solid black line represents the median of the obeserva-
tions and the dashed-lines represent the 2.5th and 97.5th quantiles. The red and blue-shaded areas show the 95% predic-
tion intervals for the predicted FVIII values, as obtained by Monte Carlo simulation (visual predictive check).
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For the 24 patients, myPKFiT™ produced estimates for clearance that were higher 
than those obtained from NONMEM®: medians were 3.1 mLh-1kg-1 versus 3.04 mLh-1kg-1 
(p<0.001, n=24), respectively. Moreover, t' as estimated by myPKFiT™ was shorter than 
the t' obtained by NONMEM® (Figure 2A); medians were 12.6 h and 13.0 h (p<0.001, n=24), 
respectively. Consequently, the reported time to 0.01 IUmL-1 was shorter for myPKFiT™ 
than for NONMEM®: 77.5 h versus 81.1 h (p<0.001, n=24), see Figure 2B. Estimates for Vss 
were not di!erent (p=0.60, n=24).
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Figure 2. Comparison of the elimination half-life (panel A), time to 0.01 IUmL-1 (panel B) and recommended doses (panel 
C) for Advate® produced by NONMEM® and myPKFiT™. The time to 0.01 IUmL-1 is defined as the time to target value of 0.01 
IUmL-1 above the endogenous baseline level. MyPKFiT™ did not support dose recommendation below 10 IUkg-1 and above 
100 IUkg-1. These thresholds are depicted by the dashed horizontal lines. Doses obtained using NONMEM® for which no 
dose recommendation was available from myPKFiT™ are depicted by stars on the le". NS: not significant, *: p-value<0.05, 
**: p-value<0.01, ***: p-value<0.001.
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MyPKFiT™ produced dosage regimens for the target trough levels of 0.01 IUmL-1, 0.03 
IUmL-1 and 0.05 IUmL-1, above the endogenous baseline level for dosing intervals of 48 
and 72 hours (Table 2). These dose regimens are only reported when they are within the 
range of 10 to 100 IUkg-1, which is in accordance with the Summary of Product Character-
istics (SmPC) of Advate® [19]. For the 48 hour dosing interval, doses targeting at trough 
levels of 0.01 IUmL-1, 0.03 IUmL-1 and 0.05 IUmL-1 were obtained for 11, 22 and 21 of the 24 
patients (Figure 2C), respectively. For the 72 hour interval, doses were obtained in 20, 12 
and 3 patients, respectively. In general, doses recommended by myPKFiT™ were higher 
than those obtained using NONMEM®. For the 48 hour interval, median doses targeting 
at 0.01 IUmL-1 were 15.1 IUkg-1 and 11.0 IUkg-1 for myPKFiT™ and NONMEM®, respectively 
(p<0.01, n=11). Corresponding doses for the 0.03 IUmL-1 target were 27.1 IUkg-1 and 23.5 
IUkg-1 (p<0.001, n=22) and 43.5 IUkg-1 and 37.5 IUkg-1 (p<0.001, n=21) for the 0.05 IUmL-1 
target. Doses, targeting at 0.01 IUmL-1 and 0.03 IUmL-1 and administered every 72 hours, 
were also higher for myPKFiT™ compared with NONMEM® (see Table 2).
Advate®: NONMEM® versus WAPPS
WAPPS produced individual PK parameters for all patients receiving Advate® (Figure 3A 
and 3B). Half-life estimated by WAPPS was shorter than the t' estimated by NONMEM®; 
respective medians were 11.2 h and 13.0 h (p<0.001, n=30). Despite the di!erence in t' 
produced by WAPPS and NONMEM®, a di!erence was observed only for the time to 0.05 
IUmL-1 (Table 3); respective medians were 51.0 h and 52.7 h (p<0.001, n=29). The time 
to 0.01 IUmL-1 could only be imputed for 23 patients, as 7 patients had an endogenous 
Table 2. Individual PK parameter estimates from NONMEM® versus myPKFiT™ (Advate® only)
NONMEM® myPKFiT™
Na Median [min-max] Median [min-max] p-valueb
Parameter
Half-life (h) 24 13.0 [9.4 - 19.7] 12.6 [8.1 - 17.9] <0.001
Clearance (mLh-1kg-1) 24 3.04 [1.54 – 5.44] 3.1 [1.7 – 6.0] <0.001
Distribution volume in steady-state (mLkg-1) 24 50.3 [37.9 – 64.6] 50 [40 - 60] 0.60
Time to 0.01 IUmL-1 above baseline level (h) 24 81.0 [56.0 - 132.1] 77.5 [47.0 - 118.0] <0.001
Recommended dose regimen (IUkg-1)
Trough 0.01 IUmL-1, per 48 hours 11 11.0 [7.5 - 30.0] 15.1 [10.0 - 57.3] <0.01
Trough 0.01 IUmL-1, per 72 hours 20 29.2 [13.6 - 69.5] 32.1 [17.6 - 85.4] <0.001
Trough 0.03 IUmL-1, per 48 hours 22 23.5 [12.6 - 56.0] 27.1 [16.8 - 88.6] <0.001
Trough 0.03 IUmL-1, per 72 hours 12 61.5 [16.9 - 100.9] 81.7 [24.5 - 97.7] <0.01
Trough 0.05 IUmL-1, per 48 hours 21 37.5 [10.7 - 73.9] 43.5 [16.1 - 88.6] <0.001
Trough 0.05 IUmL-1, per 72 hours 3 67.9 [28.1 - 72.4] 88.0 [40.8 - 89.2] 0.25
a Number of estimates used for comparison. b p-value is obtained using a paired Wilcoxon signed rank test.
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baseline level higher than 0.01 IUmL-1 No di!erences were obtained for the time to 0.01 
IUmL-1 and 0.02 IUmL-1: medians were 79.8 h versus 81.0 h (p=0.60, n=23) and 65.0 h 
versus 67.9 h (p=0.15, n=29), respectively (Table 4).
WAPPS produced dosage regimens for intervals of 48 and 72 hours and target FVIII of 
0.01 IUmL-1, 0.03 IUmL-1 and 0.05 IUmL-1 if the endogenous baseline level was not higher 
than the target FVIII itself (Table 3). For both the 48 and 72 hour interval, doses targeting 
at trough levels of 0.01 IUmL-1, 0.03 IUmL-1 and 0.05 IUmL-1 were obtained for 23, 23 and 
29 of the 30 patients (Figure 3C), respectively. In general, doses recommended by WAPPS 
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Figure 3. Comparison of the elimination half-life (panel A), time to 0.01 IUmL-1 (panel B) and recommended doses (panel 
C) for Advate® produced by NONMEM® and WAPPS. Time to 0.01 IUmL-1 was only provided by WAPPS if the endogenous 
baseline level was below this target value. Moreover, WAPPS did not provided a dose recommendation, if the target trough 
value was equal to or below the endogenous baseline level of a patient. For instance, seven patients receiving Advate® had 
an endogenous baseline of 0.01 IUmL-1 or higher. Therefore, WAPPS provided dose recommended only for 23 of 30 patients 
receiving Advate®. NS: not significant, *: p-value<0.05, **: p-value<0.01, ***: p-value<0.001.
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were higher than those obtained from NONMEM®. For the 48 hour interval, median doses 
targeting at 0.01 IUmL-1 were 9.0 IUkg-1 and 8.0 IUkg-1 for WAPPS and NONMEM®, respec-
tively (p<0.01, n=23). Corresponding doses for the 0.03 IUmL-1 target were 26.9 IUkg-1 
and 23.9 IUkg-1 (p<0.01, n=23) and 44.9 IUkg-1 and 35.3 IUkg-1 (p<0.001, n=29) for the 0.05 
IUmL-1 target. Strikingly, doses targeting at 0.01 IUmL-1, 0.03 IUmL-1 and 0.05 IUmL-1, and 
administered every 72 hours were much higher for WAPPS as compared with NONMEM®, 
whereas the maximum doses recommended for this interval by WAPPS were extremely 
high; values were 27366 IUkg-1, 82098 IUkg-1 and 136831 IUkg-1, respectively.
Kogenate®: NONMEM® versus WAPPS
In Figure 4A and 4B, a comparison between estimates for individual PK parameters for 
Kogenate® obtained using WAPPS and NONMEM® is shown. Estimates of t', produced by 
WAPPS, were longer as compared to estimates of t' produced by NONMEM®; respective 
medians were 15.0 h and 12.3 h (p<0.01, n=9). Moreover, di!erences were observed for 
the time to 0.02 IUmL-1 and 0.05 IUmL-1; corresponding medians were 84.9 h versus 81.5 
h (p<0.05, n=6) and 69.2 h versus 60.8 h (p<0.01, n=9), respectively.
For dosing every 48 and 72 hours, no di!erences were found between the dosage regi-
men as produced by WAPPS and NONMEM® for patients receiving Kogenate® (Table 4).
Table 3. Individual PK parameter estimates from NONMEM® versus WAPPS (Advate® only)
NONMEM® WAPPS
Na Median [min-max] Median [min-max] p-valueb
Parameter
Half-life (h) 30 13.0 [9.4 - 20.3] 11.2 [4.5 - 19.5] <0.001
Time to 0.01 IUmL-1 (h) 23 81.0 [56.0 - 137.6] 79.8 [35.2 - 154.5] 0.60
Time to 0.03 IUmL-1 (h) 23 67.9 [46.5 - 117.2] 65.0 [28.0 - 123.5] 0.15
Time to 0.05 IUmL-1 (h) 29 52.7 [34.1 - 132.1] 51.0 [20.8 - 108.0] <0.01
Recommended dose regimen (IUkg-1)
Trough 0.01 IUmL-1, per 48 hours 23 8.0 [1.9 - 30.0] 9.0 [1.8 - 718.9] <0.01
Trough 0.01 IUmL-1, per 72 hours 23 30.6 [5.0 - 179.1] 41.5 [4.9 - 27366.1] <0.001
Trough 0.03 IUmL-1, per 48 hours 23 23.9 [5.8 - 90.0] 26.9 [5.5 - 2156.6] <0.01
Trough 0.03 IUmL-1, per 72 hours 23 91.7 [15.0 - 537.2] 124.6 [14.6 - 82098.3] <0.001
Trough 0.05 IUmL-1, per 48 hours 29 35.3 [2.1 - 150.0] 44.9 [9.2 - 3594.3] <0.001
Trough 0.05 IUmL-1, per 72 hours 29 123.6 [5.6 - 895.3] 220.4 [120.4 - 1e+05] <0.001
a Number of estimates used for comparison. b p-value is obtained using a paired Wilcoxon signed rank test.
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Validity of the NONMEM® population PK models
The availability of an independent dataset allows the validation of the two population 
PK models programmed in NONMEM®. As the individual predicted FVIII were calculated 
using individual PK parameters, it is expected that values were similar to the measured 
FVIII for a specific time-point. Moreover, for both population PK models, the imprecision 
of the individual PK parameter estimates was less than 20%, which is generally regarded 
as an ‘accurate’ estimate (supplementary material Table 4). In this case, all individual 
predicted FVIII should be on the line x=y in the goodness-of-fit plots. In plots of observed 
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Figure 4. Comparison of the elimination half-life (panel A), time to 0.01 IUmL-1 (panel B) and recommended doses (panel 
C) for Kogenate® produced by NONMEM® and WAPPS. Time to 0.01 IUmL-1 was only provided by WAPPS if the endogenous 
baseline level was below this target value. Moreover, WAPPS did not provided a dose recommendation, if the target trough 
value was equal to or below the endogenous baseline level of a patient. For instance, five patients receiving Kogenate® had 
an endogenous baseline of 0.01 IUmL-1 or higher. Therefore, WAPPS provided dose recommended only for 4 of 9 patients 
receiving Kogenate®. NS: not significant, *: p-value<0.05, **: p-value<0.01, ***: p-value<0.001.
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FVIII versus individual predicted FVIII, only minor deviations were found indicating the 
general adequacy of the individual PK fits (Supplementary Figure 2 - upper panels). 
Nevertheless, the highest FVIII at sampling time T=4 were slightly underpredicted.
Population predicted FVIII are calculated using the population (median) PK parameters 
values and individual values for body weight and age (Supplementary Figure 2 - lower 
panels). Population predicted FVIII activity measurements will therefore deviate from 
the line x=y due to inter-patient variability. Although, it is expected that population pre-
dicted FVIII values are distributed symmetrically around the line x=y, i.e. do not display 
a trend. As in the plots of observed versus individual predicted concentrations, a minor 
trend for underprediction of the highest measured FVIII was seen for both Advate® and 
Kogenate®.
In Figure 1, prediction-corrected VPCs are shown for the population PK models used 
to describe the measured FVIII, obtained a"er administration of Advate® or Kogenate®. 
Black dots depict the measured FVIII, from which black solid-lines show the observed 
50th quantile (median) and the black dashed-lines the 5th and 95th quantile of the ob-
served FVIII. The red and blue-shaded areas show the 95% prediction interval for the 
predicted FVIII values, as obtained by Monte Carlo simulation. If the red and blue-shaded 
areas cover the corresponding quantiles from the measured FVIII, this demonstrates 
that the model is able to adequately describe the measured FVIII. In this case, the 
predicted concentrations (red and blue-shaded area) generally predicted the measured 
FVIII well, indicating the appropriateness of the models. Nevertheless, for Kogenate®, a 
minor underprediction of the measured FVIII (4 hours a"er administration) was seen. 
Furthermore, for the FVIII measured 24 hours a"er administration of Kogenate®, a minor 
overprediction was seen.
DISCUSSION
In this study, a cross-evaluation of three PK tools (myPKFiT™, WAPPS and NONMEM®) 
that perform Bayesian analysis was conducted, using data from hemophilia A patients 
receiving Advate® or Kogenate®. In general, significant di!erences between the three PK 
tools were found for CL, t' and time to target FVIII. Moreover, clinical relevant di!erences 
were found between the doses, as recommended by myPKFiT™, WAPPS and NONMEM®.
In Bayesian analysis, individual PK parameter estimation is influenced by the popula-
tion PK model parameters used in the analysis. A population PK model is comprised of 
both population parameters (medians) and their corresponding inter-patient variability. 
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For instance, the population parameter value for CL serves as a priori information and 
is used as the initial value for estimating an individual value for CL. The inter-patient 
variability, associated with CL, determines the extent to which CL may be adjusted by 
the individual’s clinical data. Moreover, if there is no variability associated to a popula-
tion parameter, as is the case for Q and V2 from the models applied in NONMEM®, the 
individual PK parameter estimates equals the population value. Furthermore, when per-
forming Bayesian analysis, the extent of residual variability also a!ects the estimation of 
individual PK parameters. The residual variability determines the weighting of a single 
observation being taken into account for estimating individual parameters. For instance, 
the fitted concentration-time profile will generally be closer to the observed concentra-
tions with low residual variability (high weighting) as compared to high residual vari-
ability (low weighting). In the latter case, observed concentrations may deviate more 
from the predicted concentration-time profile than in the former case. Therefore, using 
similar observations, di!erent population PK models may produce di!erent individual 
PK parameter estimates when Bayesian analysis is performed.
The results of the present study demonstrate how di!erences in population PK param-
eters influence individual PK parameter estimates. For both Advate® and Kogenate®, 
di!erent individual PK parameters are obtained when di!erent PK tools are applied. 
These di!erences are clinically relevant, as doses for Advate® recommended to obtain 
a certain target trough level by myPKFiT™ are 10% to 37% (3 to 20 IUkg-1) higher than 
those recommend by NONMEM®. For Advate®, WAPPS recommended 13% to 78% (1 to 
96.8 IUkg-1) higher doses than NONMEM®. These di!erences are caused by the fact that 
individual values for the primary PK parameters CL, V1, Q and V2 are not similar for the 
three evaluated PK tools. WAPPS does not provide primary PK parameters, whereas 
myPKFiT™ provides only values for clearance and volume of distribution. However, both 
PK tools provide individual estimates for t', a secondary PK parameter of which the value 
is determined by all primary parameters. The shorter t' provided by both myPKFiT™ 
and WAPPS may be explained by higher values for clearance and/or lower values for the 
volume of distribution in comparison with NONMEM®. Clearly, shorter t' correspond to 
higher recommended doses. For Kogenate®, however, this association was not found. 
WAPPS produced a longer t' than NONMEM®; recommended doses were however not 
significantly di!erent. This may be explained by the fact that data was available from 
only 4 to 9 patients (Table 4).
In clinical practice, doses are rounded up or down to a full vial of FVIII concentrate (250 
IU). The decision to round up or round down a recommended FVIII dose to a full vial de-
pends on the following reasons: personal preferences of the treating physician, amount 
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of FVIII concentrate available in the country and bleeding phenotype of the patient. 
Thus, rounding up or down of the FVIII dose to a full vial is performed subjectively.
In this study, none of the PK tools is the gold standard. A PK tool can be used as a gold 
standard for the estimation of individual PK parameters when it has been validated for 
this purpose. Validation of PK tools is relatively simple [16]. Following a loading dose, 10 
samples are obtained and individual PK parameters are estimated by fitting the data to a 
two-compartment model. Subsequently, a limited number (2-3) of samples is selected to 
estimate individual PK parameters by Bayesian analysis and are compared to the values 
obtained from the fit obtained using all data. This method has been applied by Björkman 
et al. [13]. The population PK model used in the Bayesian analysis should be developed 
on data di!erent from the data used in the validation procedure (independent datasets) 
[27]. In the present study, the described validation procedure could not be applied since 
only sparse data was available for each patient. Nevertheless, the availability of sparse 
(independent) data still allows the validation of the applied population models. Valida-
tion consisted of constructing plots of observed versus predicted FVIII (“goodness-of-fit” 
plots) and/or visual predictive checks (VPCs). These techniques are used commonly in 
pharmacometric analyses and are advocated by the EMA and FDA to validate population 
PK models [28,29]. In the present study, these validation procedures were applied to the 
models programmed in NONMEM®, as the population values of myPKFiT™ and WAPPS 
were not available. The goodness-of-fit plots and VPCs both demonstrated the adequacy 
of the applied models (Supplementary Figure 2). However, the minor underprediction on 
T=4 for FVIII from Kogenate® may cause an overprediction of the volume of distribution 
and, consequently, an overprediction of t'. These di!erences may contribute to the 
shorter t' as estimated using NONMEM®. Nevertheless, validation of the population PK 
models, implemented in myPKFiT™ and WAPPS, should be performed before the cause 
of the observed di!erences can be identified.
In this study, pre-infusion levels were taken into account for estimation of individual PK 
parameters, using myPKFiT™ and NONMEM® by specifying (at most six) doses admin-
istered prior to the investigational dose. In myPKFiT™, an estimate of the pre-infusion 
level was produced when a dose administered prior to the investigational dose was en-
tered. No prior doses can be entered in WAPPS. As an alternative, measured pre-infusion 
levels may be specified in both myPKFiT™ and WAPPS. In the present study, pre-infusion 
levels were not measured. Therefore, Bayesian estimates produced by WAPPS may be 
biased in patients that have received considerable FVIII doses before administration of 
the investigational FVIII dose. For Advate®, median (min-max) pre-infusion FVIII were 
0.016 IUmL-1 (0 – 0.159) and 0.039 IUmL-1 (0 – 0.140) for myPKFiT™ and NONMEM®, re-
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spectively (p-value=0.59). As a result, it is expected that, particularly in patients with 
high pre-infusion levels, parameter estimates produced by WAPPS will be biased.
When the pre-infusion level is not taken into account, the distribution volume of the 
first compartment (V1) may be underpredicted and/or CL may be overpredicted, result-
ing in an underprediction of t'. In the present study, it is not clear to what extent this 
phenomena contributed to the estimating of t' by WAPPS. Nevertheless, when using 
WAPPS for Bayesian analysis in a patient with significant pre-infusion levels, a sample 
should be taken before the administration of the dose, allowing this value to be entered.
The patients that will be selected for dose individualization will most likely be patients 
that are still su!ering from bleeding events despite their current prophylactic dose regi-
men or patients that are using high doses, which may be attenuated. The former type 
of patient could be ‘deviant’ from the population, from which the data was derived to 
construct the population PK model. For instance, a patient could have a much higher 
clearance or distribution volume as compared to the model population and, conse-
quently, dose estimations will also be higher. myPKFiT™ did not support doses outside 
the range 10 to 100 IUkg-1. Moreover, if a recommended dose leads to an estimated FVIII 
higher than 2.5 IUmL-1, WAPPS warns that clinical judgment with regard to dose should 
be exercised. Nevertheless, doses for Advate® within the 72 hours interval were obtained 
which are not clinically applicable (Table 3). Therefore, PK tools should be validated for 
application of dose individualization in the population, which is likely to have patient-
tailored dosing.
CONCLUSIONS
Online PK-guided dosing tools are new technologies, which may contribute to support 
clinical decision making and optimize the individualization of clotting factor dosing. 
This could be beneficial for the patients by achieving adequate FVIII levels, but may also 
be more cost-e!ective by preventing overdosing of patients. In this study, significant 
di!erences among three PK tools were found for estimated individual PK parameters 
as well as recommended dose regimen. Therefore, hematologists should be aware of 
the fact that estimates for individual PK parameters and dose recommendations may 
di!er, depending on their choice for a PK tool. Moreover, PK tools that perform Bayesian 
analysis using population PK models should be validated for this purpose.
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Supplementary Table 1. Population PK models for Advate® and Kogenate®
Model for Advate® [6] Model for Kogenate® [7]
Estimate (%RSE) Estimate (%RSE)
Structural model
Clearance (CL; mLh-1) 193 2.7 222 5
Volume of central compartment (V1; mL) 2220 1.9 3520 3
Distribution CL to compartment 2 (Q; mLh-1) 147 8.6 256 30
Volume of compartment 2 (V2; mL) 730 7.8 241 14
Baseline of endogenous FVIII (BL; IUmL-1) - 0.012 17
Inter-individual variability (%CV)
IIV on CL 30 15 28 33
IIV on V1 21 14 17 37
Correlation between CL and V1 (%) 45 22 64 44
IIV on Baseline - 31 110
Inter-occasion variability (%CV)
IOV CL - 13 31
IOV V1 - 10 36
Residual variability
Additive residual error (SD; IUmL-1) 0.089 3.5 0.012 17
Proportional residual error (%CV) - 8.5 6.7
Covariate relations
CL – Allometric exponent 0.80 5.9 -
V1 – Allometric exponent 0.95 2.8 -
V2 – Allometric exponent 0.76 18 -
CL – (% change with age di!erent from 22 years) -0.45 41 -
CL – (% change with age di!erent from 24 years) - -0.7 16
CL – (% di!erence if preparation = full-length 
recombinant)
- -20 15
V1 – (% di!erence if preparation = full-length 
recombinant)
- -20 15
IIV: Inter-individual variability; RSE: relative standard error; CV: coe!icient of variation. SD: standard deviation.
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Supplementary Table 2. Equations for the estimation of individual PK parameters
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Equations for the estimation of the individual PK parameters: CL = clearance, V1 = volume of distribution of the compartment 1, Q = inter-
compartmental clearance, V2 = volume of distribution of compartment %: ERG\ZHLJKWȘLVWKHLQGLYLGXDO%D\HVLDQ) estimate of deviance from 
WKHSRSXODWLRQW\SLFDOYDOXHRID3.SDUDPHWHUȆLVWKHLQGLYLGXDOHVWLPDWHRIWKHGHYLDQFHIURPWKHSRSXODWLRQW\SLFDOYDOXe in each (dosing) occasion. 
The latter adds extra intra-patient variability to the estimation of individual PK parameter, i.e. this variability describes to what extent the individual PK 
estimates can differ each occasion. FLRP is 1 if a full-length recombinant product has been administered, otherwise, its value is 0. Both models are 
from literature [6,7]. 
Equations for the estim tion of the individual PK p rameters: CL = clearance, V1 = volume of distribution of the 
compartment 1, Q = inter-compartmental clearance, V2 = volume of distribution of compartment 2, BW = body 
weight. ( s the ind vidual (Bayesian) estimate of devianc  f om e population typical value of a PK parameter. 
) is the individual estimate of the deviance from the population typical value in each (dosing) occasion. The 
latter adds extra intra-patient variability to the estimation of individual PK parameter, i.e. this variability 
describes to what extent the individual PK estimates can di!er each occasion. FLRP is 1 if a full-length 
recombinant product has been administered, otherwise, its value is 0. Both models are from literature [6,7].
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Supplementary Table 3. Equations for calculated dose, terminal half-life and time to target plasma 
level
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Equations were derived using the Mathematical Equations library from Dubois et al. [21]. 
Equations were derived using the Mathematical Equations library from Dubois et al. [21].
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Supplementary Table 4. Relative standard errors of individual PK parameter estimates as derived 
from Bayesian analysis.
Clearance 
(CL)
Distribution volume 
(V1)
Terminal half-life
No. of
patients
Median
(%)
[min-max] Median
(%)
[min-max] Median
(%)
[min-max]
Applied population PK 
model
Advate® a 30 15.3 [10.7 - 18.5] 13.2 [7.5 - 17.5] 15.3 [12.3 - 18.1]
Kogenate® b 9 5.6 [5.1 - 6.3] 9.2 [8.4 - 9.4] 6.2 [5.9 - 7]
A Björkman et al., 2011 [6]. B Bjorkman et al., 2009 [7].
Chapter 10
176
Supplementary Figure 1. Flowchart of the study data. In this flowchart, solid black lines describe the data analyses for 
Advate® as well as Kogenate®. The black dashed lines depict the paired comparisons, which are performed using a paired 
Wilcoxon sign rank test. GOF: goodness-of-fit, BL: (endogenous) baseline level, Vd: volume of distribution.
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Supplementary Figure 2. Observed versus predicted FVIII plasma level. Observed FVIII plasma levels for Advate® and 
Kogenate® versus individual and population FVIII plasma levels predicted using NONMEM®. Values for predicted FVIII are 
similar to measured FVIII, when depicted close to the line x=y. The blue line depicts a LOWESS curve, which is a smoothed 
line that follows the most dense part of the data. Individual predictions are expected to be close to the line x=y, whereas 
population predictions are expected to be distributed symmetrically around this line.
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STUDY OBJECTIVES AND MAIN FINDINGS
In this thesis, we have presented the conditions, strengths and limitations but also po-
tential applications of PK-guided dosing of FVIII concentrate in hemophilia A patients. 
In part 1 we evaluated Current diagnostics and treatment monitoring. Based on a case 
history of two young boys with hemophilia, we showed that variations in FVIII measure-
ments may result in misclassification or delay in treatment of hemophilia A patients 
if treating physicians are not aware of this phenomenon. This shows that quality, e.g. 
accuracy and reproducibility, of FVIII measurements are important conditions for the 
diagnosis of hemophilia and monitoring of factor replacement therapy, especially when 
PK-guided dosing is applied. In part 2, entitled Implementation of PK-guided dosing of 
factor VIII concentrate in hemophilia A, several examples of PK-guided dosing in clinical 
practice are reported. Importantly, as the first research group, we designed and per-
formed a randomized controlled trial which compared perioperative PK-guided dosing 
of FVIII concentrate with standard dosing based on bodyweight in severe and moder-
ate hemophilia A patients, the “OPTI-CLOT” trial. This trial showed that perioperative 
consumption of factor concentrate was similar between the two dosing strategies. 
However, PK-guided dosing resulted in more accurate targeting of pre-specified FVIII 
ranges and therefore improved FVIII dosing. We also observed that von Willebrand fac-
tor (VWF) increased perioperatively, but that VWF levels only minimally a!ected FVIII 
clearance. In two studies, we showed that ideal body weight best explains the interin-
dividual variability of FVIII concentrate PK in obese patients. Finally, we demonstrated 
that systematic di!erences exist in currently available PK-guided dosing tools resulting 
in di!erent dosing advices. In the following section, our main findings will be placed into 
a broader perspective, weighing up opportunities and obstacles, ultimately concluding 
that implementation of PK-guided dosing is an important innovation for daily clinical 
practice in hemophilia. 
CONDITIONS NECESSARY FOR IMPLEMENTATION OF PK GUIDED-
DOSING
Accuracy of documentation of factor concentrate dosing and timing 
PK guided-dosing can be applied by Bayesian forecasting. This technique requires a 
limited number of observations by blood sampling in the individual and availability 
of a model describing the PK in a large population. In a population PK model typical 
values of PK parameters e.g. clearance and volume of distribution are supplied with cor-
responding interpatient and intrapatient variability. O"enly, these models also describe 
relationships between a PK parameter and a specific patient characteristic e.g. weight 
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and VWF level.1 Bayesian forecasting can only be applied successfully when information 
of the individual and the population is accurate and of high quality. Accuracy of PK data 
is determined by the reliable data collection of patient-related factors, precise amount 
of drug administered, and exact information on timing of dosing and blood sampling.1 It 
is not surprising that data collection therefore requires special training and persistently 
remains challenging , especially around surgery and bleeding events, and when admin-
istered prophylactically by the patients themselves, unsupervised in the home setting. 
However, in the Netherlands, this information is generally documented in patients logs 
and a condition for distribution of factor concentrates in all Hemophilia Treatment 
Centers. The current Dutch HemoNed registry, which aims to register all patients with a 
bleeding disorder, was recently provided with a mobile phone application which facili-
tates dosing documentation by patient and/or family members.2 
PK tools, such as the PK tools described in chapter 10, are an important option to 
provide dosing advice in a user-friendly manner. Furthermore, these tools may be used 
to collect data which can subsequently be used to create and enrich existing popula-
tion PK models. However, it is important to realize that online tools can also be filled 
in inadequately, which will subsequently a!ect data quality and lead to less accurate 
estimations of individual PK parameters and predictions of best doses to acquire factor 
target levels. This aspect should therefore always be a realized and safeguarded when 
using data through e-health modules.
Population PK modeling necessitates accurate FVIII levels
Measurement of FVIII levels in itself is not challenging, however, generating accurate FVIII 
levels necessitates constant attention and diligence. Prior discussion on assay types has 
focused on the relevance of chromogenic assays (CSA) in non-severe hemophilia A, and 
which assay to use when predicting bleeding phenotype and indication for prophylactic 
treatment, as well as consequences of B-domain depletion in some FVIII concentrates 
and e!ect on FVIII assay reproducibility.3-6 When considering implications, it is important 
to realize that one-stage assay (OSA) and CSA are tests which fundamentally measure 
FVIII activity di!erently. The OSA is based on the activated partial thromboplastin time 
(aPTT).7 In the OSA, the incubation period is short and endpoint is determined as part of 
the steep part of an S-shaped curve. In CSA setting, the coagulation cascade is triggered 
resulting in factor Xa generation (FXa).8,9 This generated FXa cleaves a chromogenic 
substrate resulting in a color change, of which overall absorbance reflects the amount 
of FVIII. During CSA, the incubation period is longer than in the OSA and the endpoint 
or extinction, is set at a plateau phase. Furthermore, the CSA contains supraphysiologi-
cal concentrations of thrombin and factor IX. As a result of di!erent test methods and 
endpoints, it is not surprising that both assays may lead to di!erent FVIII results in he-
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mophilia patients with varying F8 mutations.4 Previous studies have also demonstrated 
that B-domain deleted FVIII concentrates lead to FVIII measurements that have been 
reported to be 20% lower in OSA, when compared to CSA results.10,11 Interestingly, this 
discrepancy was not observed in a FVIII concentrate of which 22 aminoacids of FVIII 
B-domain were still present.12 Due to these reports, the Scientific and Standardization 
Committee (SSC) for FVIII and FIX (Toronto 2015) recommends to measure FVIII by both 
OSA and CSA in all hemophilia A patients. Two FVIII measurements give the opportunity 
to compare values and to diagnose and initiate treatment based on lowest FVIII value 
measured, ensuring patient safety.
The discussion above has become more important with the introduction of extended 
half-life concentrates, which are increasingly used. Reports show that choice of assay 
is extremely relevant for accurate measurement of factor levels a"er administration of 
extended half-life concentrates.13 In chapter 3, we have shown that considerable varia-
tion is present when measuring endogenous FVIII levels, and that this variation is partly 
explained by the reagents used. When measuring FVIII activity in samples with (extended 
half-life) FVIII concentrate, the variation in the measurements will increase, especially 
if guidelines and information from ongoing publications on assay choice are not fol-
lowed.13 As a result, major under-or overestimations of FVIII measurements will occur, 
most importantly with consequences for clinical care but also with regard to PK-guided 
dosing. As most hemostasis laboratories are required to be able to perform validated 
measurements of plasma samples for various factor concentrates, it is challenging to 
safeguard quality and availability of diagnostic procedures 24/7, as is obligatory in 
majority of Hemophilia Treatment Centers. In addition to assay type, choice of activator 
and plasma standard are also of importance as they may influence assay outcomes, 
further complicating standardization of assays and uniformity of laboratory results. 
Discrepancies between the OSA and CSA are not only observed a"er infusing factor 
concentrates, but also when measuring the e!icacy of gene therapy. A recent multiyear 
follow-up study showed that values of OSA were higher than CSA in patients treated 
with adeno-associated virus (AAV)–mediated gene therapy.14 Education of (pediatric) 
hematologists, treating physicians and laboratory personnel on these aspects and 
limitations is vital to guarantee best treatment for each hemophilia patient. Moreover, 
the predictive performance of population PK models should be improved. This may be 
accomplished by enriching the models with data from “real-world” patients, typically 
exhibiting more variability than patients participating in registration trials. Furthermore, 
extensive information on potential covariates should be implemented in the model by 
incorporation of PK data of large heterogeneous population groups. Lastly, population 
PK modes should also be specific for the type of assay and reagents used. 
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Hemostasis tests should be associated with bleeding tendency
Novel global hemostatic tests should be able to predict bleeding tendency both reliably 
and reproducibly, as well as rapidly in both whole blood and (frozen) plasma samples. 
The largest advantage of global hemostatic tests is that they take all coagulation factors 
into account, instead of only measuring FVIII or FIX activity. Attempts to create such a 
global hemostatic test include thrombin generation tests, thromboelastography, and 
thromboelastometry (TEG® and ROTEM®). 
For the thrombin generation test, dose response curves have been created by FVIII 
concentrate spiking. Reports show that endogenous thrombin potential (ETP) and 
initial rate of thrombin generation correlate well with the amount of FVIII in plasma.15 
Additional observations show that associations can be found between clinical bleeding 
phenotype, as Santagostino et al. reported lower ETP in patients with a mild bleeding 
phenotype (annual bleeding rate or ABR $ 2 and factor concentrate consumption $ 500 
IU/kg/year) compared to patients with a more severe bleeding phenotype (ABR # 2 and 
factor concentrate consumption # 500 IU/kg/year).16 However, thrombin generation test-
ing contains several limitations regarding pre-analytical variables. Firstly, some blood-
drawing systems cause overestimations of ETP which amount to up to 29.5%, probably 
as a result of an in vitro activation of the coagulation system.17 Secondly, pneumatic tube 
transport is regularly used in large hospitals. This transport increases thrombin genera-
tion significantly when compared to hand-carrier transport.18 Thirdly, samples need to 
be processed preferably within one hour, which is an important practical issue.19 Besides 
these pre-analytical challenges, the assay is also very sensitive to source and concen-
tration of tissue factor, used to initiate thrombin generation.20 Finally, despite the fact 
that large improvements have been made to decrease inter-and intra-assay variability, 
interpatient variability is still demonstrated and overall does not seem to correlate with 
bleeding phenotype.16,21 More specifically, large di!erences in bleeding phenotype have 
been confirmed by thrombin generation tests, but clinically relevant subtle variations in 
lower range of FVIII levels of patient in vivo samples, cannot be adequately assessed by 
current thrombin generation test results.16 In conclusion, although thrombin generation 
testing may be a suitable candidate to measure hemostatic potential, these tests still 
require optimization before practically applicable in hemophilia care. However, the Sci-
entific and Standardization Committee of the International Society of Thrombosis and 
Hemostasis has published a guideline which helps to uniform and standardize thrombin 
generation tests.22 
Viscoelastic testing in TEG® or ROTEM® was originally developed as promising in small 
pioneering studies in hemophilia A patients.23,24 As in thrombin generation testing, large 
di!erences in factor levels and bleeding phenotype could be quantified by TEG® but 
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interindividually the more subtle changes in levels and bleeding phenotype, such as 
the di!erence between mild hemophilia and normal controls, could not be detected.25,26 
Similar to the thrombin generation test, viscoelastic testing is also sensitive to (pre-)
analytical variables, such as needle size and time between blood collection and labora-
tory analysis to minimize platelet activation. In addition, TEG® coe!icient of variation 
is variable and may increase up to 19% for the TEG 5000®.27 However, intra-laboratory 
variation was reported acceptable compared to a high inter-laboratory variation, which 
was stated to rise up to 49% for TEG 5000® and 83% for the ROTEM delta®.28 There is 
ongoing discussion if viscoelasticity testing remains a promising global hemostatic test 
in hemophilia due to its disadvantages. 
Alternative tests that predict overall bleeding tendency are also important with regard 
to upcoming non-replacement therapies such as bispecific antibodies that mimic 
FVIII or drugs that inhibit anticoagulant pathways. Nevertheless, it will always remain 
questionable if an in vitro test is able to measure in vivo hemostasis in the context of 
patients treated with various hemostatic agents. Hopefully, future studies focusing on 
development of novel global hemostatic tests will reveal more knowledge on this as-
pect, bringing us closer to the ultimate goal of actually assessing an individual’s bleed-
ing tendency. This may improve treatment significantly, as it can be based on clinical 
phenotype instead of residual factor levels.
STRENGTHS AND LIMITATIONS OF PK-GUIDED DOSING
Improved targeting of pre-specified FVIII levels
Previous studies have demonstrated that standard perioperative dosing of factor con-
centrates based on bodyweight leads to factor levels #0.20 IU/mL below or above pre-
defined target ranges29-34, resulting in either underdosing with increased risk of bleeding 
or overdosing associated with high treatment costs.35-38 This can be at least partially 
explained by well-known interindividual di!erences in PK of factor concentrates.39,40 
PK-guided dosing using Bayesian forecasting takes the interindividual di!erences in PK 
parameters into account and generates the individualized dose that will produce the 
target activity level thereby increasing e!icacy and patient safety. 
We have shown that PK-guided dosing has the potential to improve targeting of pre-spec-
ified FVIII levels both perioperatively and in the prophylactic setting in several varying 
circumstances.41-43 Furthermore, the OPTI-CLOT trial is the first randomized controlled 
trial that underlines the superiority of factor level targeting in the perioperative setting. 
Although, alternative treatments with non-factor replacement therapy are upcoming, 
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factor replacement therapy is still considered treatment of choice. Individualization 
of prophylaxis does not only consist of adjusting of dosing according to individual PK 
parameters, but also according to developmental phase and lifestyle, taking patient 
age, bleeding phenotype, most practical dosing intervals, joint status, physical activity 
and sporting activities into account, and should become standard clinical practice in 
our opinion. As it improves quality of care and regulates costs of treatment, taking cost 
and benefit into account.44-46 As experience with PK-guided dosing of extended half-life 
products is increasing and dosing is still mainly based on population PK models derived 
from data of drug trials in homogeneous selected patient populations, further enriching 
of population PK models is indicated and is currently ongoing in the OPTI-CLOT TARGET 
study. 
Expensive treatment under PK guidance may lead to cost reduction 
The OPTI-CLOT trial was designed to detect a di!erence in perioperative FVIII concen-
trate consumption between PK-guided and standard dosing based on bodyweight. This 
endpoint was chosen to investigate cost-e!ectiveness of this approach, but also to be 
able to power the study adequately as endpoint perioperative bleeding was calculated 
not be feasible due to low bleeding risk and scarcity of hemophilia A patients undergo-
ing surgery. Nevertheless, PK-guided dosing did not result in lower perioperative FVIII 
concentrate consumption. Based on our retrospective perioperative study, we calcu-
lated that potential savings of FVIII consumption could amount to 44%, if all FVIII levels 
were kept within target ranges.32 Interestingly, we did not demonstrate such a reduction 
in factor concentrate consumption. There are a number of factors that may explain this 
unexpected outcome. Firstly, more optimal and e!icient targeting in the first 24 hours 
a"er surgery by PK-guided dosing leading to higher factor VIII concentrate doses may 
have compensated a decrease in consumption >120 hours a"er surgery. Importantly, 
if this is the case this will increase patient safety as bleeding and thrombosis risk may 
decrease. Unfortunately lack of factor VIII measurements at end of the perioperative pe-
riod with a median number of 6.5 factor VIII measurements per patient in the total study, 
corresponding with a time point approximately 96 - 120 hours a"er surgery, hampers 
statistical analyses to prove this. Secondly, median hospitalization period in the retro-
spective study was 9.0 (IQR 5.0 – 12.0) versus 3.5 (IQR: 0.0 – 9.0) days in the OPTI-CLOT 
trial. This does not coincide with severity of surgery but seems related to changes in 
clinical practice, leading to shorter hospital admissions as no di!erences in severity of 
surgery were demonstrated in treatment arms. Post hoc analyses were performed to see 
if di!erences were due to earlier discharge and switch to bolus infusion and thus higher 
consumption in the home treatment setting, this could not be demonstrated. 
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Additional studies in OPTI-CLOT data will investigate actual cost-benefit ratio of PK-
guided dosing in clinical practice in more detail, both perioperatively as well as prophy-
lactically. Already in 1997, Carlsson et al. showed that PK-guided dosing was feasible 
and resulted in decreased consumption of FVIII concentrate in the prophylactic setting.46 
However, in this study only 14 of 21 participants completed the study protocol. Another 
small prospective trial by Lindvall et al. showed that daily dosing of FVIII concentrate 
may substantially reduce factor concentrate consumption, with higher patient burden 
due to intensive infusion schedule. Such cost-e!ectiveness studies should not only 
calculate amount of factor concentrate but also take other miscellaneous costs into 
account. These miscellaneous costs should include team e!orts to perform iterative 
PK-guided dosing by clinical pharmacologist, (pediatric) hematologist, nurse, labora-
tory technician as formulated in guidelines for economic evaluation of new healthcare 
interventions by Hakkaart-van Roijen.47 In the near future, costs for PK-guided dosing 
may decline as more detailed population PK models will minimize PK profiling to one 
blood sample, decreasing costs associated with laboratory measurements, and logistics 
performed by hemophilia team. Furthermore, implementation of web-based PK tools 
using validated population PK models, may also further decrease costs of treatment as 
e!orts by clinical pharmacologist will concomitantly decline. 
Unknown association between factor levels and bleeding 
Dutch guidelines prescribe target factor ranges perioperatively, but it is well known that 
the relationship between these target ranges and bleeding is unclear and not evidence 
based. It is unethical to lower perioperative target factor ranges to test cut o! levels 
defining bleeding risk. Therefore, prospective studies on factor levels and perioperative 
bleeding are di!icult to perform. Nevertheless, future studies should merge datasets 
from perioperative and prophylactic hemophilia A and hemophilia B patients and 
bleeding events to unravel these associations. In addition, these combined datasets are 
an opportunity to construct PK-pharmacodynamic (PD) models, correlating predicted 
factor levels with bleeding events and other relevant factors influencing bleeding risk. 
Phenotypic heterogeneity in bleeding risk is intriguing in hemophilia,48,49 as two patients 
with similar baseline FVIII levels may di!er considerably in bleeding phenotype. In this 
thesis, we have reviewed several factors (chapter 4) that influence bleeding phenotype, 
such as developmental phase, age, bodyweight, blood type and von Willebrand factor 
(VWF), life style, and sporting activities among others.50 Besides these known and mea-
surable factors there remain unknown modifying factors that are yet to be investigated. 
Importantly, the endothelial compartment is known to play a role in this interindividual 
variation as it produces, stores and secretes VWF. VWF is carrier protein for FVIII, protect-
ing it from proteolytic cleavage, premature activation and clearance from the circula-
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tion. Therefore, VWF behavior should be analyzed to better understand FVIII clearance 
long term. Factors that delay or inhibit production and secretion cause lower plasma 
VWF levels and thereby less VWF to protect FVIII.51 
Another component influencing bleeding phenotype may be the presence and mobiliza-
tion of patient’s own, endogenous FVIII. In non-severe hemophilia A patients, this may 
play an important modulating role. Desmopressin administration may mimic activation 
of the hemostatic system during bleeding, trauma or stress. Therefore desmopressin 
administration, may serve as a model to study interindividual variation of bleeding 
phenotype.52 Such a model may be used to analyze patients with atypical bleeding 
phenotypes with regard to their proteomic plasma profiles present before and a"er des-
mopressin administration. Research into proteomic profiling, construction of induced 
pluripotent stem cell (iPSC) lines and endothelial cell models, forms an important 
part of the novel Dutch multicenter, interdisciplinary research consortium SYMPHONY. 
Biomarkers uncovering underlying mechanisms leading to interindividual variation in 
bleeding phenotype, are expected to be found in these studies and can be integrated 
into future population PK-PD models. 
In the prophylactic setting, mainstay of prophylaxis has been that factor concentrate 
trough levels should be kept equal to or above 0.01 IU/mL by regular factor concentrate 
dosing. However, it remains to be elucidated if this minimal trough level is su!icient to 
prevent all bleeding and accomplishing an annualized bleeding rate (ABR) of zero. Sev-
eral research groups have attempted to associate PK and PD, with PD defined as bleed-
ing in hemophilia A.53-55 Nevertheless, a recent prospective randomized controlled trial 
comparing two di!erent FVIII trough target ranges e.g. 0.01-0.03 versus 0.08-0.12 IU/mL 
showed that despite trough levels of 0.08 – 0.12 IU/mL, zero bleeds was not achieved. 
Additionally, it was observed that many patients (15/58) withdrew from the study, the 
majority of which were randomized into the higher trough level arm, creating attri-
tion bias and causing di!iculties to generalize study results to the general hemophilia 
population.56 Study withdrawal was most probably due to frequent dosing, obligatory to 
achieve the high troughs indicated. Importantly, it should also be realized that not only 
trough levels are meaningful. Moreover, importance of FVIII peak levels should not be 
underestimated. Valentino et al. have already reported that higher peak FVIII levels may 
create more e!ective protection from bleeding.57 
Furthermore not unimportantly, increased knowledge on PK and PD in general, acquired 
through studies on factor replacement therapy will also promote application in novel 
upcoming non-factor replacement therapies, and gene therapy. 
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Su"icient representation of specific patient groups in population PK models
Bayesian adaptive dosing is only possible when PK models are representative of the 
individual patient and his or her specific clinical setting or circumstances. Therefore, 
special attention should be paid to include all patient populations and settings in 
constructed models. Most population PK models available did not include or report the 
amount number of overweight or obese patients included in constructed models.39,40 
Due to rising prevalence of obesity in the global population, we developed a prophy-
lactic population PK model applicable for multiple standard half-life FVIII concentrates 
with a representative number of patients who were overweight or obese. As FVIII 
concentrate remains mainly intravascular, it was not surprising that the morphometric 
variable ideal bodyweight (IBW), that is generally seen as a reflection of the intravas-
cular compartment, described inter- and intraindividual variation in FVIIII PK best.42 
Our study substantiated the study described by McEneny-King et al.58 In this simulation 
study, 1000 normal weight (BMI<29.6 kg/m2) and 1000 overweight/obese (BMI 29.6-40.0 
kg/m2) patients were simulated for use of a one specific FVIII concentrate. Although a 
di!erent cut-o! point (BMI: 29.6 kg/m2) was applied to distinguish between normal 
weight and overweight or obese patients, our results are in line with this study. Another 
o"en underrepresented group is the pediatric hemophilia population. As FVIII clearance 
decreases with age, children have a more rapid FVIII clearance (expressed per kilogram) 
than adults, while volume of distribution per kilogram remains stable.39,40,59 This results 
in shorter factor concentrate half-lives, and therefore need of higher and more frequent 
dosing of FVIII concentrate in children. Furthermore, as children grow, an individual PK 
profile may change and is therefore only valid for a short period of time.40 Extensive 
data collection in pediatric hemophilia A patients on timing and amount of dosing is 
therefore recommended to create more accurate population PK models also applicable 
in children. 
Finally, especially older hemophilia A patients may have abnormal liver function tests 
due to hepatitis B or C (HCV) infections a"er contamination of plasma derived factor 
concentrates or due to the actual medication to treat these viral liver diseases. Previ-
ous studies have shown that liver disease a!ects coagulation factor levels as FVIII is 
synthesized in sinusoidal cells in the liver.60 Hemophilia A patients with liver disease 
may demonstrate lower FVIII clearance, most probably due to increased VWF levels. To 
our knowledge, only one study in a small patient sample has been performed without 
appropriate estimation of clearance.61 Therefore, further studies investigating this re-
lationship are needed but di!icult to perform due to strongly decreasing numbers of 
a!ected patients. 
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Continuing importance of factor replacement therapy 
In an era with many new treatment options including non- factor replacement therapy 
and gene therapy, the question arises if the hemophilia community should still rely on 
factor replacement therapy as mainstay of treatment? We believe that it is a safe and 
e!ective option to prevent and treat bleeding with low thrombosis risk. For the novel 
treatment modalities, safety profiles and risk factors are still to be determined and in 
many cases treatment in case of bleeding or during surgery is still under investigation. 
Furthermore, for gene therapy existing antibodies against viral vectors may limit gene 
therapy options.62 Recently, a multiyear follow-up showed that FVIII expression levels of 
approximately 0.20 IU/mL decreased slightly over time.14,63 Although clinically relevant, 
these factor levels do not rule out bleeding altogether. Moreover, gene therapy may be 
a once only option as re-treatment with the same vector is not yet possible. Finally, ac-
curate monitoring by hemostasis laboratories for novel products or gene therapy are 
still under development. 
Moreover, developing countries may finally be able to a!ord treatment if factor replace-
ment therapy becomes less expensive and therefore more widely available. Currently, 
the World Federation of Hemophilia estimates that 70-75% of all hemophilia patients 
worldwide do not receive any form of appropriate treatment.64 Simulations show that 
low dose frequent prophylaxis decreases bleeding risk compared to on demand treat-
ment, but saves 75% of costs associated with high dose prophylaxis schedules.65 The 
concept of PK-guided dosing, achieving best results with minimal but more frequent 
dosing is therefore of great relevance for countries with limited health care resources. 
In conclusion, in our opinion factor replacement therapy will not disappear and innova-
tions in factor replacement therapy for hemophilia are still extremely relevant. 
APPLICATION OF PK-GUIDED DOSING IN CLINICAL PRACTICE
User friendly PK guidance web portals and measurement of patient reported 
outcome measures
The development of a digital interactive shared-decision-making tool will further 
facilitate implementation of PK-guided dosing into clinical practice. Before develop-
ing such a tool, focus groups should reveal most important patient-related factors e.g. 
frequency of treatment, e!icacy, safety, and costs. These factors should be incorporated 
and discussed with patients to ensure most suitable dosing strategy for each patient. 
Implementation of PK-guided dosing into clinical practice also needs a user friendly PK 
tool. Currently, two web-based PK tools are available, myPKFiT and WAPPS. Both tools 
perform Bayesian forecasting, but the precise population PK models behind these tools 
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are unknown. In chapter 10 we demonstrate that di!erent population models produce 
di!erent individual PK parameters and as a consequence di!erent dose recommenda-
tions.66,67 Therefore, new PK tools should 1) be transparent with respect to the incorpo-
rated population model ; 2) be able to calculate dosing advices for every available con-
centrate (standard half-life and extended half-life); 3) be applicable in di!erent settings 
(prophylactic and perioperative); and 4) be representative for all patient populations. 
Last but not least, it is essential to include patient-reported outcome measures (PROMs) 
to evaluate the impact of PK-guided dosing and more importantly of other upcoming 
novel treatment modalities on patients. PROMs incorporate patients’ perspective and 
positive coping capacities. Furthermore, they provide valuable information and facili-
tate implementation of value based health care.68,69 A combination of a shared decision 
making tool, PROMs and PK tool will facilitate implementation of PK-guided dosing. But 
will also set the stage for obligatory choices by governmental health care institutions 
and health care payers in the upcoming era of novel treatment modalities, with regard 
to which treatment is best for each patient, in which phase of life at what societal cost. 
Personal approach and good communication
As mentioned previously by Jameson and Longo in the New England Journal of Medi-
cine, “Precision medicine is personalized, problematic and promising“.70 Personalized 
treatment does not only consist of accurate targeting of factor level ranges, taking 
troughs and peak levels into account during activities and other risk factors, but also 
consists of close collaboration with patients to accommodate treatment according to 
developmental phase, lifestyle, practical and emotional preferences. 
For PK-guided dosing, our research group has shown that both patients and health 
care professionals are willing to cooperate intensively to personalize treatment accord-
ingly.71 Good communication between patients and family members, nurses, (pediatric) 
hematologists and clinical pharmacologists is crucial to achieve optimal results. Current 
and future more refined PK tools will facilitate implementation and lower time invest-
ments by hemophilia treatment team and clinical pharmacologist. 
In conclusion, we believe that taking necessary conditions, strength and limitations of 
PK-guided dosing into account as well as potential applications which may facilitate 
implementation of PK-guided dosing into daily clinical practice, that PK–guided dosing 
is an important improvement of factor replacement therapy leading to personalization of 
hemophilia treatment. 
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SUMMARY
Hemophilia A is characterized by a (partial) deficiency of coagulation factor VIII (FVIII), 
caused by a mutation in the F8 gene. As FVIII is crucial to maintain adequate secondary 
hemostasis. A deficiency in FVIII leads to (spontaneous) bleeding in joints and muscles 
or (prolonged) bleeding a"er trauma and/or surgery. Mainstay of treatment in hemo-
philia, is the replacement of the deficient coagulation factor with intravenously admin-
istered factor concentrate, also called factor replacement therapy. However, dosing of 
FVIII concentrate is challenging. Standard practice is to dose based on bodyweight and 
crude estimations of in vivo recovery and FVIII clearance. Several studies have shown 
that large interindividual di!erences exist in FVIII concentrate pharmacokinetics (PK), 
resulting in underdosing with a higher risk of bleeding, or overdosing with concomitant 
unnecessary high costs. Dosing based on a patient’s individual PK takes interindividual 
di!erences of FVIII PK into account and therefore optimizes treatment. In this thesis, 
we focus on the conditions needed, strengths, limitations and potential applications of 
PK-guided dosing of FVIII concentrate in hemophilia A patients. In the first part, we focus 
on current practice with regard to diagnostics and treatment monitoring. In the second 
part, implementation of PK-guided dosing is addressed. 
Firstly, the background for the studies presented in this thesis by description of clini-
cal symptoms and complications of hemophilia A are provided in chapter 1. We also 
highlight current knowledge gaps in hemophilia care which we will address. 
Part I - Current diagnostics and treatment monitoring 
As FVIII measurements are essential to optimize diagnosis and to safeguard quality of 
treatment monitoring, accuracy of measurements is of great importance. Implementation 
of PK-guided dosing is only feasible if data on factor levels on which population PK models 
are constructed, are accurate and reproducible. Therefore, knowledge and expertise on 
coagulation factor laboratory assays are indispensable when providing PK-guidance of 
factor concentrate dosing.
Measurements of FVIII coagulation activity (FVIII:C) vary considerably and may result 
in misclassification of hemophilia A with delay in initiation of prophylactic treatment 
if not recognized as is reported in chapter 2. We reported on two young brothers who 
were diagnosed as moderate hemophilia A patients and therefore not prophylactically 
treated with factor VIII concentrate despite frequent bleeding events. At ages of 6 and 
5 years, both brothers were referred to our hemophilia treatment center. Laboratory 
analyses in our center revealed FVIII:C of <0.01 IU/mL, indicating severe hemophilia, 
which was confirmed by DNA analysis showing an inversion of intron 22. These findings 
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emphasized the relevance of (i) multiple FVIII:C measurements by certified laboratories; 
(ii) centralized treatment for rare diseases in centers with expertise; (iii) importantly, 
critical adjustment of treatment when test results do not correspond with clinical symp-
toms, (iii) relevance of additional DNA mutation analysis in patients with hemophilia. 
A study on the analytical variation in FVIII:C measurements, both in the one-stage as-
say (OSA) and chromogenic substrate assay (CSA) is reported in chapter 3. Both assays 
can be used to measure FVIII activity, however factors explaining analytical variation 
in FVIII activity levels are still to be completely elucidated. We collaborated with the 
External Quality Assessment Program for Thrombosis and Hemostasis (ECAT) Founda-
tion and studied factors potentially determining analytical variation in lyophilized 
plasma samples with varying FVIII:C levels. To investigate causes of OSA variation, we 
exchanged deficient plasma between three manufacturing company set-ups. On aver-
age, 206 (range: 164-230) laboratories worldwide used OSA to measure FVIII activity 
and 30 (range: 12-51) used CSA. The coe!icient of variation of OSA and CSA increased 
with lower FVIII levels (FVIII <0.05 IU/mL). This resulted in misclassification of a severe 
hemophilia A sample into a moderate or mild hemophilia A sample in 4/30 (13.3%) of 
CSA measurements, while this was 37/139 (26.6%) for OSA. The variation in FVIII activity 
levels was partly explained by specificity of manufacturer. Exchange of deficient plasma 
into a set-up with equipment of another manufacturing company however did not 
change FVIII level results. We concluded that standardization of FVIII measurements and 
further research into the etiology of analytical variation is required.
Part II - Implementation of pharmacokinetic-guided dosing of factor VIII 
concentrate in hemophilia A 
To implement pharmacokinetic (PK)-guided dosing of replacement therapy with factor 
concentrates in hemophilia, it is essential to investigate the strengths and limitations of 
this innovative intervention in order to analyze its potential. 
We reviewed the current insights on PK-guided dosing in hemophilia care and discussed 
its advantages and limitations in a broader sense in chapter 4. Dosing of factor concen-
trates is now primarily based on bodyweight and on crude estimates of in vivo recovery 
(IVR) and clearance, o"en resulting in underdosing with a higher risk of bleeding or 
overdosing resulting in unnecessary high costs. Benefits of PK-guided dosing include 
individualization of treatment with more optimal FVIII and FIX targeting, more flexible 
blood sampling, potential lowering of overall treatment costs and increased insight 
into association of coagulation factor levels and bleeding. The latter ultimately leading 
to PK-pharmacodynamic (PD) modelling. Limitations include a slight patient burden, 
consisting of outpatient clinic visits and blood sampling in a population accustomed to 
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frequent intravenous administration of medication. Conditional is availability of a close 
collaboration with population PK modeling, Bayesian analysis experienced clinical 
pharmacologists and hospital pharmacists. 
In chapter 5, we presented the design of a unique randomized controlled trial (RCT) 
which compares PK-guided perioperative dosing of FVIII concentrate with standard dos-
ing based on bodyweight in severe and moderate hemophilia A patients. The OPTI-CLOT 
trial is an open-label, prospective, multicenter RCT, aiming to detect a 25% di!erence in 
perioperative FVIII concentrate consumption. Minimally sixty hemophilia A patients # 12 
years of age, with FVIII plasma levels $ 0.05 IUmL-1 had to be included. Stratification was 
performed for mode of FVIII concentrate administration (bolus administration versus 
continuous infusion) and severity of elective surgery (low versus medium risk surgery). 
The results of the OPTI-CLOT RCT trial are presented in chapter 6. The main question in 
this RCT was to test the impact of PK-guided dosing on factor concentrate consumption 
perioperatively. We found that PK-guided dosing in the perioperative period resulted in 
similar consumption of FVIII concentrate (mean: 365±202 IU/kg) compared to standard 
treatment arm (mean: 379±202 IU/kg) (P=0.90). However, achievement of FVIII target 
levels was more e!ective in the PK-guided arm than in the standard dosing arm. PK-
guided treatment resulted in 69% of FVIII measurements within prescribed target range 
while this was only 37% for standard treatment (P<0.001). Hospitalization period and 
the amount of perioperative bleeding events were similar between treatment arms. 
Therefore, PK-guided dosing leads to more optimal targeting of pre-specified FVIII levels 
and more precise perioperative dosing. 
In chapter 7, we investigated the dynamics of von Willebrand factor (VWF) in periop-
erative severe and moderate hemophilia A patients. VWF is hypothetically crucial when 
determining FVIII concentrate dosage as VWF protects FVIII from premature clearance 
from the circulation. To date, it is unknown how VWF behaves and what its impact is 
on FVIII clearance in the perioperative setting. Therefore, VWF antigen (VWF:Ag), VWF 
activity (measured as VWF:GPIbM) and VWF propeptide (VWFpp) were determined in 
perioperative blood samples collected in the OPTI-CLOT RCT trial. Linear mixed e!ects 
modeling was applied to analyze VWF dynamics. It showed that VWF:Ag and VWF:GPIbM 
increased significantly postoperatively. Blood type non-O and medium risk surgery were 
associated with higher VWF:Ag and VWF:GPIbM levels compared to blood type O and 
low risk surgery. Unexpectedly, VWF:Ag had only a minimal e!ect on perioperative FVIII 
clearance. VWF levels were not associated with perioperative bleeding, although sample 
size was small. Future research is needed to investigate PK/PD of VWF and FVIII and 
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bleeding. Furthermore, a future population PK model should be created incorporating 
VWF levels to investigate VWF e!ects on FVIII PK more extensively. 
As the prevalence of overweight and obese individuals in the general population is 
increasing, hemophilia A patients are also increasingly a!ected. Under-and especially 
overdosing of factor replacement therapy in hemophilia A patients may be prevented 
by applying other morphometric variables than bodyweight to dose FVIII concentrates. 
Chapter 8 reported which morphometric variable best describes interindividual vari-
ability (IIV) of FVIII concentrate PK parameters in overweight and obese hemophilia A 
patients. We concluded that ideal body weight best explained observed variability 
between patients, as IIV for clearance and volume of distribution (V1) was reduced by 
incorporating ideal body weight from 45.1% to 37.6% and 26.8% to 14.1%, respectively. 
Strikingly, clearance, V1, and half-life were shown to remain similar when normal weight 
(BMI <25 kgm-2), overweight (BMI 25-30 kgm-2) and obese patients (BMI >30 kgm-2) were 
compared. Simulated FVIII trough and peak levels using real world data were similar 
when FVIII concentrate dosing was based on ideal body weight, also in cases of dosing 
for life-threatening bleed. We therefore concluded, that ideal body weight most accu-
rately predicts necessary FVIII concentrate doses in overweight and obese hemophilia A 
patients. Moreover, it seems that ideal body weight can be safely applied in all situations 
including life threatening bleeding. Although, we do remain careful and therefore still 
advise regular monitoring when dosing is critical. 
We reported an extremely obese severe hemophilia A patient who underwent a lapa-
roscopic sleeve gastrectomy to lose weight in chapter 9. We investigated the influence 
of extreme weight loss on the patient’s individual FVIII PK parameters. Individual PK 
parameters were estimated with a prophylactic population PK model based on ideal 
body weight as most important morphometric variable for allometric scaling. One year 
postoperatively, our patient lost 27.1 kg and weighed 106.4 kg with a BMI of 34.0 kgm-2. 
IVR decreased significantly with decreasing bodyweight. Strikingly, FVIII clearance and 
volume of distribution remained similar over time, resulting in a similar half-life over 
time. Time to 0.01 IUmL-1 was calculated a"er a hypothetical prophylactic FVIII con-
centrate dose of 3500 IU. Simulations using the patient’s individual PK parameters also 
showed that time to 0.01 IU/mL was not subject to change and remained a calculated 
period of 75.0 hours both before and a"er gastric bypass surgery. In conclusion, extreme 
weight loss does not influence individual FVIII parameters significantly and therefore 
does not lead to dose changes of prophylaxis. However, as hemostatic balances change, 
as is the case with extreme weight loss or obesity, monitoring of pharmacodynamics e.g. 
bleeding may become more relevant than pharmacokinetics. 
205
Summary / Samenvatting
In chapter 10, three PK tools e.g. myPKFiT®, Web-Accessible Population Pharmacoki-
netic Service-Hemophilia or WAPPS, and a prophylactic population PK model according 
to Bjorkman applied by a dedicated clinical pharmacologist (OPTI-CLOT group) using 
NONMEM, were compared. Patients underwent individual PK profiling. Subsequently, 
FVIII dose, FVIII levels and patient characteristics were entered into the three separate 
PK tools. Obtained PK parameters and dosing advises were then compared. MyPKFiT® 
provided PK parameters for 24 of 30 patients receiving Advate®, whereas WAPPS and 
NONMEM provided estimates for all patients. Half-life was di!erent among the three 
methods: medians were 12.6 hours (n = 24), 11.2 hours (n = 30) and 13.0 hours (n = 30) 
for myPKFiT®, WAPPS and NONMEM, respectively. To maintain a FVIII trough level of 0.01 
IUmL-1 a"er 48 hours, doses for myPKFiT® and NONMEM were 15.1 and 11.0 IUkg-1 and 
for WAPPS and NONMEM were 9.0 and 8.0 IUkg-1. In nine patients receiving Kogenate®, 
WAPPS and NONMEM produced di!erent PK-parameter estimates; half-life was 15.0 and 
12.3 hours and time to 0.05 IUmL-1 was 69.2 and 60.8 hours. However, recommended 
doses to obtain these levels were not di!erent. In conclusion, the three evaluated PK 
tools produced di!erent PK parameters and doses for recombinant FVIII concentrate. 
Hematologists should take this into account when obtaining dosing advices from the 
currently available PK tools. 
The last chapter of this thesis, chapter 11, compromises an overview of the most 
important findings and discusses their clinical implications. Furthermore, we provide 
recommendations for future research. 
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SAMENVATTING
Hemofilie A wordt gekenmerkt door een tekort aan stollingsfactor VIII (FVIII) dat ver-
oorzaakt wordt door een mutatie in het F8 gen. Aangezien FVIII van belang is voor een 
adequate secundaire hemostase, leidt een tekort aan FVIII tot (spontane) bloedingen in 
spieren en gewrichten en forse bloedingen na minimaal trauma en/of een operatie als 
geen adequate behandeling wordt toegepast. De belangrijkste behandeling bij hemofilie 
is suppletie van de ontbrekende stollingsfactor met factor concentraat dat intraveneus 
wordt toegediend. Het doseren van factor concentraat is echter lastig. Het is gebruikelijk 
om te doseren op basis van lichaamsgewicht en door middel van ruwe schattingen van 
de opbrengst en klaring van het factor concentraat. Meerdere studies hebben laten zien 
dat er grote interindividuele verschillen bestaan in de farmacokinetiek (PK) o"ewel wat 
het lichaam doet met het concentraat van FVIII concentraat waardoor beoogde factor 
spiegels in het bloed per individu niet goed kunnen worden voorspeld. Dit leidt in de 
praktijk tot onder doseren met een verhoogd risico op bloedingen of over doseren met 
bijkomende excessieve kosten aangezien factor concentraat behoort tot de categorie 
dure geneesmiddelen. Om deze reden is het doseren van factor concentraat op basis van 
een patiënts eigen PK een interessant concept aangezien op deze wijze de interindividu-
ele verschillen van het FVIII concentraat PK in acht worden genomen en de behandeling 
wordt geoptimaliseerd. 
In dit proefschri" beschrijven wij de voorwaarden die nodig zijn, als ook de voor-en 
nadelen en potentiele toepassingen van PK-gestuurd doseren van FVIII concentraat in 
hemofilie A patiënten. In het eerste deel focussen we op de huidige klinische praktijk 
met betrekking tot diagnostiek en het monitoren van een behandeling met FVIII concen-
traat. In het tweede deel wordt nader ingegaan op de implementatie van PK-gestuurd 
doseren in de praktijk. 
In hoofdstuk 1 wordt de achtergrond van de ziekte met de klinische symptomen en 
complicaties beschreven Daarnaast komen mogelijke verbeterpunten in de huidige van 
hemofilie behandeling aan bod.  
Deel I – Huidige diagnostiek en monitoring van behandeling
Aangezien FVIII metingen essentieel zijn om de diagnose hemofilie A te stellen en om de 
kwaliteit van de behandeling te monitoren, is het van belang dat deze metingen nauwkeu-
rig en betrouwbaar zijn. Implementatie van PK-gestuurd doseren is dan ook alleen moge-
lijk als de FVIII metingen waarop PK modellen zijn gebouwd, accuraat en reproduceerbaar 
zijn. Kennis en expertise met betrekking tot stollingsfactor testen zijn daarom onmisbaar 
wanneer PK-gestuurd doseren van stollingsfactor concentraat wordt toegepast. 
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FVIII activiteit metingen (FVIII:C) variëren en kunnen resulteren in misclassificatie van de 
ernst van hemofilie A met een mogelijke vertraging in het starten van een profylactische 
behandeling zoals beschreven in hoofdstuk 2. We beschrijven hier twee jonge broers die 
in eerste gediagnosticeerd zijn als matige-ernstige hemofilie A patiënten op basis van de 
uitgevoerde stollingstesten. Hierdoor werden ze niet tijdig profylactisch behandeld met 
stollingsfactor concentraat ondanks frequente bloedingen. Op de lee"ijd van vijf en zes 
jaar oud werden de broers verwezen naar ons hemofiliebehandelcentrum. Laboratorium 
testen lieten FVIII:C waardes zien van <0.01 IU/mL, dat past bij een diagnose van ernstige 
hemofilie A. Dit werd bevestigd door DNA analyse waarbij een inversie van intron 22 
werd aangetoond. Deze bevindingen benadrukken de noodzaak van (i) meerdere FVIII:C 
metingen rondom diagnose door gecertificeerde laboratoria; (ii) belang van concentra-
tie van zorg voor zeldzame ziektes in centra met expertise; (iii) een kritische instelling 
en aanpassing van de behandeling als de laboratorium resultaten niet corresponderen 
met klinische symptomen; (iv) en als laatste de relevantie van additionele DNA mutatie 
analyses in patiënten met hemofilie. 
Een studie over de variatie in FVIII:C metingen, zowel in de one-stage assay (OSA) als 
in de chromogene substraat assay (CSA), is opgenomen in hoofdstuk 3. Beide testen 
worden gebruikt om FVIII activiteit te meten, maar niet alle factoren die de analytische 
variatie verklaren zijn bekend. Samen met de External Quality Assessment Program voor 
Trombose en Hemostase (ECAT) Foundation hebben we de factoren onderzocht die de 
analytische variatie zouden kunnen beïnvloeden en verklaren in bloed plasma monsters 
met verschillende FVIII:C levels. Om de variatie in de OSA te onderzoeken, werd er FVIII 
deficiënt plasma uitgewisseld tussen drie verschillende instrumentarium opstellingen 
van drie verschillende leveranciers. Gemiddeld werd de OSA gebruikt door 206 (range: 
164-230) en de CSA door 30 (range: 12-51) laboratoria. De variatie coë!iciënt nam toe 
wanneer de FVIII levels resultaten lager werden (FVIII<0.05 IU/mL). Dit resulteerde in 
misclassificatie van een ernstige hemofilie A patiënten monster in een matig of milde 
hemofilie A in 4 van de 30 (13.3%) CSA metingen, terwijl dit in 37 van de 139 (26.6%) 
plaats vond wanneer de OSA gebruikt werd. De variatie in FVIII activiteit metingen werd 
voor een gedeelte verklaard door specifieke leverancier. Het testen van het FVIII defici-
ent plasma met de opstelling van een andere fabrikant veranderde de FVIII activiteits 
metingen echter niet. We concludeerden daarom dat verdere standaardisatie van FVIII 
metingen en minimaliseren van de analytische variatie van belang is. 
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Deel II – Implementatie van farmacokinetisch-gestuurd doseren van factor 
VIII concentraat in hemofilie A. 
Om farmacokinetisch(PK)-gestuurd doseren van factor concentraat te implementeren in 
de huidige behandeling van hemofilie is het essentieel om de voor-en nadelen te onder-
zoeken van deze innovatieve techniek. 
We bespreken de laatste ontwikkelingen ten aanzien van het PK-gestuurd doseren van 
factor concentraat binnen de hemofilie zorg en bediscussiëren de voordelen en beper-
kingen van deze behandeling in hoofdstuk 4. Voordelen van PK-gestuurd doseren zijn 
het individualiseren van de behandeling met meer als gevolg het beter bereiken van 
beoogde FVIII en FIX spiegels in het bloed, grotere flexibiliteit ten aanzien van bloedaf-
names, een mogelijke verlaging van kosten gerelateerd aan een behandeling met duur 
factor concentraat, en beter inzicht in de associatie tussen stollingsfactor spiegels in het 
bloed en (het risico op) bloedingen. Wanneer meer data beschikbaar is die stollingsfac-
tor spiegels relateert aan het optreden van bloedingen dan is het mogelijk niet alleen 
populatie PK modellen te construeren, maar ook populatie PK-farmacodynamiek (PD) 
modellen. Beperkingen van een PK-gestuurde behandeling met factor concentraat zijn 
enige belasting voor de patiënt wegens alsnog frequentere bloedafnames en polikliniek-
visites. Een belangrijke voorwaarde voor het toepassen van het PK-gestuurd doseren is 
een goede samenwerking met de afdeling Klinische Farmacologie of de ziekenhuisapo-
theek en ervaring met de complexe toepassingen van populatie PK modellen. 
In hoofdstuk 5 presenteren we de studie opzet van een unieke gerandomiseerd gecon-
troleerde trial (RCT) die perioperatief PK-gestuurd doseren van factor concentraat ver-
gelijkt met het standaard doseren gebaseerd op gewicht in ernstige en matig-ernstige 
hemofilie A patiënten. De OPTI-CLOT trial is een open-label, prospectieve, multicenter 
RCT, met als doel om een 25% verschil in het perioperatief verbruik van FVIII concentraat 
aan te tonen. In de studie is gestratificeerd voor toedieningswijze (bolus infusies versus 
continu infuus) en complexiteit van de operatie (laag risico versus medium risico).
De resultaten van de OPTI-CLOT RCT trial worden gepresenteerd in hoofdstuk 6. Het pri-
maire eindpunt van deze RCT was of het verbruik van FVIII concentraat met behulp van 
PK-gestuurd doseren verlaagd kon worden in een perioperatieve setting. Belangrijkste 
uitkomsten waren dat het verbruik van FVIII concentraat tussen de twee behandelarmen 
niet verschilde (PK gestuurde behandelarm FVIII concentraat gemiddelde: 365±202 IU/
kg en standaard doseren (379±202 IU/kg) (P=0.90)). Echter, PK-gestuurd doseren leidde 
tot het feit dat 69% van de FVIII spiegels binnen de streefwaarden werden gemeten en 
dat bij standaard doseren dit slechts in 37% het geval was (P<0.001). De opnameduur en 
het voorkomen van bloedingen waren vergelijkbaar in beide behandelarmen. Conclude-
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rend, PK-gestuurd doseren leidt een meer optimale behandeling doordat de streefwaar-
den in klinische richtlijnen en van tevoren bepaald door de behandelaar beter worden 
behaald doordat er nauwkeuriger wordt gedoseerd. 
In hoofdstuk 7 is binnen de OPTI-CLOT RCT trial gekeken naar hoe von Willebrand factor 
(VWF) zich gedraagt in perioperatieve ernstige en matig-ernstige hemofilie A patiënten. 
VWF beschermt FVIII voor vroegtijdige klaring uit de lichaamscirculatie. Daarom was 
onze hypothese dat de hoeveelheid VWF van belang is voor de PK van het FVIII concen-
traat. Er is tot op heden weinig bekend over hoe VWF zich gedraagt en wat de impact is 
van de hoeveelheid VWF op FVIII spiegels in de perioperatieve periode. Daarom is VWF 
antigeen (VWF:Ag), VWF activiteit (gemeten als VWF:GPIbM) en VWF propeptide (VWFpp) 
bepaald in perioperatieve bloed monsters die verzameld zijn binnen de OPTI-CLOT RCT 
trial. Linear mixed e!ects modelering werd toegepast om de VWF dynamiek te analyse-
ren. Dit toonde aan dat VWF:Ag en VWF:GPIbM toenamen direct na de operatie. Patiënten 
waarbij sprake was van bloedgroep non-O en een operatie met een middelmatig risico 
vertoonden hogere VWF:Ag and VWF:GPIbM waarden dan patiënten met bloedgroep 
O of een operatie met een laag risico. Opvallende bevinding was dat de VWF waardes 
een kleiner e!ect hadden op de perioperatieve klaring van het FVIII concentraat dan 
verwacht. De hoogte van de VWF waardes was ook niet geassocieerd met bloedingen die 
plaats vonden rondom de operatie. Van belang is dat de hoeveelheid patiënten binnen 
deze studie uiteraard klein was. Meer onderzoek is daarom nodig om de belangrijke re-
latie tussen de PK en farmacodynamiek van VWF en FVIII en bloedingen te onderzoeken. 
Daarnaast zou er gestreefd moeten worden naar een populatie PK model waarbij de 
interactie van FVIII en VWF wordt geïncorporeerd zodat de e!ecten van VWF op FVIII 
beter kunnen worden onderzocht. 
Aangezien de prevalentie van overgewicht en obesitas in de algemene bevolking 
toeneemt, zijn er ook steeds meer hemofilie A patiënten die zich hiermee presente-
ren. Onder-en vooral overdoseren van FVIII concentraat in hemofilie A patiënten kan 
waarschijnlijk worden voorkomen door andere morfometrische variabelen in plaats 
van lichaamsgewicht te gebruiken om het FVIII concentraat te doseren. In hoofdstuk 
8 beschrijven wij welke morfometrische variabele het beste de interindividuele variabi-
liteit (IIV) van FVIII concentraat beschrij" in hemofilie A patiënten met overgewicht en 
obesitas. We observeerden dat “ideaal lichaamsgewicht” (IBW) het beste deze variabili-
teit verklaart aangezien de IIV voor klaring en distributievolume werd gereduceerd van 
45.1% naar 37.6% en 26.8% naar 14.1%, respectievelijk. Klaring, V1 en de halfwaardetijd 
waren gelijk wanneer normaal gewicht (BMI <25 kg/m2), overgewicht (BMI 25-30 kg/
m2) en obese patiënten (BMI >30 kg/m2) werden vergeleken. Daarnaast waren de gesi-
muleerde FVIII dal- en topspiegels gelijk wanneer data van patiënten werd gebruik om 
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FVIII te doseren op basis van IBW, vooral belangrijk in het geval van een levensbedrei-
gende bloeding. We concludeerden dat IBW moet worden gebruikt om meer accuraat 
FVIII doseringen te berekenen in hemofilie A patiënten met overgewicht en obesitas. 
Wel adviseren we ook bij het gebruik van IBMW nog steeds FVIII waardes regelmatig te 
monitoren wanneer doseringen en bereikte FVIII waardes van kritisch belang zijn. 
We beschrijven een ernstige hemofilie A patiënt met extreme obesitas, die een laparo-
scopische gastrectomie hee" ondergaan om gewicht te verliezen in hoofdstuk 9. We 
onderzochten de invloed van dit extreme gewichtsverlies op de individuele FVIII PK 
parameters van deze patient. De individuele PK parameters werden geschat met een 
profylactisch populatie PK model waarbij IBW werd gebruikt voor de allometrische scha-
ling. Een jaar na operatie, was de patiënt 27.1 kilogram afgevallen en woog nog 106.4 kg 
met een Body Mass Index (BMI) van 34.0 kg/m2. De in vivo recovery daalde significant 
met afname van het lichaamsgewicht. FVIII klaring en het distributievolume bleef echter 
gelijk over de tijd, waardoor er uiteindelijk sprake was van een gelijke FVIII halfwaar-
detijd. De tijd tot 0.01 IU/mL werd berekend na een hypothetische profylactische FVIII 
dosering van 3500 IU. Simulaties waarbij de individuele PK parameters van de patiënt 
werden gebruikt, lieten zien dat de tijd tot een FVIII van 0.01 IU/mL niet veranderde na 
zijn gewichtsverlies en dat deze rond de 75 uur was zowel voor als na de operatieve 
maagverkleining. We concludeerden dat extreem gewichtsverlies de individuele FVIII 
PK parameters niet significant beïnvloedt en dus dat dit niet leidt tot veranderingen in 
de dosering van FVIII profylaxe. Aangezien, er nog weinig kennis is met betrekking tot 
verschuivingen binnen hemostatische balans na extreem gewichtsverlies, is monitoring 
van de farmacodynamiek, o"ewel registratie van bloedingen, waarschijnlijk meer rele-
vant dan de FVIII PK in deze omstandigheden.
In hoofdstuk 10 zijn drie PK tools (myPKFiT®, Web-Accessible Population Pharma-
cokinetic Service-Hemophilia o"ewel WAPPS en een profylactisch populatie PK model 
beschreven door Björkman en toegepast door een klinisch farmacoloog met behulp van 
NONMEM) met elkaar vergeleken. Na een individueel PK profiel werden de FVIII dose-
ring, FVIII waardes en patiënt karakteristieken ingevoerd in deze drie PK tools, waarna 
de verkregen PK parameters en doseeradviezen werden vergeleken. MyPKFiT® gaf de PK 
parameters voor maar 24 van de 30 patienten die FVIII-Advate® kregen, waarbij WAPPS 
en NONMEM de PK parameters gaven van alle patiënten. De FVIII halfwaardetijden 
verschilden tussen de drie tools, waarbij de medianen 12.6 uur (n = 24), 11.2 uur (n = 
30) en 13.0 uur (n = 30) waren voor respectievelijk myPKFiT®, WAPPS en NONMEM. Om 
boven een FVIII dal spiegel van 0.01 IU/mL te blijven na 48 uur, waren de doseringen 
van myPKFiT® en NONMEM 15.1 en 11.0 IU/kg, en voor WAPPS en NONEM 9.0 en 8.0 IU/
kg. In de negen patiënten die Kogenate® kregen toegediend , produceerden WAPPS en 
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NONMEM verschillende PK parameters; de FVIII halfwaardetijd was hierbij 15.0 en 12.3 
uur en de tijd tot 0.05 IU/mL was 69.2 en 60.8 uur. Desondanks waren de geadviseerde 
FVIII doseringen niet verschillend. We concludeerden dat de drie PK tools verschillende 
PK parameters en doseringen voor recombinante FVIII concentraten berekenen en dat 
kinderarts-hematologen en internist-hematologen hiervan bewust moeten zijn bij de 
keuze van een PK tool. 
In het laatste hoofdstuk van dit proefschri", hoofdstuk 11, geven we een overzicht van 
de meest belangrijke bevindingen van de verrichtte studies en bediscussiëren wij de 
klinische implicaties en aanbevelingen voor toekomstig onderzoek. 
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Een promotietraject doorloop je niet alleen, daarom zou ik graag de volgende mensen 
willen bedanken voor hun hulp in de afgelopen jaren. 
Zonder patiënten geen onderzoek! Daarom wil ik als eerst alle patiënten en ouders 
bedanken voor hun deelname en vertrouwen in de OPTI-CLOT studies. Ieder verhaal van 
elke patiënt was weer anders en inspirerend, wat ertoe leidde dat ik nog meer passie 
voor dit onderzoek kreeg en doorzettingsvermogen om studies voort of op te zetten. 
Daarbij een speciaal bedankje voor de Nederlandse Vereniging voor Hemofilie Patiënten 
(NVHP), bedankt voor jullie hulp en toewijding!
Lieve Marjon, o"ewel dr. Cnossen. Vijf jaar geleden hadden we gelijk een ‘klik’ bij het 
sollicitatiegesprek. Ondanks dat ik niet kon bloedprikken, had jij het vertrouwen dat dit 
‘wel goed moest komen’ en dat ‘goedkomen’ is zeker gelukt! Dank je voor al je hulp, cap-
puccinootjes als het onderzoek even niet liep zoals het zou moeten lopen, je inspiratie 
en vooral de mogelijkheden die jij mij gaf tijdens mijn promotie. Een meer ‘personalized 
promotietraject’ bestaat er denk ik niet. Als kers op de taart hebben we samen met het 
SYMPHONY consortium de NWO-NWA toegewezen gekregen. Daarom nemen we geluk-
kig niet helemaal afscheid en blijven we nog een klein beetje samenwerken. Ik kijk er 
naar uit! 
Beste Frank, beste prof. dr. Leebeek. Toen ik startte, was ik een van de weinige ‘niet-
artsen’ tussen alle dokters, maar daardoor hebben jullie mij veel geleerd over het vak 
van de benigne hematologie. Dank je voor al je hulp in de kliniek, constructieve feedback 
en ook vooral de humor! Ik vergeet niet snel meer dat we samen met de Rotterdamse 
hemofiliepatiënten gingen ijskarten, en wie was er nou ook alweer sneller, jij of ik? 
Beste Ron, beste prof. dr. Mathôt. Een OPTI-CLOT-patiënt in het weekend? Jij stond 
klaar om doseeradviezen te controleren op zondagochtend. Daarnaast is je PK kennis 
niet up-to-date als je niet bij de maandelijkse NONMEM meeting in het AMC bent. Door 
jou en Reinier was er iedere maand een leerzame meeting, waar alle ins en outs van het 
PK modelleren werden besproken. Ik wil je bedanken voor alle goede feedback en tijd 
in de afgelopen jaren. 
Een studie opzetten in alle hemofiliebehandelcentra’s in Nederland gaat ook niet 
zonder slag of stoot. Daarom wil ik ieder hemofiliebehandelcentrum en vooral de trial-
bureaus en/of verpleegkundigen/verpleegkundig specialisten bedanken. Jullie hebben 
ervoor gezorgd dat in alle centra de OPTI-CLOT-studie ging lopen, van contracten tot 
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site files, van bloedafnames tot databases aanvullen. Zonder jullie was dit niet gelukt, 
bedankt! Vooral Ineke wil ik in het bijzonder bedanken, zonder jouw kennis over alle 
regels van METC, CCMO en andere instanties kon de OPTI-CLOT niet bestaan. Daarnaast 
wil ik ook alle hematologen bedanken voor hun inzet 24/7 rondom de operaties, we 
konden altijd bij jullie terecht, dank! 
Beste prof. dr. Voorberg, prof. dr. de Wildt en prof. dr. de Maat, dank dat jullie plaats 
willen nemen in de kleine promotiecommissie. Daarnaast wil ik prof. dr. Meijer, prof. 
dr. van der Ploeg en prof. dr. Rings bedanken voor hun deelname aan de grote promo-
tiecommissie. 
Beste Sander en Maartje, beste prof. dr. Meijer en dr. van den Biggelaar. Nadat de 
OPTI-CLOT-studie opgestart was in ieder centrum, miste ik het laboratorium. Bedankt 
voor de mogelijkheid om in jullie lab de wereld van proteomics te ontdekken. Samen 
gaan we nog een mooi project afronden. 
Directe collega’s maken of kraken het werkplezier, nou bij de stolling in het Erasmus MC 
en Sophia Kinderziekenhuis is het een gezellige boel! Zonder jullie was deze promotie 
zeker niet zo leuk geweest! Carolien, nadat jij al het voorwerk hebt uitgevoerd voor de 
OPTI-CLOT, nam ik het stokje van je over. Dank je voor je adviezen, goede gesprekken op 
congressen (als we “op tijd” gingen slapen en het dan toch weer 2 uur ’s nachts was) en 
vooral de gezelligheid. Jij bent een super kinderarts! Johan, Jossi en Caroline, samen 
waren we toch een lekker ko!ieclubje (en oké Lisette hoorde er ook bij met haar theetje). 
Johan, wat mis ik jouw humor en wat hebben we gelachen op ‘ons eiland’ samen met 
Jossi. Gelukkig komen we elkaar nog tegen op congressen. Jossi, naast dat we samen 
heel goed Jochem Meijer na konden doen op de vroege ochtend, konden we daarna 
ook heel hard werken. Hopelijk komt er (binnenkort?) een moment dat je je passie voor 
stolling en statistiek weer oppakt? Lijkt mij heel leuk! Lisette, samen begonnen we aan 
het avontuur ‘promotie’, ik zie ons nog braaf zitten met zijn tweetjes in het kantoor in 
ons eerste jaar tussen kerst en oud en nieuw. Dankjewel voor alle goede gesprekken en 
leuke discussies! Caroline, of zal ik dr. Veen zeggen? Samen hebben we heel wat meege-
maakt, van een lach tot een traan, baby-en puppyverhalen en van logistieke zaken in het 
onderzoek tot statistische uitdagingen, altijd konden (en kunnen!) we bij elkaar terecht. 
Ik vind het dan ook echt heel fijn dat je bij het laatste deel van mijn promotietraject 
naast me wil staan als mijn paranimf! 
Uiteraard zijn er ook een heleboel “nieuwe” PhD studenten begonnen tijdens mijn pro-
motie, die ik ook graag wil bedanken voor alle serieuze en minder serieuze momenten! 
Jessica, een rots in de branding. Jouw kalmte, gezelligheid en kennis over VWD en het is 
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daarnaast ook heerlijk om lekker even bij te kletsen over van alles en nog wat. Daarnaast 
was de OPTI-CLOT zonder jou niet doorgegaan tijdens mijn vakantie; daarvoor ook heel 
erg bedankt! Tine, ook al kennen we elkaar nog niet heel lang, het voelt toch heel ver-
trouwd. Ik heb er dan ook het volledige vertrouwen in dat die PhD en kinderartsencar-
rière bij jou goed gaat komen. En als je nog eens een li" nodig hebt in Brabant, weet je 
me te vinden. Ferdows, mijn statistiekmaatje! Na de statistiekcursussen samen, neem 
ik aan dat we nog vaak met elkaar gaan sparren over de juiste statistiek en waarom een 
statistiekprogramma niet doet wat het zou moeten doen. Daarnaast zal ik de Indische 
waterlelies uit Madrid ook niet snel vergeten. Judith, ik hoop dat we, naast dat we 
elkaar nog regelmatig tegen gaan komen op het lab, ook nog regelmatig naar een hard-
loopwedstrijdje gaan. Is een van de beste manieren om te ontspannen, toch? Ook wil ik 
Maite, Samantha,  Lorenzo en Joppe bedanken voor de gezellige momenten gewoon 
op het kantoor of op congressen!
Laura en Tim, zonder jullie had de OPTI-CLOT niet draaiende gehouden kunnen worden. 
Tim, met onze gezamenlijke OPTI-hobby in het weekend hebben we toch stiekem best 
lol gehad, wat hee" geleid tot mooie artikelen. Succes met je opleiding tot ziekenhuis-
apotheker! Laura, jij hebt je vliegensvlug ingewerkt in alle studies in de hemofilie. Petje 
af! Ook jij bedankt voor je hulp en gezelligheid bij de OPTI-CLOT. 
Daarnaast is de OPTI-CLOT in het Erasmus MC ook vlekkeloos verlopen door de hulp van 
de geweldige hemofilieverpleegkundigen/verpleegkundig specialisten: Marjo, Floor, 
Greta, Carolien en Sasja. Dames ontzettend bedankt voor al jullie hulp, het meedenken 
over de logistiek van de studie, helpen met het bijvullen van de prikko!er (“even shop-
pen” he Marjo) en uiteraard het leren prikken (Floor dank je!). Greta, dank je wel voor 
je oplettendheid tijdens iedere poli, de gezellige momenten en goede adviezen. Zonder 
jullie had Rotterdam niet de “beste includeerder” kunnen zijn. 
Ook het hemostaselab in het Erasmus MC moet natuurlijk even genoemd worden. De 
‘cadeautjes’ die ik langs kwam brengen met citraatbuisjes werden altijd keurig door 
jullie verwerkt en de FVIII bepalingen werden vliegensvlug uitgevoerd als een patiënt 
opgenomen lag. Daarnaast is het gewoonweg ook heel gezellig bij jullie op het lab, dat 
heb ik wel gemerkt tijdens het uitvoeren van de VWF bepalingen. Dank je voor jullie as-
sistentie! Ook de andere hemostaselaboratoria in Nederland wil ik bedanken voor hun 
bijdrage!
Many thanks for all my colleagues from Sanquin! Nadia, Iris, Gosia, Bart, Eelke, Esmee, 
Arjan, Carmen, Floris and Mariette, many thanks for all your help and assistance in 
the laboratory. You taught me how to prepare mass spectrometry (MS) samples, create 
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beautiful figures in R and the basics of the MS. Thanks for answering all my questions, 
and for the introduction into this very interesting and promising field. Most of all, thank 
you for all the enjoyable moments, good jokes and good conversations. 
Beste dr. Kruip en prof. dr. de Maat, beste Marieke en Moniek. Marieke, dank voor al 
je hulp met de OPTI-CLOT en ook de goede gesprekken en adviezen. Moniek, jij ook 
bedankt dat ik altijd even binnen kon lopen met een lab of statistiekvraag. Daarnaast 
vind ik het een eer dat je wilt plaatsnemen in mijn promotiecommissie!
Beste dr. Bierings, beste Ruben, dank je dat ik tijdens het begin van mijn postdoc soms 
nog ‘even’ aan mijn proefschri" kon werken. Hierdoor is de overgang van hemofilie naar 
BOECs vloeiend verlopen. Ik kijk er naar uit om verder te werken aan het SYMPHONY 
project binnen de gezellige “Bierings” groep samen met Petra, Maurice en Bas!  
Naast collega’s zijn er ook genoeg andere mensen die indirect een bijdrage hebben 
geleverd aan dit proefschri". Mijn wetenschappelijke carrière begon op de VU samen 
met jullie dames: Valerie, Maralinde, Willemijn en Iris. Het klinkt gewoon gek om jullie 
namen voluit te schrijven, dus Val, Mara, Wil en Ier, gewoon even lekker zo. Zo begint 
een vriendschap met een naamsverwisseling in de collegezaal (wie verzint het ook, Iris 
van Moort en Iris van Noord), en zo zijn we opeens volwassen vrouwen met een huis en 
baan. Nu we allemaal weer in Europa wonen, komt dat weekendje London (of Oxford!) 
eraan! Val, na ons geweldige avontuur in Londen, hebben we je heel lang moeten missen 
door je verhuizing naar Melbourne. Hoe toevallig was het ook dat het stollingscongres 
(ISTH) in het laatste jaar van mijn PhD in Melbourne werd gehouden! Heerlijk was het om 
eindelijk weer in ‘real life’ met elkaar te kletsen bij jouw favoriete tentje in Brunswick. Ik 
bewonder je doorzettingsvermogen (“even” emigreren naar Australië!) en relativerings-
vermogen. Daarnaast is het ook gewoonweg heerlijk om keihard met jou te lachen over 
de serieuze en minder serieuze zaken van het leven. Mara, jij als mede-PhD’er, of nou, nu 
dr. Mara, wat is het heerlijk om samen de hoogte-en dieptepunten over de wetenschap 
te bespreken onder het genot van een wijntje. Je staat op je strepen bij de zaken die er 
toe doen, en je hebt altijd een oplossing klaar staan. Ik vind het dan ook super fijn dat je 
mijn paranimf wilt zijn! Je bent een kanjer!
Ook mijn oude huisgenootjes, Linda en Karlijn, wil ik graag bedanken. Zoals Lin zo mooi 
zei, van diner in badjas naar dames met een ‘echte’ baan. Lin en Karlijn, door jullie heer-
lijke baksels, goede gesprekken en diners hadden we altijd een heerlijk ‘thuis’ tussen de 
colleges, feestjes en sportlesjes door. Ondanks dat we nu niet meer samenwonen, hoop 
ik dat onze etentjes nog heel vaak plaats gaan vinden! 
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Dankwoord
Je kan het meisje uit Zeeland halen, maar Zeeland niet uit het meisje. Jessica en Hel-
een, dank jullie voor de Zeeuwse nuchterheid, die ons denk ik verder brengt dan dat we 
zelf bese!en! Binnenkort maar weer eens in de mooiste provincie van Nederland een 
wijntje drinken? 
Maartje en Maartje, dames ook jullie bedankt voor de gezelligheid en het aanhoren van 
mijn PhD verhalen. Maartje Heitzman, van een drankje in de tuin tot serieuze gesprekken 
op de bank, ik ben blij dat we daarvoor terecht kunnen bij elkaar. Maartje Thompson, na 
alle avonturen die we samen hebben gedeeld, van carnaval tot aan het kerstdiner bij de 
schoonfamilie, hebben we ondertussen een nieuwe hotspot, onze etentjes bij Mangiare 
zijn ondertussen een begrip. Er zijn weinig mensen die ik ken die zo goed op de hoogte 
zijn en zo weinig vergeten over iemands leven. De wereld zou een beetje meer Maartjes 
moeten hebben.  
Het liefst had ik vijf wetenschappelijke stellingen over sporten aan mijn proefschri" 
toegevoegd, en dat is niet zonder reden. De bootcamp in Bergen op Zoom en Halsteren 
is gewoonweg een van de gezelligste sportclubs van Nederland en die zorgt voor de 
perfecte ontspanning! Mitchell, Madeleine, Matthijs, Joyce, Tessa, Marchel, Ascania, 
Marije en Eveline, dank jullie voor de slappe lach tijdens de meest vervelende oefenin-
gen, de heerlijke competitie tijdens een sprintje, de gezelligheid tijdens een obstakelrun 
of tijdens een Ardennenweekend rondom het kampvuur. Madeleine, ik ken weinig 
mensen die blij zijn met een verjaardagscadeautje van 14 km door de duinen rennen en 
daarom vind ik onze vriendschap ook zo fijn. Dank je voor je luisterend oor tijdens, maar 
vooral naast het sporten! 
Lieve Rien, Loes en Gijs, na al die jaren voelen jullie als een ‘tweede paar ouders en 
broer’ en is het ook in het Eindstraatje een gevoel van thuiskomen. Dankjewel voor 
alle fijne goede gesprekken en natuurlijk voor de oppas op onze kleine Joep! Volgens 
mij heb ik Rien nog bijna nooit zo blij gezien nadat we hadden verteld dat we voor een 
puppy gingen kijken. 
Lieve Papa, Mama, Joris en Roosmarijn. Wie kent je beter dan je eigen familie? Pap en 
Mam, dank je voor de vrijheid die jullie me hebben gegeven om zelf een studie te kiezen 
die ik leuk vond (en geen zeevaartschool…). Jullie staan altijd voor me klaar en voelden 
het haarfijn aan als iets toch anders gaat dan ik in mijn hoofd had gepland. Ik denk dat 
de uitspraak: “A ship in a harbor is safe, but that is not what ships are built for”, zowel 
letterlijk als figuurlijk op jullie van toepassing is. Ik ben trots op hoe jullie alles regelen 
op de schepen en ons (Joris, Roos en ik) de vrijheid geven om zelf met ons figuurlijke 
bootje vanuit het veilige Veerse Meer richting de wilde zee gaan. Joris, jouw passie voor 
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muziek is eindeloos. Muziek maken, luisteren, recensies schrijven en publiceren, en dat 
allemaal in je vrije tijd. Ik ben trots op je en ik wacht op de dag dat jij je eigen column 
of wekelijkse reportage in de krant krijgt! Roosmarijn, hoe jij je binnen een paar jaar 
hebt ontwikkeld van een verpleegkundige die net begon tot een verpleegkundige die 
praktisch een heel complex regelt en bijspringt als er (weer) te weinig personeel is, vind 
ik bewonderingswaardig. Ik ben trots op je dame! En je weet het, de hemofiliezorg zou 
een verpleegkundige als jij heel goed kunnen gebruiken. 
Dan als laatst, had ik dit boekje niet kunnen afmaken zonder Bart. Ik denk dat jij onder-
tussen ook een PhD kan behalen over PK-gestuurd doseren van stollingsfactor VIII na al 
mijn verhalen. Zoals Rosalind Franklin zei: “Science and everyday life cannot and should 
not be separated.” Lieverd, jij houdt me met beide benen op de grond, stimuleert me om 
vol voor het onderzoek te gaan, maar remt me af waar nodig en zorgt ervoor dat ook de 
kleine successen worden gevierd. Ik wil je bedanken voor je warmte, liefde en vooral 
betrokkenheid. Voordat het echt heel sentimenteel gaat worden, hoop ik dat we deze 
dag vooral goed gaan vieren en samen nog heel veel heerlijke reizen gaan maken, mooie 
avonturen gaan beleven met Joep en nog vele kilometers door de polders gaan rennen; 
samen onze mooie toekomst tegemoet. 
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PHD PORTFOLIO
Name PhD student: Iris van Moort PhD period: October 2014 – October 2019
Erasmus MC Department: Pediatric Hematology Promotors: Prof.dr. F.W.G. Leebeek, Prof.dr. R.A.A. Mathôt
Research School: COEUR Co-promotor: Dr. M.H. Cnossen
1. PhD training Year Workload(ECTS)
General academic skills
Biomedical English Writing and Communication 2017 3
Research integrity 2017 0.3
Good Clinical Practice (BROK) 2015 1
Open Clinica course 2015 0.3
CPO course (Center for Patient Oriented Research) 2015 0.3
Systematic Literature Retrieval 2014 0.5
Specific courses
Repeated Measurements (NIHES) 2019 1.7
3x NVTH annual PhD course on hemostasis and thrombosis 2015-2018 3.0
NONMEM journal clubs 2014-2018 3.0
Biostatistical Methods II: classical regression models (NIHES) 2017 4.3
Biostatistical Methods I: Basic Principles (NIHES) 2015 5.7
Vascular Medicine (COEUR) 2015 1.5
Clinical cardiovascular epidemiology (COEUR) 2014 1.5
(Inter)national scientific presentations and conferences 
Oral presentations 
Dutch Association of Thrombosis and Hemostasis (NVTH) 2019 1.0
ECAT symposium (invited) 2018 1.0
Dutch Society of Pediatrics 2017 1.0
Hemophilia Nursing Conference (invited) 2017 1.0
International Society on Thrombosis and Hemostasis Congress, Berlin (2x oral 
presentation)
2017 1.0
Pharmacology meeting Erasmus MC 2017 1.0
COEUR PhD day (2x) 2016, 2017 1.0
Netherlands association for Hemophilia Patients (NVHP), patient day (invited) 2016 1.0
COEUR symposium 2016 1.0
ESDK day – Day for young hemophilia patients (invited) 2016 1.0
Sophia Research Day 2016 1.0
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Poster presentations
International Society on Thrombosis and Hemostasis Congress, Melbourne, 
Australia
2019 0.3
European Congress on Thrombosis and Hemostasis, Den Haag 2016 0.3
International Society on Thrombosis and Hemostasis Congress, Toronto, Canada 2015 0.3
International conferences 
3x International Society on Thrombosis and Hemostasis Congress 2015, 2017, 2019 4.4
2x European Association of Hemophilia And Allied Disorders Congress 2015, 2018 1.8
European Congress on Thrombosis and Hemostasis 2016 1.0
Bari international conference, Bari, Italy 2014 0.9
National conferences
NVTH Symposium 2015-2019 1.5
Annual meeting of the Dutch Society of Pediatrics 2016, 2017 0.6
AMSTOL Symposium 2016 0.3
Von Creveld Symposium 2014 0.3
Seminars and workshops
Masterclass with Prof.dr. David Lillicrap 2019 0.3
Sophia Research Day 2015-2019 1.5
COEUR PhD Day 2015-2018 1.2
Nijmegen Symposium on Hemophilia and Rare Bleeding disorders 2015, 2017 0.6
TULIPS Young Investigator Day 2015-2017 0.9
COEUR symposium personalized medicine 2015 0.1
Masterclass with Prof.dr. Evan Sadler 2015 0.3
2. Teaching activities 
Lecturing
Teacher ‘Biochemistry of coagulation’ & ‘PK and Hemophilia’ - second year 
medical students 
2015-2019 0.3
Lecturing at massive blood loss symposium for anesthesiology department 2018 0.1
Supervision of master’s thesis
Sam Reerds, medical student 2016 1.0
Supervision of scientific internship 
Colin Spence, medical student 2018, 2019 0.3
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Hematology PhD training
Work discussions and journal clubs Erasmus MC 2014-2019 8.0
Work discussions at Sanquin 2017-2019 0.5
3. Other
Participation in Female Talent Class–Erasmus MC 2019 0.6
Participation in TULIPS PhD program 2016-2018 3.0
TULIPS - Organizing Young Investigator Day 2016, 2017 1.0
Pediatric Pharmacology meetings 2014, 2015 0.6
4. Awards and grants
Top scoring abstract, EAHAD 2020
Dutch National Research Agenda, SYMPHONY consortium (%4.100.000) 2019 -
Sobi Dutch research grant for translational research in hemophilia (%25.000) 2018 -
Ulla Hedner Haemostasis Award (%15.000) 2017 -
Young Investigator Award International Society on Thrombosis and Haemostasis 
(%750)
2017 -
Winner Slam session Bayer Hemophilia nurse conference 2017 -
Poster Award International Society on Thrombosis and Haemostasis 2015 -
Total 69.1 
ECTS = European Credit Transfer and Accumulation System (1 ECTS represents 28 hours).
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